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Abstract 
Hip replacement is the main therapeutic intervention for end-stage osteoarthritis (OA). 
Metal-on-metal (MoM) hip implants were introduced to provide a durable alternative to 
ceramic and polyethylene devices, particularly in a younger patient population. However 
they are associated with the development of adverse reactions to metal debris (ARMD) 
which includes osteolysis, soft tissues necrosis, and inflammatory pseudotumours.  
MoM implants are usually fabricated from a cobalt-chrome alloy. Cobalt activates human 
Toll-like receptor 4 (TLR4), an innate immune receptor also activated by bacterial 
lipopolysaccharide (LPS). This study set out to investigate the inflammatory 
consequences of cobalt-mediated TLR4 activation through a series of in vitro assays 
developed throughout this work.  
In human MonoMac 6 macrophages cobalt was found to increase secretion and 
expression of pro-inflammatory cytokines including IL-8, IL-6 and CCL20. Using IL-8 
as a marker of TLR4 activation a small molecule TLR4 antagonist, CLI-095, was shown 
to inhibit these effects, indicating that they are TLR4-dependent. Similar responses were 
observed in endothelial cells and osteoblasts. A monoclonal anti-TLR4 neutralising 
antibody inhibited cobalt-mediated IL-8 expression and secretion, while a polyclonal 
anti-TLR4 neutralising antibody did not.  
Further investigation showed that cobalt-mediated TLR4 activation increases expression 
of intercellular adhesion molecule 1 (ICAM1) and its soluble form sICAM-1. It also 
promotes primary monocyte and neutrophil migration. A TLR4 mutation did not prevent 
inflammatory responses to cobalt, although further assay optimisation is required. Co-
stimulation of MonoMac 6 cells with cobalt and LPS or nickel caused downregulation of 
IL6, CCL2 and IL8 expression. Finally, unlike cobalt, chromium and strontium ions did 
not activate TLR4 and did not induce IL-6 or IL-8 secretion in macrophages.  
In summary, this study has shown that TLR4 activation by cobalt ions from MoM hip 
implants results in increased cellular inflammatory responses. The use of TLR4 inhibitors 
in this study suggests that TLR4 is a potential therapeutic target in ARMD. Overall, the 
TLR4 signalling pathway is an interesting avenue for further investigation into factors 
underlying MoM implant failure.  
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Chapter 1. Introduction 
1.1. Total hip replacement 
Total hip replacement (THR) is a major therapeutic intervention for those with end-stage 
joint diseases such as osteoarthritis and rheumatoid arthritis. In these conditions the 
cartilage that forms the articulating surface of the hip joint is worn away, increasing 
friction and causing pain. The modern THR was devised by Sir John Charnley in 1962 
and involves removal of the femoral head and acetabular component of the affected hip 
and replacement with a prosthetic joint implant. The structure of a modern THR is shown 
in Figure 1.1. In the majority of cases THR restores hip function and alleviates the pain 
caused by damaged joints (Ng et al., 2007), making it one of the most successful surgical 
interventions of recent times.  
1.1.1. THR biomaterials 
Charnley’s first THR consisted of a metal femoral stem and a polyethylene (plastic) 
acetabular component, cemented into the bone using an acrylic cement (Charnley, 1964, 
Knight et al., 2011). Most modern day THRs have a metal femoral stem and trunnion 
(Figure 1.1) while the bearing surfaces are made from metal, ceramic or polyethylene; 
these can be used in combination, for example a metal femoral head with a polyethylene 
liner (termed metal-on-polyethylene, MoP). The same materials can be used for both 
bearing surfaces, such as the metal-on-metal THR shown in Figure 1.1. The material 
composition of THRs is constantly being modified to reduce wear rates, provide 
improved biocompatibility, and increase implant longevity. These changes are also 
increasingly required to meet the needs of a patient population with a rapidly altering 
demographic.  
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Figure 1.1: Total hip replacement structure 
Structure of a metal-on-metal total hip replacement. Image obtained and adapted 
from www.medicalplasticsnews.com. 
1.1.2. THR patient demographic 
Osteoarthritis (OA) is usually the result of joint ‘wear and tear’ and is the leading 
indication for THR (Powers-Freeling, 2015). OA can result from the damage caused by 
constant joint use over a lifetime, as well as increased stress placed on a joint if an 
individual is overweight. As such, OA development is closely correlated with age and 
obesity (Messier et al., 2005, Sowers and Karvonen-Gutierrez, 2010). The UK has an 
ageing population and an ever-increasing problem with obesity meaning that the number 
of OA cases is on the rise (Conaghan et al., 2014). Higher obesity rates coupled with 
improved methods of OA detection have resulted in rising rates of hip OA; 8% of people 
over the age of 45 have hip OA (Chidambaram and Cobb, 2009, Jordan et al., 2009). To 
combat obesity and the effects of ageing, an active lifestyle is encouraged and this also 
contributes to the joint damage that can result in OA.  
Increased numbers of OA cases, as well as those of other joint conditions, have caused 
the number of THRs performed worldwide annually to grow rapidly. In 2003 there were 
14,424 reported primary THR surgeries in England and Wales and by 2014 this had 
reached 88,125 (Powers-Freeling, 2015) (Figure 1.2). As each THR procedure costs 
upwards of £6000 they place a considerable financial burden on the NHS (Hamilton et 
al., 2009). In the USA the number of hip replacements per year is predicted to reach 
572,000 by 2030 (Kurtz et al., 2007) and similar increases are forecast across Europe 
(Singh, 2011). In addition younger patients increasingly require THR surgery with 50% 
of all hip replacements predicted to be in people under 65 by 2030 (Kurtz et al., 2009). 
Acetabular cup (metal)
Femoral head (metal)
Trunnion
Femoral stem
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Figure 1.2: Total number of primary hip replacement procedures in England 
and Wales from 2003-2014.  
Figure adapted from data in the National Joint Registry 2015 (Powers-Freeling, 
2015). 
THR is very successful at restoring joint mobility and improving patient quality of life 
(O'Boyle et al., 1992). However the changing THR patient demographic has revealed 
problems with conventional ceramic-on-polyethylene and metal-on-polyethylene hip 
implants. Younger THR patients (i.e. under 50 years old) are more likely to experience 
THR failure (Girard et al., 2011) and require revision surgery in which the failed hip 
implant is replaced with a new device. The revision procedure is more complex than a 
primary THR procedure because of reduced bone stock but remains the only way of 
resolving a failed joint replacement. Higher THR failure rates among a younger 
population also means that they may require multiple surgeries in their lifetime (Berry et 
al., 2002); this issue is compounded by the UK’s ageing population and therefore the 
number of revisions performed each year is rising rapidly (Powers-Freeling, 2015). There 
is a higher rate of complications for revisions in younger individuals (Girard et al., 2011). 
Consequently the need has arisen for hip implants that will be hard-wearing and long-
lasting with the aim of reducing the risk of revision. This has led to the development of 
metal-on-metal (MoM) hip implants.  
1.2. Metal-on-metal hip replacement 
In a MoM THR both of the bearing surfaces (i.e. femoral head and acetabular cup liner) 
are fabricated from metals including cobalt, chromium and molybdenum. Titanium can 
also be used in the trunnion and femoral stem of MoM implants The first generation of 
MoM implants (McKee and Watson-Farrar, 1966) was used from the 1960s to the 1980s 
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with mixed results. Although successes were reported (Djerf and Wahlström, 1986) the 
hip implants ultimately showed unacceptably high levels of failure(August et al., 1986). 
This was largely due to osteolysis (breakdown of the bone surrounding the implant) which 
reduced the stability of the implant. In the absence of infection this is termed aseptic 
loosening. Following improvements in design and manufacture, second generation MoM 
hip replacements were introduced in the 1990s. In these newer implants the bearing 
surfaces are usually made from a cobalt-chrome-molybdenum (CoCrMo) alloy and they 
were considered to have decreased wear rates compared to metal-on-polyethylene and 
ceramic-on-polyethylene devices. Second generation MoM implants also allowed the 
reintroduction of MoM hip resurfacing in which a shorter femoral stem is used meaning 
that more bone is preserved (Figure 1.3A). Resurfacings were more commonly used in 
younger patients and were reported to have similar success rates to conventional THRs 
(Figure 1.3B) (Mont et al., 2009).  
 
Figure 1.3: Metal-on-metal hip resurfacing versus hip replacement 
A. Hip resurfacing in which a shorter femoral stem is used for greater bone 
preservation. B. Conventional total hip replacement. Images were provided by Mr Jim 
Holland (Consultant orthopaedic surgeon, Freeman Hospital, Newcastle upon Tyne). 
 
Initial reports on these new MoM hip implants were positive (Long, 2005) and showed 
little indication of the component loosening or osteolysis that led to the failure of first 
generation MoM implants (Dorr et al., 2000). As a result their use increased dramatically, 
particularly among the younger patient population. However studies soon began to report 
high failure rates for MoM implants compared to ceramic-on-polyethylene and metal-on-
polyethylene devices. Some types of implant seemed at greater risk of failure than others; 
the DePuy Articulating Surface Replacement (ASR) has a 7-year failure rate of 48.8% for 
the total hip replacement and 25% for the hip resurfacing  (Langton et al., 2011a). In 
contrast, a 10-year survival rate of 92% is reported for the Birmingham Hip Resurfacing 
(Holland et al., 2012, Jameson et al., 2012).  
A. B.
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1.3. Adverse reactions to metal debris (ARMD) 
The major cause of MoM implant failure is the development of adverse reactions to metal 
debris (ARMD) (Langton et al., 2011b). ARMD is an umbrella term given to conditions 
associated with MoM implants including soft tissues necrosis, osteolysis, metallosis, 
aseptic implant loosening, and the development of benign growths known as 
pseudotumours (Daniel et al., 2012). It has also been termed adverse local tissue reaction 
(ALTR) but for the purposes of this study ARMD will be used. ARMD can present as 
pain or swelling in the joint and groin area, or the feeling that the hip is ‘giving way’. 
Predicting and diagnosing ARMD is made more challenging because it is estimated that 
up to 50% of MoM patients could have asymptomatic ARMD (e.g. where a pseudotumour 
is detected by an MRI scan (Kwon et al., 2011, Wynn-Jones et al., 2011)). MoM failure 
as a result of adverse reactions normally requires revision to a different type of implant 
(e.g. metal-on-polyethylene) and is responsible for the high MoM THR and resurfacing 
revision rates shown in Figure 1.4A. MoM patients have a 12-13% risk of revision 7 
years post-surgery while for other bearing types the incidence is just 2-3% within the 
same timeframe (Powers-Freeling, 2015). The revision procedure usually reduces metal 
ion levels in the body and resolves ARMD (Lainiala et al., 2015) which strongly suggests 
a link between metal release from the hip implant and the development of ARMD.   
The impact of concerns surrounding MoM implants, ARMD development, and the 
increased revision risk can be clearly seen in Figure 1.4B. The use of primary MoM hip 
replacements peaked in 2007 and has since declined dramatically, now representing <1% 
of all hip replacements (Powers-Freeling, 2015). However understanding ARMD remains 
important because there are still an estimated 1 million patients with MoM hips 
worldwide (AAOS, 2012) and ARMD can develop at any time. Furthermore, MoM hip 
joints are still being implanted and metals are present in existing and new medical devices 
such as knee replacements and dental implants. A greater understanding of their 
biological effects could therefore benefit many patients with a broad range of conditions.  
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Figure 1.4: MoM hip revision rates and use 
A. Estimated revision rates for metal-on-metal hip replacement (MoM), metal-on-
metal hip resurfacing (MoM resurfacing) and metal-on-polyethylene hip 
replacement (MoP). B. Use of MoM hip replacements from 2003-2014 shown as a 
percentage of all uncemented primary hip replacements. Data for figures was 
obtained from the National Joint Registry Annual Report 2015, available online at 
www.njrcentre.org.uk.
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1.3.1. Metal debris 
Release of wear debris occurs in all hip replacements because of the large range of motion 
and constant surface articulation. Although MoM implants were designed to have low 
wear rates compared to their counterpart ceramic-on-polyethylene and metal-on-
polyethylene devices, many have actually been shown to have increased wear rates and 
consequently more debris is released than was previously anticipated (De Smet et al., 
2008, Kwon et al., 2011, Bosker et al., 2012). In most hip replacements the main debris 
release comes from the two articulating bearing surfaces and in the case of MoM implants 
this results in cobalt and chromium being released as debris or ions. Larger debris can 
also be corroded by the biological environment, resulting in the generation of metal ions. 
In addition to bearing surface articulation, corrosion at the femoral head-neck junction or 
trunnion can occur (see Figure 1.1 for THR structure). Trunnions are usually 
manufactured from a titanium-aluminium or CoCr alloy (Porter et al., 2014) and wear at 
this junction can result in metal debris and ion release. Trunnion wear is a significant 
clinical problem because metal trunnions are used in metal-on-polyethylene and ceramic-
on-polyethylene implants as well as MoM, and have been associated with adverse 
reactions in MoP devices (Whitehouse et al., 2015). Consequently, although the majority 
of ARMD cases develop in MoM implant patients, patients with other types of hip implant 
can also be affected.  
1.3.2. Cobalt as a biomaterial 
The main focus of this study is on cobalt ions as they are often found at higher levels 
around MoM implants than chromium or molybdenum (Whitehouse et al., 2015), and 
also have a stronger association with adverse responses (Ninomiya et al., 2013). Cobalt 
is present in the body in trace amounts (<0.3µg/L) as an important human micronutrient 
that forms a component of vitamin B12 (Yamada, 2013). Vitamin B12 is required for 
DNA synthesis, amino acid metabolism (Boss, 1985) and nervous system function 
(Reynolds, 2006, Kandula et al., 2014). Environmental exposure to cobalt comes from 
industrial sources such as in dust formed from tungsten carbide synthesis, or medical 
implants including MoM hip replacements, coronary artery stents, and spinal hardware 
used in scoliosis treatment.  
Even before problems surrounding MoM implants emerged, the potential toxic or harmful 
effects of cobalt have been studied because of exposure of industry workers to the metal 
via inhalation or skin contact (Bucher et al., 1999). Cobalt toxicity, also referred to as 
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cobaltism, can lead to neurological symptoms including dizziness, blindness and impaired 
cognitive function, as well as cardiomyopathy (Stephen, 2012). Cobaltism is a rare 
condition associated with high systemic levels of cobalt ions (>60μg/L (Tower, 2010)) 
and is not usually linked to MoM hip implants, although a small number of cases have 
been reported (Machado et al., 2012, Stephen, 2012, Bradberry et al., 2014). In MoM hip 
replacement patients, cobalt concentrations are at their highest around the joint as debris 
and ions are released during implant articulation. Cobalt cannot be broken down 
metabolically but it can travel systemically and has been detected in the blood, urine and 
hair of MoM hip patients (Rodríguez De La Flor et al., 2013). 
Following the reports of high MoM failure rates and debris release, as well as local and 
systemic adverse effects, safe upper limits were proposed for blood metal ion 
concentrations, above which clinical investigation is recommended. The safe levels vary 
from study to study; Van Der Straeten et al reported 95% specificity in using 4μg/L 
(unilateral) or 5μg/L (bilateral) cobalt as a predictor of poor MoM implant function (Van 
Der Straeten et al., 2013). The Medicines and Healthcare Products Regulatory Agency 
(MHRA) set the upper cobalt limit slightly higher at 7 parts per billion or 119nmol/L 
(MHRA, 2015). However patients with metal concentrations within these limits may still 
develop adverse reactions.  
1.3.3. Patient variability in ARMD development 
It is evident from previous studies that excessive wear of MoM implants is associated 
with ARMD development, although the mechanisms that result in these effects remain 
unknown. However the situation is more complicated than a direct correlation between 
implant wear, metal ion release, and progression to ARMD. Firstly, not every patient with 
a MoM implant develops an adverse reaction, showing that they can be beneficial and 
work effectively in the ‘right’ patient. Secondly, there is a proportion of patients that do 
not show any association between metal ion concentrations and risk of ARMD 
development. Langton et al found that tissue damage observed in patients undergoing 
revision for MoM failure was not related to increased wear or metal ion concentrations 
(Langton et al., 2011b), and similar results have been reported in more recent studies 
(Bayley et al., 2014, Campbell et al., 2014, Ebramzadeh et al., 2014, Krishnan et al., 2015, 
Hjorth et al., 2016).  
Identifying patients who will respond well to a MoM implant is extremely difficult due 
to the multifactorial nature of ARMD which appears to involve both mechanical (e.g. 
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implant misalignment and increased wear) and biological factors. The biological factors 
can vary both in terms of the exact presentation of the reaction (i.e. a pseudotumour may 
be a solid fibrotic mass or a fluid-filled cyst-like growth (Pandit et al., 2008)) and in 
severity; some patients may be asymptomatic and a pseudotumour is only detected by an 
MRI scan while others experience severe pain and considerable loss of mobility (Kwon 
et al., 2011).  
Additional patient variability is introduced by gender. Sixty percent of patients receiving 
a primary THR in 2014 were female (Powers-Freeling, 2015) and ARMD is also more 
common in women than men (Smith et al., 2012). This bias is particularly prevalent 
following hip resurfacing and applies to aseptic loosening, osteolysis and overall risk of 
revision, as well as to rarer complications such as dislocation (Glyn-Jones et al., 2009, 
Haughom et al., 2015). Studies have suggested that the gender disparity is due to the 
smaller implant size used in female patients, or an increased likelihood of metal ion 
sensitisation in women through wearing nickel-containing jewellery. However these 
factors cannot explain every ARMD case. It has also been noted that while being female 
does increase a patient’s risk of MoM implant failure, there must be underlying causative 
factors that lead to this outcome, rather than gender alone (Amstutz and Le Duff, 2015), 
supporting a role for additional biological factors in ARMD.  There is also a correlation 
between age, gender and risk of revision, with young female patients most at risk of MoM 
implant failure and subsequent revision (Table 1.1) (Powers-Freeling, 2015). No data 
was available for females aged 75+ and this is probably because resurfacings are used in 
younger individuals.  
The lack of association between ARMD and metal ion levels, coupled with the high 
degree of patient variability, point to complex biological factors involved in adverse 
reactions. Consequently it is essential to improve the understanding of the biology 
underlying ARMD to reduce its incidence and improve the longevity of hip replacements.  
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Risk of revision at 10 years (%) 
MoM hip replacement 
Age (years) Males Females 
<55 19.48 28.37 
55-64 17.72 24.04 
65-74 16.04 23.37 
75+ 9.83 12.31 
MoM hip resurfacing 
<55 8.86 21.63 
55-64 8.21 19.54 
65-74 9.09 16.32 
75+ 5.24 - 
MoP hip replacement 
<55 6.35 5.33 
55-64 6.22 4.91 
65-74 4.79 3.40 
75+ 3.94 3.53 
Table 1.1: Risk of revision 10 years post-THR by gender, age and implant 
material 
Risk of revision 10 years after surgery is increased in younger women with MoM 
replacements and resurfacings compared to older women and men. MoP data is 
included for comparison (Powers-Freeling, 2015).  
  
1.4. Immune response to wear debris 
The focus of this study was to understand the cellular responses to metal ions from MoM 
joint replacements. However there is a large body of work on the inflammatory response 
to wear debris from other types of hip implant that can inform the specific study of 
reactions to metal ions. In the following sections ‘wear debris’ will be used in reference 
to studies of non-metal bearings (e.g. ultra-high molecular weight polyethylene 
(UHMWPE) and ceramic) while ‘metal debris’ or ‘metal ions’ will be used for MoM 
implants.  
Ceramic-on-polyethylene and metal-on-polyethylene hip replacements generally have 
excellent survival rates compared to MoM implants (Kandala et al., 2015) but can still 
fail after many years of use. Given significant advances in biomedical engineering, the 
causes of failure are usually due to biological factors such as osteolysis and subsequent 
implant loosening. Studies have indicated that osteolysis is a result of persistent, low-
grade inflammation caused by the presence of wear debris from the implant (Goodman et 
al., 2013a), and suggests a role for the immune system in hip implant failure. The other 
clinical signs of ARMD such as swelling, pain and soft tissue necrosis are all hallmarks 
of inflammation, further suggesting involvement of the immune system.  
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All patients undergoing THR surgery will develop an immune response as a natural and 
necessary reaction to surgical trauma and the presence of a foreign implant. In the 
majority of cases this initial ‘running-in’ phase is short-lived and the immune system soon 
adapts to the presence of the implant because they are designed to have excellent 
biocompatibility. In a minority of patients it appears that the immune system remains 
activated, resulting in the persistent production of inflammatory mediators, chronic 
inflammation, and ultimately implant failure. This is likely to be a result of exposure to 
wear debris, and in the case of ARMD to metal debris and ions. However the mechanisms 
that lead to the immune response to metals are unknown.  
The innate immune system is at the forefront of the inflammatory response to pathogen 
invasion and as such is also the first component of the immune system to encounter wear 
debris from orthopaedic implants. Innate immune cells such as macrophages are present 
in the synovial fluid that lubricates the hip implant as well as in the synovial membrane, 
and they participate in pathogen and debris removal. Innate immunity appears to be the 
main mediator of wear particle-induced inflammation because mice without functioning 
adaptive immunity develop similar adverse responses to wear debris as those with a full 
immune system (Taki et al., 2005). Neutrophils and eosinophils are found at low levels 
in failed MoM peri-implant tissues but it is macrophages that dominate the innate immune 
cell infiltrate (Mahendra et al., 2009, Pajarinen et al., 2010, Dapunt et al., 2014, Perino et 
al., 2014). As such they are considered one of the main targets for wear debris and metal 
ions (Gu et al., 2012) and therefore there has been considerable research into their role in 
adverse reactions to orthopaedic implants. 
1.4.1. Development and function of monocytes, macrophages and 
neutrophils 
The majority of immune cells are derived from pluripotent haematopoietic stem cells 
(HSCs) in the bone marrow. HSCs have the potential to become any type of immune cell 
but begin to differentiate down two distinct lineages, the lymphoid or myeloid lineage. 
Lymphoid progenitor cells ultimately develop into B and T lymphocytes, or natural killer 
cells. Myeloid progenitor cells develop into crucial innate immune cells, including 
eosinophils, neutrophils, monocytes and basophils. As the present study is investigating 
innate immune responses, the focus of this section will be on the development of 
monocytes, macrophages and neutrophils.   
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HSCs destined for the monocyte lineage first develop into common myeloid progenitor 
cells, followed by monoblasts and pro-monocytes before becoming monocytes. This 
differentiation requires growth factors including macrophage colony-stimulating factor 
(M-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF). Following 
their differentiation in the bone marrow, monocytes enter the circulation where they have 
a surveillance function and can phagocytose any encountered pathogens. After several 
days in the circulation monocytes migrate into the tissues where they undergo further 
maturation to become macrophages. Myeloid progenitor cells can also develop into 
immature dendritic cells which ultimately become mature dendritic cells upon entering 
the tissues. It should be noted that as well as bone marrow-derived macrophages, other 
tissue resident macrophages arise directly in the tissues during embryonic development 
and do not develop from monocytes or enter the circulation.  The exact macrophage 
phenotype depends on specific stimuli received in the tissues, including factors secreted 
or expressed on the surface of neighbouring cells and the extracellular matrix. Examples 
of tissue-specific macrophages are Kupffer cells (liver) and Langerhans cells (dendritic 
cells in the skin and mucosa). Monocytes can also be recruited directly to pathogen-
affected tissues by inflammatory cytokines such as CCL2, and once at the site of 
inflammation they mature into macrophages.  
The most widely described function of macrophages is phagocytosis (‘macrophage’ 
means ‘big eaters’ in Greek) but they are also capable of inflammatory cytokine and 
chemokine secretion, and antigen presentation to stimulate adaptive immune responses. 
In addition, many specialised tissue macrophages (e.g. Kupffer cells) also regulate tissue 
homeostasis, for example by clearing senescent or dead cells. They can also fuse together 
to form multi-nucleated giant cells (MGCs) which promote inflammation. MGCs have 
been identified in failed MoM peri-implant tissues (Carli et al., 2011) where they aid 
osteoclast formation (known as osteoclastogenesis) and this could in turn contribute to 
aseptic loosening. The function of macrophages in inflammatory responses is described 
in more detail later in this section. 
Neutrophils arise from the same pluripotent HSCs as monocytes but develop down a 
different lineage, becoming myeloblasts, promyelocytes and then neutrophilic 
myelocytes. This process includes the development of intracellular granules that 
eventually characterise mature neutrophils. Like monocytes, neutrophils are also released 
into the circulation from the bone marrow but only circulate for 6-10h before they enter 
the tissues. Neutrophils perform several functions that are critical to pathogen eradication. 
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They phagocytose pathogens into intracellular vesicles where the ingested organism is 
degraded by enzymes; this process is described in more detail in the next paragraph. 
Degranulation is another feature of neutrophils and involves the release of factors 
previously stored in granules, including matrix metalloproteinases (collagenases and 
gelatinases), defensins, and lysozymes which target bacterial cell walls. Neutrophils also 
released nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and through a 
series of chemical reactions this results in the generation of hydrogen peroxide and then 
hypochlorous acid, which is highly toxic to bacteria. All of these factors function to 
provide an initial and effective response against pathogen invasion.  
As mentioned previously, phagocytosis is a major function of both macrophages and 
neutrophils, and wear debris phagocytosis has been studied in-depth in the context of 
ARMD. Phagocytosis involves pathogen endocytosis, which occurs when a phagocyte 
uses its plasma membrane to surround and internalise a pathogen in an intracellular 
vesicle known as a phagosome. The phagosome then fuses with lysosomes to form a 
phagolysosome. Here the pathogen is degraded by a range of mechanisms including 
enzymes (NADPH oxidase, DNases, lipases and proteases) and antimicrobial peptides 
(defensins, lactoferricin). Pathogen internalisation also leads to further macrophage 
activation and increased release of pro-inflammatory cytokines and chemokines to 
coordinate subsequent immune responses. In some cases, digested components of the 
antigen may also be presented by the phagocyte to trigger adaptive immunity. Wear debris 
from joint replacements can be opsonised by human serum proteins, including 
complement proteins, albumin and alpha-1 antitrypsin, which promotes macrophage 
activation and particle phagocytosis (Sun et al., 2003). Sun et al found that the pattern of 
opsonising proteins was unique to each particle tested; for example, CoCr debris was 
opsonised by albumin and alpha-1 antitrypsin, while polyethylene debris could also be 
opsonised by apolipoprotein (Sun et al., 2003).  
Phagocytosed debris has been observed in macrophages present in tissues surrounding 
aseptically-loosened hip implants (Lähdeoja et al., 2009). However wear debris presents 
a complex problem to phagocytes for several reasons. Firstly, implant wear results in the 
constant generation of debris to challenge the immune system and if the debris is difficult 
to break down it may result in persistent cell activation and inflammation. Secondly, 
Scharf et al showed that macrophages can generate ions from phagocytosed cobalt and 
chromium nanoparticles, which could perpetuate the inflammatory response (Scharf et 
al., 2014). Finally, in the case of MoM implants, cobalt ions have been shown to reduce 
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the phagocytic function of neutrophils (Rae, 1983) which could complicate the response 
to both the metal ions themselves and any infection that may develop around the joint. 
1.4.2. Cytokine and chemokine release 
As previously mentioned phagocytosis leads to cytokine and chemokine secretion by the 
phagocytic cell. However cytokines and chemokines are not just by-products of 
phagocytosis but can also be released via different mechanisms such as activation of 
innate immune receptors, and they have critical functions in inflammation. Cytokines are 
small (<30kDa) secreted molecules involved in cell signalling and communication. 
Chemokines (chemotactic cytokines) are a subclass of cytokines that coordinate cell 
migration or chemotaxis. Chemokines can be classified into structurally distinct groups 
based on the location of the first cysteine residues in their amino acid sequences. The 
main classes of chemokines described in this study belong to either the CC chemokines 
where there are two adjacent cysteine residues near the N-terminus (e.g. CCL2), or to the 
CXC chemokines where one amino acid separates the two cysteine residues (e.g. 
CXCL12).  
Cytokines and chemokines are released when a cell encounters a pathogen such as a 
bacteria or virus. They coordinate cell migration, adhesion, proliferation, activation and 
maturation, and exert their effects by binding to specific receptors on their target cell. 
There is a high degree of redundancy among cytokines and chemokines with many having 
overlapping functions and binding to the same receptor. Although they mediate 
inflammatory responses their release is not limited to immune cells as endothelial cells, 
fibroblasts and numerous other cell types can also secrete cytokines and chemokines. In 
the context of adverse reactions to wear debris, persistent chemokine release results in 
chronic inflammation, fibrosis, and osteolysis (Fahey et al., 2014, Chu et al., 2015). 
Macrophages secrete cytokines and chemokines but their activity can also be regulated 
by them, particularly in the context of polarisation and differentiation. Macrophage 
polarisation occurs when cells are driven towards a particular phenotype by external 
stimuli. Macrophages are often classified into two phenotypically distinct subsets, M1 
(pro-inflammatory) and M2 (anti-inflammatory), although it has been suggested that there 
should be a more comprehensive classification based on pathogen recognition, cell 
activation, and interaction with other immune cells (Martinez and Gordon, 2014). As 
most wear particle studies describe M1 and M2 macrophages, the nomenclature will be 
used in this section. However as the classification needs updating to reflect the complexity 
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and diversity of macrophage activation and function, it will not be used extensively 
elsewhere in this thesis.  
M1 macrophages are induced by lipopolysaccharide (LPS) and interferon gamma (IFNγ) 
and secrete high levels of pro-inflammatory cytokines and chemokines such as 
interleukin-12 (IL-12), interleukin-23 (IL-23), and chemokine (C-C motif) ligand 2 
(CCL2) (Duque and Descoteaux, 2014). They are also responsible for driving Th1 (pro-
inflammatory, microbicidal) inflammatory responses. In contrast, M2 macrophages 
develop upon interleukin-4 (IL-4) exposure and have an immunomodulatory phenotype, 
secreting anti-inflammatory interleukin-10 (IL-10) and promoting tissue repair functions 
such as fibrosis.  
There is conflicting data on the role of macrophage polarisation in adverse reactions to 
wear debris. Jämsen et al found that the cytokine profile induced by wear debris does not 
induce a specific M1 or M2 macrophage profile, indicating the importance of cellular 
activation by the wear debris itself (Jämsen et al., 2014). However other studies have 
reported increased levels of M1 polarising macrophages in tissues surrounding aseptically 
loosened hip implants, suggesting that M1 macrophages may promote osteolysis and 
implant loosening (Gallo et al., 2013).  
1.4.3. Osteolysis 
The balance of osteoblast (bone-forming) and osteoclast (bone-resorbing) cells is crucial 
to maintaining bone homeostasis. These cells regulate the bone remodelling that is 
required for normal development but their balance can be disrupted, resulting in skeletal 
disorders including osteoporosis. The role of osteoblasts and osteoclasts is of interest to 
the present study because a drive towards osteoclastogenesis can promote the osteolysis 
that leads to aseptic implant loosening. Aseptic loosening is the leading indication for hip 
implant failure (regardless of bearing surface type), accounting for 46% of all revision 
procedures in 2009-2014 (Powers-Freeling, 2014), and is also one of the characteristics 
of ARMD. Loosening is the result of osteolysis, which is mediated by osteoclasts and 
macrophages. Consequently, considerable research has focused on the effects of wear 
debris on these cells (Ingham and Fisher, 2005, Nich et al., 2013) and their potential as 
therapeutic targets in the prevention of aseptic loosening (Chen et al., 2015).   
Osteoclasts are essential in normal physiology, and resorb bone by secreting acid, matrix 
metalloproteinases (MMPs), and cathepsin K, a hydrolytic enzyme that degrades 
collagen. However in ARMD they appear to have a detrimental effect, resulting in 
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osteolysis and implant loosening. Like macrophages, osteoclasts are of haematopoietic 
stem cell origin and develop down the same lineage to become monocytes. Osteoclast 
precursor cells develop when monocytes are exposed to TNFα and IL-1. The 
differentiation of these precursor cells into osteoclasts is driven by interactions between 
receptor activator of nuclear factor kappa-B (RANK) on their surface, and its ligand 
RANKL which is expressed by osteoblasts on the bone surface (Figure 1.5). Interaction 
between these two cell surface proteins initiates a signalling cascade in osteoclast 
precursor cells that promotes the upregulation of osteoclastogenic genes such as tartrate-
resistant acid phosphatase (TRAP) and ultimately drives osteoclast formation. The 
precursor cells also fuse together to form multinuclear osteoclasts. Osteoprotegerin 
(OPG) can act as a soluble decoy molecule for osteoclastogenesis by binding to RANKL 
and preventing its interaction with RANK, which stops the precursor cell from developing 
into an osteoclast (Figure 1.5). Cobalt and chromium ions can have a direct effect on the 
RANK/RANKL/OPG axis by decreasing the ratio of OPG to RANKL and promoting 
osteolysis (Zijlstra et al., 2012). In addition they can also have an indirect effect by 
increasing the secretion of pro-inflammatory cytokines and chemokines which creates an 
environment favouring M1 macrophage formation and thus osteoclast development 
(Adamopoulos and Mellins, 2015).  
 
Figure 1.5: RANK/RANKL/OPG axis in osteoclast formation 
RANK is expressed by osteoclast precursors and can bind RANKL which is 
expressed on osteoblasts and stromal cells. Engagement of the two molecules drives 
cell fusion, multinuclear osteoclast formation and subsequent osteolysis. 
Osteoprotegerin is a decoy molecule that can bind RANKL, preventing osteoclast 
differentiation.  
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It is widely recognised that cytokines and chemokines contribute to ARMD development 
and progression but the nature of their involvement is highly complex and not fully 
understood. Much of the current research into adverse reactions focuses on cytokines and 
chemokines in osteolysis as bone breakdown causes aseptic loosening of the implant. The 
role of inflammatory cytokines in osteolysis is complex and the same cytokine can have 
multiple and even opposing functions in osteoclastogenesis. This is particularly the case 
for IL-6 which can reportedly promote osteoclastogenesis by RANKL-dependent 
(Hashizume et al., 2008) and independent (Kudo et al., 2003) mechanisms. However 
other studies have indicated that the IL-6 signalling pathway has a protective effect on 
bone by downregulating NFκB signalling, decreasing the expression of osteoclastogenic 
genes, and thereby preventing osteoclast development (Yoshitake et al., 2008). Other 
cytokines including tumour necrosis factor α (TNFα) can also stimulate osteoclast 
formation by increasing cellular RANKL expression (Zhang et al., 2001, Kitaura et al., 
2004) while IL-8 can drive osteoclastogenesis via RANKL-independent mechanisms 
(Bendre et al., 2003, Kamalakar et al., 2014).   
In addition to increased activity of osteoclasts, osteolysis can also develop through 
reduced activity of bone-forming osteoblasts. Wear debris increases inflammatory 
cytokine and matrix metalloproteinase-1 (MMP-1) secretion by osteoblasts and at the 
same time decreases their ability to synthesise collagen (Lochner et al., 2011); it is 
particularly interesting to note that the most dramatic effects were observed with CoCrMo 
debris compared to titanium and stainless steel. Furthermore, osteoblasts exposed to 
cobalt ions secrete IL-8 and CCL2, and display compromised calcium deposition ability 
compared to untreated controls (Queally et al., 2009). Taken together this information 
highlights the importance of cytokines and chemokines in adverse reactions to wear 
debris. 
1.4.4. Adaptive immune response in ARMD 
As well as innate immunity, the adaptive immune system is also implicated in ARMD as 
immunohistochemical analysis has shown that MoM peri-implant tissues are infiltrated 
by lymphocytes (Davies et al., 2005, Natu et al., 2012). This is termed aseptic 
lymphocyte-dominated vasculitis-associated lesion, or ALVAL (Watters et al., 2010). 
The lymphocyte-dominated nature of ALVAL led researchers to suggest that adverse 
reactions to metal ions are due to Type IV hypersensitivity (Catelas et al., 2015). Type IV 
hypersensitivity or delayed hypersensitivity is a cell-mediated response driven by T 
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helper 1 (Th1) cells. Metal ions can act as haptens and are presented by dendritic cells to 
T lymphocytes causing them to assume a Th1 (pro-inflammatory) phenotype (Thierse et 
al., 2005). The activity of Th1 cells stimulates further macrophage proliferation and 
inflammatory responses including fibroblast development. In view of the apparent 
hypersensitivity response, patch testing for metal allergies has been suggested as a 
method of predicting implant failure and has been reported as an effective method in some 
cases (Granchi et al., 2012). However the role of Type IV hypersensitivity as the sole 
cause of MoM implant failure has been contradicted by several studies. Kwon et al used 
a lymphocyte proliferation assay to investigate the cellular response in patients with 
pseudotumours following MoM arthroplasty (Kwon et al., 2010). They found that there 
was no difference in lymphocyte proliferation in response to cobalt, chromium and nickel 
between patients with or without pseudotumours (Kwon et al., 2010). Furthermore, metal 
allergies are not associated with increased risk of revision surgery (Thyssen et al., 2009). 
Although this does not rule out metal hypersensitivity as a cause of ARMD, it suggests 
that there are other reactions taking place in response to MoM implants and this is 
supported by ARMD cases where macrophages dominate the inflammatory infiltrate.  
In summary, the immune system clearly plays a significant role in the development of 
adverse reactions to wear debris, including metal ions. Cytokines and chemokines 
released by immune cells mediate adverse effects including osteoclast formation and 
osteolysis. However the mechanisms that lead to the initiation of these responses are 
unclear.    
1.5. Metal ions and the Toll-like receptor family 
1.5.1. Nickel and TLR4 
Nickel is widely used in everyday items such as jewellery and coins, and generates the 
metal ions most commonly associated with hypersensitivity. More than 8% of North 
American and European populations has a nickel allergy (Thyssen et al., 2007) and in 
young females the prevalence can reach nearly 20% (Carøe et al., 2011). The major 
clinical manifestation of this allergy is skin hypersensitivity and resulting allergic contact 
dermatitis.  
In 2010 Schmidt et al investigated the mechanisms by which nickel can cause contact 
hypersensitivity reactions. It was already understood that nickel hypersensitivity is the 
result of antigen presentation to T lymphocytes by dendritic cells which creates a 
population of T cells sensitised to the metal ion. Upon re-exposure the T cells react against 
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nickel but a second inflammatory stimulus is required for a complete immune response 
and it was not clear what this stimulus might be. Nickel ions upregulate NFκB activity 
and increase release of pro-inflammatory cytokines (Goebeler et al., 1995). Schmidt et al 
recognised that the first step in pathogen-mediated pro-inflammatory cytokine secretion 
is usually activation of a series of cell surface and intracellular receptors known as pattern 
recognition receptors (PRRs) which recognise pathogens. These include receptor families 
such as the Toll-like receptors (TLRs) and nucleotide oligomerisation domain (NOD)-
like receptors (NLRs). The authors hypothesised that nickel ions can activate one or more 
of these PRRs leading to an immune response (Schmidt et al., 2010).  
The first challenge for Schmidt et al was to identify which receptor family might be 
implicated in the inflammatory response to nickel. PRRs induce diverse intracellular 
signalling cascades and therefore specific proteins involved in these cascades were 
investigated. Myeloid differentiation primary response gene 88 (MyD88) is an adaptor 
protein essential for signalling via the TLRs. Knockdown of MyD88 in endothelial cells 
was found to abrogate nickel-induced cytokine secretion, suggesting that the TLRs are 
involved in the response (Schmidt et al., 2010).   
TLR4, a member of the TLR family, is activated by bacterial lipopolysaccharide (LPS). 
The study authors observed similarities between the LPS and nickel-induced cytokine 
responses, including increased IL-8 secretion. TLR4 was transfected into human 
embryonic kidney (HEK) 293 cells which do not express any endogenous TLRs and the 
cells were then challenged with nickel ions. HEK293/TLR4 cells significantly increased 
IL-8 production in response to nickel ions compared to untransfected controls, and 
showed that nickel can activate TLR4. The involvement of other TLRs was eliminated 
because their transfection into HEK293 cells did not elicit inflammatory responses to 
nickel ions (Schmidt et al., 2010).  
The same study (Schmidt et al., 2010) found that although murine TLR4 is activated by 
LPS, it is unresponsive to nickel ions. Expression of human TLR4 by a murine model 
conferred nickel sensitivity, showing that the effect is species-specific. The species 
difference arises from a so-called ‘histidine pocket’ consisting of 3 histidine residues at 
positions 431, 456 and 458 in the human TLR4 sequence (Figure 1.6). TLR4 homodimer 
formation brings these six residues into close proximity, creating a binding site for nickel 
ions. Although H431 is conserved, murine TLR4 lacks H456 and H458 and as a result it 
is not activated by nickel ions (Schmidt et al., 2010).  
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The study concluded that TLR4 activation by nickel could play a crucial role in the 
development of hypersensitivity to the metal ion, but that the observed receptor activation 
may be an inflammatory mechanism occurring independently of hypersensitivity. 
Furthermore, TLR4 was proposed as a potential therapeutic target for allergic contact 
dermatitis because nickel does not share the LPS binding site. Finally, the authors 
cautioned the use of animal models in the study of inflammatory responses to chemical 
agents because of the species differences in nickel activation of TLR4 (Schmidt et al., 
2010).  
 
Figure 1.6: Human and murine TLR4 sequences 
A. Proposed model of TLR4 homodimer showing the histidine residues (H431, 
H456 and H458) that bind nickel and cobalt ions for receptor activation. The model 
is based on the crystal structure of TLR4 and is adapted from Schmidt et al (Schmidt 
et al., 2010) B. Human and mouse TLR4 sequences were aligned using the UniProt 
online database. H431 is shown in the first box and H456 and H458 are shown in 
the second box. Murine TLR4 lacks H456 and H458 and is therefore unresponsive 
to nickel (Schmidt et al., 2010).  
Cobalt/nickel ions
A. 
B. 
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Nickel is present in most MoM joints but because of its close association with 
hypersensitivity reactions it is only used in trace amounts and is therefore unlikely to be 
responsible for ARMD. Instead the composition of most MoM implants is around 60-
70% cobalt-chromium. Cobalt is a less common allergen than nickel, affecting around 3-
5% of the population (Carøe et al., 2011, Diepgen et al., 2016) and accounting for 4% of 
all contact dermatitis cases (Athavale et al., 2007). However nickel and cobalt are 
adjacent transition metals in the periodic table (Figure 1.7) which means that they share 
a number of similar properties, including ionic radius and charge density. Both metals are 
known to bind histidine as nickel and cobalt columns can be used in the laboratory to 
isolate histidine-tagged proteins. Given that histidine binding is a critical step in nickel-
mediated TLR4 activation, it was hypothesised that cobalt ions could also activate human 
TLR4.  
 
Figure 1.7: Periodic table of elements 
Cobalt and nickel (red circles) are adjacent transition metals within the periodic 
table and share a number of similar properties including the ability to bind to 
histidine residues. 
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1.5.2.  Cobalt and TLR4 
A preliminary study (MRes project) to the work described in this thesis used a TLR4 
reporter cell assay to assess the effect of cobalt ions on human and murine TLR4 
activation. The reporter cells contained a secreted alkaline phosphatase (SEAP) reporter 
gene induced by NFκB activation. When TLR4 is activated, NFκB activity increases and 
SEAP is released. SEAP secretion can then be quantified by a colorimetric assay.  
An initial positive control experiment demonstrated human and murine TLR4 
responsiveness to LPS (Figure 1.8A&B) (Tyson-Capper et al., 2013a). Nickel ions also 
activated human TLR4 (Figure 1.8C) but not murine TLR4 (Figure 1.8D), confirming 
the findings of previous work (Schmidt et al., 2010). The addition of cobalt ions to the 
assay caused a significant increase in SEAP secretion by human TLR4-expressing 
reporter cells showing that cobalt can activate human TLR4 (Figure 1.8E). However 
murine TLR4-expressing cells did not produce SEAP following cobalt stimulation, 
indicating that murine TLR4 does not respond to cobalt ions (Figure 1.8F). These 
findings were supported by the work of Raghavan et al  and Potnis et al, and showed for 
the first time that cobalt ions from MoM implants can have immunological activity 
through direct activation of human TLR4 (Raghavan et al., 2012, Potnis et al., 2013).  
The study described above used reporter cell assays and consequently the focus was on 
TLR4 activation using SEAP as a marker. This provides insight into the potential of a 
ligand to activate a receptor but does not allow investigation into responses such as 
inflammatory cytokine secretion, and therefore the effect of cobalt-mediated TLR4 
activation on these factors remains unclear. 
23 
 
 
Figure 1.8: Human and murine TLR4 activation by LPS, NiCl2 and CoCl2 
Human and murine TLR4 reporter cells were used to determine TLR4 activation by 
a range of LPS, NiCl2 or CoCl2 concentrations. Human TLR4 was activated by A. 
LPS, C. NiCl2 and E. CoCl2. Murine TLR4 was activated by B. LPS, but not by D. 
NiCl2 or F. CoCl2. Figure adapted from previously published work (Tyson-Capper 
et al., 2013a). 
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1.6. Toll-like receptors 
TLRs are an evolutionarily conserved family of PRRs and were first discovered in Drosophila 
melanogaster (Anderson et al., 1985, Gay and Keith, 1991). They are essential in defence 
against pathogen invasion and are responsible for initiating immune responses when a cell 
encounters a foreign organism. To date 10 human TLRs have been identified. Of these, TLR1, 
2, 4, 5, 6 and 10 are on the cell surface while TLR3, 7, 8 and 9 are intracellular. TLRs recognise 
pathogen-associated molecular patterns, which are unique to individual pathogens; for example 
TLR3 is activated by double-stranded RNA (Alexopoulou et al., 2001) while TLR9 recognises 
CpG nucleotides which are prevalent in bacterial DNA (Hemmi et al., 2000). Between them the 
TLRs recognise many diverse ligands, although compared to the antigen recognition capacity 
of the adaptive immune system this is a relatively small number. There is some overlap between 
ligands recognised by the TLRs, with TLR1 and TLR2 both recognising peptidoglycan and 
lipopeptides. The full list of human TLRs and their ligands is shown in Table 1.2. 
The ligand repertoire of TLRs is not limited to PAMPs as they can also recognise damage-
associated molecular patterns (DAMPs, also known as ‘alarmins’). DAMPs are self-derived 
molecules that are released by damaged or stressed cells, often when they are undergoing 
necrosis. Among the major DAMPs known to be TLR ligands is high mobility group box 
protein 1 (HMGB1), which is a nuclear protein released by necrotic but not apoptotic cells. 
HMGB1 can activate TLR2, TLR4 and TLR9. A second TLR-stimulating DAMP is serum 
amyloid A, which is primarily expressed by hepatocytes and activates TLR2 and TLR4. A 
comprehensive list of TLR-activating DAMPs is shown in Table 1.2. 
Activation of TLRs by DAMPs is usually beneficial to the host because it drives TLR-mediated 
innate and adaptive immune signalling (described later in this section) in a similar way to 
PAMPs; this is known as ‘sterile inflammation’ because immune responses occur in the absence 
of a pathogen. For example, DAMP activation of TLRs on innate immune cells can recruit and 
stimulate dendritic cells, resulting in increased antigen presentation to the adaptive immune 
system. They also promote repair mechanisms such as fibrosis, which is important for 
redressing homeostasis after an inflammatory response. However, their ability to promote self-
recognition also means that DAMPs are implicated in the development of autoimmune 
conditions such as rheumatoid arthritis (Goh and Midwood, 2012). Consequently, DAMPs and 
TLRs have been proposed as therapeutic targets in the prevention of autoimmune diseases 
(Midwood and Piccinini, 2010).  
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For effective pathogen recognition most TLRs undergo dimerisation; homodimerisation is more 
common but heterodimers can also form, particularly in the case of TLR2 which can 
heterodimerise with TLR1 and TLR6. Heterodimerisation is thought to expand the repertoire 
of PAMPs recognised by the TLRs (Farhat et al., 2008). Dimerisation is also important for 
bringing the intracellular TIR domains of the receptors into closer proximity, creating a binding 
site for adaptor proteins such as MyD88. Following receptor dimerisation a downstream 
intracellular signalling cascade is initiated which activates transcription factors including 
NFκB, AP-1 and IRF3. These factors regulate transcription of pro-inflammatory cytokines and 
chemokines such as IL-8 and tumour necrosis factor alpha (TNFα). There is also upregulation 
of co-stimulatory molecules like intercellular adhesion molecule-1 (ICAM-1) to assist in the 
cell-cell interactions required for adaptive immune responses. TLR activation also results in 
increased phagocytosis and antigen presentation to the adaptive immune system. The exact 
nature of the cellular immune response depends on which TLR is activated, and the downstream 
adaptor proteins that are recruited; the result is an inflammatory response that is appropriate to 
the activating PAMP or DAMP. For example, TLR3 and TLR4 activation can drive a Type I 
interferon response, but TLR2 and TLR5 cannot do so (Toshchakov et al., 2002). This study 
will focus on TLR4 and the inflammatory consequences of its activation.  
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Toll-like 
receptor PAMPs (source) DAMPs References 
1 Peptidoglycan, lipopeptide (Gram positive 
bacteria) Β-defensin 3 (Takeuchi et al., 2002) 
2 Peptidoglycan, lipopeptide (Gram positive 
bacteria) 
Heat shock proteins, HMGB1, biglycan, 
antiphospholipid antibodies, hyaluronic acid 
fragments, serum amyloid A 
(Aliprantis et al., 1999) 
3 Double-stranded RNA (viruses) mRNA (Alexopoulou et al., 2001) 
4 Lipopolysaccharide (Gram negative 
bacteria) 
HMGB1, heat shock proteins, fibronectin, 
hyaluronan fragments, heparan sulphate, fibrinogen, 
lung surfactant protein A, antiphospholipid 
antibodies, serum amyloid A 
(Poltorak et al., 1998) 
5 Flagella (bacteria) None identified (Hayashi et al., 2001) 
6 Lipopeptide (bacteria and fungi) None identified (Takeuchi et al., 2001) 
7 Single-stranded RNA (viruses) Antiphospholipid antibodies, ssRNA (Hemmi et al., 2002, Lund et al., 
2004) 
8 Single-stranded RNA (viruses) Antiphospholipid antibodies, ssRNA (Heil et al., 2004) 
9 CpG nucleotides (bacteria and viruses) Hypomethylated CpG-DNA, HMGB1 (Bauer et al., 2001) 
10 Unknown None identified (Chuang and Ulevitch, 2001) 
Table 1.2: Human Toll-like receptors and their ligands 
The table shows the 10 human TLRs and the pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) 
that activate them. DAMPs section of table was adapted from (Midwood and Piccinini, 2010). The table is not exhaustive but describes the major 
DAMPs identified for each TLR. To-date no endogenous ligands for TLR5, TLR6 and TLR10 have been identified.  
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1.6.1. Toll-like receptor 4 
Toll-like receptor 4 (TLR4) is a type I transmembrane receptor with a molecular weight of 
95kDa. It is expressed on numerous cell types including monocytes, macrophages, dendritic 
cells and endothelial cells. Human TLR4 was first discovered by Medzhitov et al in 1997 
(Medzhitov et al., 1997) and subsequently identified as the receptor for bacterial 
lipopolysaccharide (LPS) from Gram negative bacteria (Poltorak et al., 1998).  
1.6.2. LPS activation of TLR4 
TLR4 cannot initiate an immune response against LPS without accessory proteins that aid in 
the transfer of LPS to the receptor. LPS first binds to LPS-binding protein (LBP) which forms 
a complex with cluster of differentiation 14 (CD14), a protein usually expressed in either 
soluble or membrane-bound form alongside TLR4. This complex then transfers LPS to myeloid 
differentiation protein 2 (MD2), which is complexed with TLR4. MD2/TLR4 binding of LPS 
induces receptor homodimerisation. MD2 is essential to the LPS-mediated response as MD2-
negative cells are unable to respond to LPS (Zhang et al., 2009). A TLR4/MD2 dimer and its 
adaptor proteins are shown in Figure 1.9. 
 
Figure 1.9: TLR4/MD2 dimer and its adaptor proteins 
TLR4 is a cell surface receptor and requires adaptor proteins LBP, MD2 and CD14 for 
activation by LPS. LPS is initially bound by LBP, which complexes with CD14 and then 
transfers LPS to MD2, which is present in a heterodimer with TLR4. This causes 
TLR4/MD2 complex homodimerisation and results in the recruitment of intracellular 
adaptor proteins (e.g. MyD88, TRIF) and subsequent initiation of downstream signalling 
cascades (described in later figures). Image adapted from (Needham and Trent, 2013) 
Cell membrane
Homodimer
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TLR4 contains Toll IL-1 resistance (TIR) domains which, following activation 
andhomodimerisation, recruit other adaptor proteins with TIR domains. These include MyD88, 
TIRAP, TIR domain-containing adaptor-inducing interferon-β (TRIF, also known as TIR 
domain-containing adaptor molecule 1 or TICAM1) and TRIF-related adaptor molecule 
(TRAM or TICAM2) (O'Neill et al., 2013). The recruitment of adaptor proteins activates 
downstream signalling pathways via interleukin-1 receptor-associated kinase (IRAK) and TNF 
receptor-associated factor (TRAF) molecules, and transcription factors including NFκB. This 
leads to increased transcription of pro-inflammatory cytokines and chemokines such as 
interleukin-6 (IL-6) and interleukin-8 (IL-8). Whilst TLR4 activation is an essential first step 
in the immune response to LPS, it is these effector molecules that go on to promote an 
inflammatory response against the pathogen. An outline of the TLR4 signalling pathway is 
shown in Figure 1.10. 
29 
 
 
Figure 1.10: TLR4 signalling pathway 
Figure shows an outline of human TLR signalling. TLRs can be expressed on the cell surface (TLRs 1, 2, 4, 5, 6 and 10) or in intracellular endosomes (TLRs 3, 7, 
8 and 9). There is considerable overlap in the downstream signalling pathways induced by the different TLRs. TLR4 (red box) is activated by LPS, resulting in 
receptor homodimerisation and recruitment of adaptor proteins such as MyD88 and TRIF. This initiates a downstream signalling cascade involving IRAK protein 
complexes and activation of MAP kinases, among the many other factors shown in the figure. The outcome of TLR4 signalling is increased activity of transcription 
factors including NFκB, AP-1 and IRF3; this is dependent on adaptor proteins, for example the MyD88 pathway tends to activate NFκB signalling. Transcription 
factor activity results in increased expression of pro-inflammatory cytokines and chemokines. Image adapted from (Joosten et al., 2016).  
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LPS was the first TLR4 ligand to be identified and as such remains the most widely studied. 
However, as discussed earlier, TLR4 is activated by other factors including high-mobility group 
box protein 1 (HMGB1) (Yu et al., 2006), hyaluronic acid fragments (Termeer et al., 2002), 
and heat shock protein 60 (HSP60) (Cohen-Sfady et al., 2005). There is considerable debate 
over whether or not these DAMPs are ‘true’ TLR4 ligands or if their effects are enhanced by 
endotoxin contamination (Erridge, 2010). However it is clear that TLR4 can respond to a range 
of stimuli that includes pathogens and host-derived factors, as well as ligands not classified as 
PAMPs or DAMPs, such as nickel and cobalt ions.   
1.6.3. Cobalt activation of TLR4 
Unlike LPS, which requires transfer across several adaptor proteins to access and activate 
TLR4, cobalt and nickel ions bind directly to the receptor. Raghavan et al observed that cobalt 
activation of TLR4 requires histidine residues at positions 456 and 458 in the TLR4 sequence, 
which is the same as those that facilitate nickel binding (Raghavan et al., 2012). Murine TLR4 
lacks these histidine moieties and consequently cobalt cannot activate the murine receptor. 
Mutation of H456 and H458 significantly reduces the inflammatory response to cobalt ions but 
does not affect the LPS response (Raghavan et al., 2012), suggesting that there are differences 
between LPS- and cobalt-mediated TLR4 activation.  
The same study (Raghavan et al., 2012) aimed to elucidate the role of MD2, a TLR4 co-
receptor, in cobalt activation of TLR4. It was found that both LPS and cobalt ions cause receptor 
homodimerisation. However while MD2 is essential for homodimerisation following LPS 
stimulation, it is not required following cobalt stimulation. In contrast, a more recent study 
showed that cobalt cannot activate TLR4 in the absence of MD2 (Oblak et al., 2015). Raghavan 
et al found that mutating N433, an asparagine residue present in the TLR4 dimerisation 
interface, prevented TLR4 homodimerisation in response to cobalt and LPS and subsequent 
inflammatory cytokine release (Raghavan et al., 2012), indicating the importance of this process 
in TLR4 activation by cobalt.   
There is limited information on the downstream signalling pathways that may be induced 
following cobalt activation of TLR4. Silencing of the MyD88 and IRAK1 genes inhibits 
inflammatory responses to cobalt ions in THP-1 macrophages (Rachmawati et al., 2013) but 
little is known about the cytokine and chemokine profile produced, or the functional effects that 
this may have.  
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1.7. Inflammatory effects of LPS-mediated TLR4 activation 
The following sections describe the inflammatory effects of LPS-mediated TLR4 activation. 
These are important to the present study because they provide insight into the potential 
immunological consequences of cobalt activation of TLR4.  
1.7.1. Cytokine and chemokine secretion 
LPS activation of the TLR4 signalling pathway causes increased secretion of pro-inflammatory 
cytokines and chemokines including IL-8 (Yoshimura et al., 1987), IL-6 (Song et al., 2007) and 
CCL2 (Guijarro-Muñoz et al., 2014). The cytokine profile release following LPS activation of 
TLR4 depends on which transcription factors are activated. NFκB and AP-1 activation tends to 
drive secretion of cytokines and chemokines like IL-6, IL-8 and TNFα, while IRF3 activation 
promotes type I interferon release, which is often associated with anti-viral responses. The 
cytokines and chemokine released by LPS-mediated TLR4 activation have a broad range of 
immunological functions that combine to produce an effective inflammatory response. For 
example, TNFα increases vascular permeability to allow immune cells and complement access 
to the affected tissues. IL-8 recruits neutrophils and basophils to the site of inflammation, while 
IL-12 can activate natural killer cells which are cytotoxic for pathogens. It also promotes 
differentiation of CD4+ T cells into Th1 cells, showing a clear link between TLR4 activation 
and stimulation of adaptive immunity (Section 1.7.4). 
As with any aspect of the inflammatory response, TLR4 signalling must be tightly regulated. 
Very high doses of LPS result in overwhelming cytokine and chemokine secretion (sometimes 
referred to as a ‘cytokine storm’), and increased vascular permeability; these are the events that 
occur in septic shock. One of the most well-studied negative regulators of TLR4 is IRAKM, 
which functions by preventing the formation of the IRAK1-TRAF6 complex (Figure 1.10) that 
is required for downstream signalling. Suppressor of cytokine signalling 1 (SOCS1) is a second 
inhibitor of TLR4 signalling and is thought to act by binding IRAK1 and preventing IRAK 
complex formation (Naka and Fujimoto, 2010). Most endogenous negative regulators of TLR4 
are also increased by LPS stimulation of the receptor in order to prevent the overwhelming 
cytokine response; mice negative for such factors (e.g. SOCS1) develop severe sepsis 
(Nakagawa et al., 2002). 
1.7.2. Phagocytosis 
Activation of TLR4 by LPS also promotes phagocytosis. The role of TLRs in phagocytosis was 
first identified by Blander and Medzhitov in 2004; they identified that TLR4-/- mice had a 
reduced ability to phagocytose E. coli compared to wildtype control mice (Blander and 
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Medzhitov, 2004). Since their discovery, other studies have reported similar central roles for 
TLR4 in phagocytosis, although the exact pathways involved are not entirely clear. Chen et al 
reported that TLR4-MyD88 interactions are essential for phagocytosis  while others have 
described activation of a MyD88-independent pathway that promotes phagocytosis (Kong and 
Ge, 2008). Given the apparent number of factors critical to TLR4-dependent phagocytosis 
reported in different studies, it is feasible that the exact signalling pathway induced is specific 
to the pathogen encountered. However the eventual outcome is increased phagocytic 
capabilities, particularly in the case of macrophages; this is due to elevated expression of 
scavenger receptors and increased complement production which drives phagocytosis (Doyle 
et al., 2004). The function of macrophages as phagocytes is described in more detail in section 
1.4.1. 
1.7.3. Leukocyte extravasation 
The presence of a pathogen in the tissues requires movement of circulating leukocytes from the 
blood, across the endothelial barrier and into the affected tissues where they can coordinate an 
inflammatory response. This process is known as extravasation and is a multi-step process 
involving local and systemic cytokine and chemokine signals from immune cells and 
endothelial cells that promote leukocyte adhesion (Section 1.7.3.1) and migration (Section 
1.7.3.2). TLRs are critical in these processes because they identify the specific pathogen and 
mediate the secretion of a unique cytokine and chemokine profile required for an appropriate 
immune response to the pathogen. In particular, LPS activation of TLR4 can promote adhesion 
molecule expression, both directly and indirectly, through increased expression of cytokines 
and chemokines such as TNFα (Section 1.7.3.1).  
1.7.3.1. Adhesion 
Circulating immune cells such as monocytes and neutrophils must adhere to the endothelial cell 
layer in order for them to move from the blood into the surrounding tissues. The process 
requires interaction between adhesion molecules expressed on both cell types. As blood flows 
rapidly through vessels at a high shear rate, the first step in cell adhesion is a low-level 
(‘rolling’) adhesion that slows the passage of circulating leukocytes. This involves engagement 
of carbohydrate structures such as Sialyl LewisX expressed on monocytes and neutrophils with 
selectins (e.g. E-selectin) on the endothelial cell surface (Table 1.3). The interaction allows 
cells to roll more slowly along the endothelial cell layer and progress to firm adhesion via 
engagement of different groups of adhesion molecules.  
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Endothelial cell 
factor 
Constitutively 
expressed? 
Ligand on 
monocytes/neutrophils 
Function 
Selectins, e.g. E-
selectin 
Yes Sialyl LewisX Rolling adhesion 
ICAM-1 Yes 
LFA-1 (CD18/CD11a), 
Mac-1 (CD18/CD11b) 
Firm adhesion 
VCAM-1 No VLA-4 (CD49d, CD29) Firm adhesion 
Table 1.3: Factors involved in endothelial cell-monocyte/neutrophil adhesion 
Table adapted from Panés and Granger (Panés and Granger, 1998) 
Most endothelial cells constitutively express two forms of intercellular adhesion molecule 
(ICAM) for firm adhesion; these are ICAM-1 and ICAM-2. Soluble forms of these factors (e.g. 
soluble ICAM-1 or sICAM-1) also exist. Upon cell stimulation, ICAM-1 expression is 
increased and an additional adhesion molecule, vascular adhesion molecule-1 (VCAM-1), is 
induced (Panés and Granger, 1998). The integrin family are capable of rapid conformational 
changes, which allows them to switch rapidly between binding and release of their ligands; this 
is important for binding the cell and then allowing it to migrate through the endothelial cell 
layer.  
The ligands for ICAM-1 are the integrins CD18/CD11a (lymphocyte function-associated 
antigen-1, LFA-1) and CD18/CD11b (macrophage-1 antigen, Mac-1) while VCAM-1 binds 
very late antigen-4 (VLA-4) (Table 1.3). LFA-1 is expressed constitutively, mostly by 
neutrophils, whilst Mac-1 is mainly stored in granules. Upon cell stimulation, Mac-1 can be 
rapidly trafficked to the cell surface and at the same time the selectins involved in the initial 
low adherence step are shed by the endothelial cell, allowing rapid transition from rolling to 
firm adhesion. The cell adhesion process is summarised in Figure 1.11. 
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Figure 1.11: Monocyte adhesion and migration 
Monocyte infiltration of tissues (extravasation) requires adhesion molecules and 
chemotactic stimuli. Rolling adhesion occurs through interaction between molecules 
including Sialyl LewisX (monocyte) and selectins (endothelial cell). This is followed by 
firm adhesion mediated by LFA-1 or VLA-4 (monocyte) and ICAM-1 and VCAM-1 
(endothelial cell). Adhesion allows monocyte extravasation and maturation into a 
macrophage following exposure to a pathogen in the tissues. Macrophages secrete 
chemokines in response to the pathogen that recruit more inflammatory cells and facilitate 
their migration through the endothelial cell layer. Circulating monocytes are shown in the 
diagram but the process is the same for neutrophils, which are usually the first immune 
cells to enter affected tissues.  
. 
ICAM-1/VCAM-1
LFA-1/VLA-4
IL-8, TNF etc
Blood flow
E-selectin
Sialyl Lewis X
Pathogen
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Adhesion molecule expression is tightly regulated under non-pathogenic conditions to prevent 
unwanted inflammation. In the presence of a pathogen expression is increased and this is largely 
due to the regulation of adhesion molecules by cytokines including IL-6, IFNγ and TNFα 
(Zhang et al., 2011), which induce endothelial inflammation including increased expression of 
adhesion molecules. LPS can also directly affect ICAM-1 expression; breast cancer cells 
challenged with LPS increase ICAM-1 expression via a TLR4 and MyD88-dependent pathway 
(Park and Kim, 2015) and a similar mechanism has been demonstrated in endothelial cells 
(Sawa et al., 2008). TLR4 inhibition can prevent these changes, suggesting that they are 
mediated by receptor activation and upregulation of the transcription factors NFκB and AP-1 
(Sawa et al., 2008, Hung et al., 2010). 
The effect of TLR4 ligands on adhesion molecules is not limited to ICAM-1 and VCAM-1 as 
LFA-1 and VLA-4 can also be regulated through activation of TLR4 (Liu et al., 2015). 
Engagement of ICAM-1 on endothelial cells with LFA-1 on neutrophils is a crucial aspect of 
neutrophil recruitment in the inflammatory response to LPS (Basit et al., 2006) and interaction 
between the two molecules also promotes neutrophil phagocytosis and the oxidative burst 
(Schnitzler et al., 1999). VLA-4 binds to VCAM-1 and plays a similar role to LFA-1; it is 
required for neutrophil recruitment following endotoxin challenge (Burns et al., 2001), showing 
its importance in TLR4-mediated inflammatory responses.  
In addition to its role in innate immune cell binding, LFA-1 is expressed on T lymphocytes and 
in this case its binding to ICAM-1 on an antigen-presenting cell is a key step in T cell activation. 
Consequently LFA-1 is important in a broad range of pro-inflammatory responses by mediating 
cellular interactions and, as such, has been proposed as a therapeutic target in autoimmune 
conditions such as psoriasis because of its role in coordinating T cell-mediated inflammation 
(Cather et al., 2003).   
1.7.3.2. Migration 
Following cell adhesion the next step is migration of the leukocyte through the endothelial cell 
barrier and into the tissue. This occurs in response to a local chemokine gradient generated by 
tissue-resident cells (such as macrophages) upon pathogen recognition. The process also 
requires homophilic interactions between platelet endothelial cell adhesion molecule-1 
(PECAM-1) on the leukocyte and the endothelial cell, which allows the leukocyte to pass 
through the endothelial cell barrier. The type of leukocyte recruited to the tissues is dependent 
on the secreted chemokine profile and receptor expression on the target cells, e.g. IL-8 acts via 
chemokine (C-X-C motif) receptors 1 and 2 (CXCR1 and CXCR2) to promote neutrophil 
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migration. Chemokine receptors are G protein-coupled receptors and when activated they 
initiate cytoskeletal changes in the cell that drive migration. They also promote conformational 
changes in the adhesion molecules described earlier, which allows for more effective leukocyte-
endothelial binding. Once the newly recruited cells arrive at the site of inflammation they can 
promote an immune response. For example, monocyte extravasation results in cell maturation 
into a macrophage which can carry out functions such as phagocytosis. When migrated cells 
encounter the pathogen they also begin to secrete chemokines that recruit more inflammatory 
cells to the site which ultimately leads to eradication of the pathogen.    
1.7.4. Role of TLR4 inand adaptive immune responses 
As well as its crucial role in innate immunity, TLR4 signalling can also promote adaptive 
immunity. TLR4 is expressed on dendritic cells, which provide a bridge between the innate and 
adaptive immune systems. Upon LPS challenge and TLR4 activation, immature DCs begin to 
mature by upregulating their expression of MHC molecules for antigen presentation and co-
stimulatory molecules for cell-cell interactions; these include cluster of differentiation 40 
(CD40), CD80 and CD86, and are essential for initiating a Th1-dependent adaptive immune 
response (Fang et al., 2011). The result of LPS-driven DC maturation is migration to the lymph 
nodes where they present antigen for priming naïve T cells. Interestingly, a recent paper has 
shown that LPS activation of TLR4 can cause a transient decrease in phago-lysosomal fusion 
(and thereby phagocytosis).  This was accompanied by a temporary increase in antigen cross-
presentation to cytotoxic CD8+ cells (Alloatti et al., 2015), suggesting that TLR4 is involved in 
improving the antigen presenting ability of DCs. 
Expression of TLR4 by T and B lymphocytes confers their responsiveness to LPS and other 
TLR4 ligands (Cohen-Sfady et al., 2005, Zanin-Zhorov et al., 2007). Although T cells do not 
usually display increased cytokine secretion following TLR4 activation (Reynolds et al., 2012), 
LPS activation of TLR4 on T cells increases cell adhesion (Zanin-Zhorov et al., 2007) and 
promotes clonal expansion (Gandhapudi et al., 2013). In TLR4-mediated inflammatory 
responses, TLR4 and MyD88 inhibition significantly generation of antigen-specific T cells (Uto 
et al., 2011). TLR4-deficient mice also have a reduced CD4+ T cell population in response to 
Salmonella infection compared to wildtype controls. However other studies have found that 
LPS activation of TLR4 promotes immunomodulatory IL-10 secretion by regulatory T cells 
(Higgins et al., 2003, Den Haan et al., 2007), which may be a mechanism of controlling 
inflammation.  
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Activation of TLR4 on B lymphocytes results in cytokine secretion (IL-6, IL-10 (Barr et al., 
2007)), cell maturation (Hayashi et al., 2010), increased antigen presentation and antibody 
production. However, unlike for T lymphocytes, there appears to be species differences in B 
cell expression of TLR4 (for example murine TLR4 expression is constitutive but this is not the 
case in humans) (Bekeredjian-Ding and Jego, 2009). Consequently the exact effects of TLR4 
activation on human B cells remain to be elucidated.    
The primary focus of the present study will be on the role of TLR4 as an innate immune receptor 
but it is important to note that the receptor and its signalling pathway are also crucial in adaptive 
immune system activation. Furthermore, activation can occur via either direct (i.e. LPS 
activation of TLR4 on T and B lymphocytes) or indirect (i.e. stimulation of DC maturation for 
increased antigen presentation) mechanisms, highlighting the central role of TLR4 in immunity.  
1.8. Toll-like receptors in hip arthroplasty 
TLR4 expression has been demonstrated in tissues surrounding aseptically-loosened joint 
replacements (Takagi et al., 2007, Pajarinen et al., 2010). The majority of this expression is 
attributed to monocytes and macrophages infiltrating the peri-implant tissues, as well as 
macrophage clustering in response to wear debris, known as foreign body macrophage giant 
cells. Small numbers of TLR4-expressing neutrophils are also present (Lähdeoja et al., 2009) 
and together these are indicative of an innate immune response. TLRs are expressed in vascular 
endothelial and synovial cells surrounding aseptically-loosened implants and TLR4 expression 
is particularly high; this appears to be a response to the presence of the hip replacement as 
expression levels are increased in tissues from aseptically-loosened implants compared to in 
osteoarthritic tissues (Lähdeoja et al., 2009). These studies suggest that the cells and tissues 
around MoM implants can be responsive to TLR4 PAMPs and DAMPs, including cobalt ions. 
However little is known about how this may be linked to the inflammation observed in ARMD.   
1.9. ARMD therapy 
The only current treatment for ARMD is revision to an implant made from an alternative 
material (e.g. metal-on-polyethylene). Although this is an effective intervention it is also costly 
and more complex than primary hip replacement surgery. The development of a treatment 
option that could prevent or reduce ARMD without the need for surgery is consequently an 
attractive area for research. Current research into ARMD therapies focuses on modifying the 
existing inflammatory response, for example by polarising the macrophage population towards 
the M2 (anti-inflammatory or immunomodulatory) phenotype through IL-4 treatment 
(Pajarinen et al., 2015). Another option is introducing mutant and therefore dysfunctional 
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chemokines such as a mutant form of CCL2 known as 7ND, which dominantly inhibits activity 
of the wildtype form. In a murine model of wear particle-induced osteolysis, 7ND significantly 
decreased bone breakdown through downregulation of osteoclast formation (Jiang et al., 2015). 
Other targets include NFκB as it plays a key role in inducing inflammatory cytokine secretion 
in response to wear debris (Lin et al., 2014, Sato et al., 2015).  
Understanding the cause of ARMD is the greatest obstacle in the development of novel 
therapies but challenges are also presented by the method of delivery (i.e. targeting the joint in 
isolation) and nature of the treatment itself (e.g. use of an antibody or other immune-modulating 
agent). Several methods of therapy delivery have been suggested, including coating hip 
implants with the therapeutic agent so that they are released as a product of the wear process 
(Goodman et al., 2013b). An insight into the molecular mechanisms underlying ARMD could 
aid in the development and delivery of preventative therapies.  
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1.10. Hypothesis 
In summary of the current situation, cobalt-containing MoM implants fail at high rates because 
of adverse tissue reactions including osteolysis, pain, soft tissue necrosis, and pseudotumour 
development. These reactions are inflammatory and mediated by cytokines and chemokines, 
but the mechanisms that initiate them are unclear. Cobalt is known to activate human TLR4, an 
innate immune receptor that also recognises LPS from Gram negative bacteria, usually resulting 
in a pro-inflammatory response. This study therefore hypothesises that cobalt activation of 
human TLR4 leads to cellular inflammatory responses that may be linked to ARMD. The aim 
of the study is to investigate inflammatory effects induced by cobalt ions using a series of in 
vitro cell culture assays, and to assess the role of TLR4 in these responses.  
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1.11. Objectives 
A. To investigate the overall effect of cobalt ions on cellular immune responses 
Quantitative real-time polymerase chain reaction (qRT-PCR) arrays and proteome profiling 
arrays were performed to assess gene expression and protein secretion changes following 
stimulation of MonoMac 6 cells with cobalt ions.  
B. To determine the role of TLR4 in inflammatory responses to cobalt ions 
qRT-PCR and enzyme-linked immunosorbent assays (ELISA) were conducted to investigate 
more closely potential markers of TLR4 activation by cobalt. A small molecule TLR4 
antagonist and two different anti-TLR4 neutralising antibodies were studied for their potential 
to inhibit the cellular inflammatory response induced by cobalt.  
C. To investigate the effect of cobalt ions on immune cell adhesion and migration 
Inflammatory cytokine secretion by cobalt-stimulated endothelial cells was assessed by ELISA 
with the aim of selecting an appropriate in vitro cell culture model. The effect of cobalt ions on 
membrane-bound adhesion molecule expression in human macrophages and endothelial cells 
was assessed by qRT-PCR, and soluble adhesion molecule secretion was quantified by ELISA. 
Inflammatory cell migration following cobalt stimulation was investigated using transwell 
chemotaxis assays.  
D. To investigate factors that may impact upon patient variability in adverse reactions to 
metal ions 
Stable cell lines expressing wildtype or mutant TLR4 were generated and investigated for their 
response to cobalt stimulation using qRT-PCR and ELISA assays. Co-stimulation assays were 
conducted using LPS or nickel ions to determine their effect on the cellular response to cobalt. 
The effect of chromium and strontium ions on TLR4 activation was also investigated. 
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Chapter 2. Materials and Methods 
2.1. General laboratory practice 
All experiments were carried out in accordance with the university standards for safe working 
with chemical substances in laboratories, which comply with the Control of Substances 
Hazardous to Health (COSHH) regulations. All laboratory work was conducted in compliance 
with the university safety policy.  
2.2. Cell culture 
Cell culture was carried out in compliance with regulations for the containment of Class II 
pathogens. All cells were maintained in 25 or 75cm2 flasks in a humidified incubator at 37oC 
with 5% CO2. 
2.2.1. Cell lines 
MonoMac 6 
MonoMac 6 cells are a human monocytic cell line derived from acute monocytic leukaemia. 
They are known to express TLR4 (part of MRes project) and respond to LPS by secreting IL-8 
(Dr Jem Palmer, Institute of Cellular Medicine, Newcastle University personal 
communication). MonoMac 6 cells were cultured in RPMI-1640 medium (Sigma-Aldrich, 
Gillingham, UK) supplemented with 10% v/v foetal bovine serum (FBS), 2mM L-glutamine, 
50U/ml penicillin and 50µg/ml streptomycin (all Sigma-Aldrich). 
THP-1 
THP-1 monocytes are derived from acute pro-monocytic leukaemia and were cultured in RPMI-
1640 medium supplemented with 10% v/v FBS, 2mM L-glutamine, 50U/ml penicillin and 
50µg/ml streptomycin.  
U2OS 
U2OS cells are a human osteoblast cell line derived from osteosarcoma. They were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) 1g/L glucose supplemented with 10% v/v 
FBS, 2mM L-glutamine, 50U/ml penicillin and 50µg/ml streptomycin.  
J774 
J774 murine macrophages are from BALB/c mice and were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (1g/L) glucose supplemented with 10% v/v FBS, 2mM L-glutamine, 
50U/ml penicillin, 50µg/ml streptomycin, 1mM non-essential amino acids and 1mM sodium 
pyruvate (both Lonza, Basel, Switzerland).  
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HUVEC 
Human umbilical vein endothelial cells (HUVEC) from pooled donors (Promocell, Heidelberg, 
Germany) were cultured in Endothelial Cell Growth Medium with Supplement Mix containing 
FBS and additional required nutrients (all Promocell). 50U/ml penicillin and 50μg/ml 
streptomycin was also added. 
HMEC-1 
Human microvascular endothelial cells (HMEC-1) are derived from dermal foreskin. Cells 
were cultured in MCDB131 medium supplemented with 10% v/v FBS, 50U/ml penicillin, 
50μg/ml streptomycin, 10ng/ml epidermal growth factor (EGF) and 1μg/ml hydrocortisone (all 
Sigma-Aldrich).  
2.2.2. Cell maintenance and passage 
All cell culture experiments were performed under aseptic conditions in a Class II laminar flow 
microbiological safety cabinet. Cells were maintained in the media described in section 2.2.1 
and passaged at 70-80% confluency. Passage methods were dependent on the cell line and cell 
characteristics affecting passage methods are detailed below. 
Suspension cells Adherent cells 
MonoMac 6 U2OS 
THP-1 HMEC-1 
J774 HUVEC 
Table 2.1: Cell line characteristics 
Suspension cells were centrifuged at 179g for 5 minutes, supernatant was discarded and pelleted 
cells were resuspended in fresh complete media. Adherent cells (except HUVEC) were rinsed 
with phosphate-buffered saline (PBS) (Sigma Aldrich) following removal of supernatant. Cells 
were then trypsinised in 2mM trypsin-EDTA (Sigma-Aldrich) at 37oC, centrifuged at 179g for 
5 minutes and resuspended in complete media. HUVEC were passaged using a DetachKit 
(Promocell); the kit contained HEPES-buffered saline solution (HEPES-BSS) for washing, 
trypsin–EDTA and a trypsin neutralisation solution. All reagents were used according to the 
manufacturer’s protocol.  
2.2.3. Cryopreservation of cells 
Cell cryopreservation was routinely performed for stock maintenance. Cells were frozen in 
cryovials at approximately 1 million per ml in FBS with 10% v/v dimethyl sulphoxide (DMSO) 
(Sigma-Aldrich) at -80oC and then moved to liquid nitrogen for long-term storage. To thaw 
stocks, cryovials were rapidly warmed in a 37oC water bath and the contents transferred to a 
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vial of pre-warmed PBS. Cells were then centrifuged at 179g for 5 minutes to remove DMSO 
and seeded in pre-warmed culture medium.  
2.2.4. Mycoplasma testing 
All cell lines were routinely tested for mycoplasma contamination using a MycoAlert 
mycoplasma detection kit (Lonza, Slough, UK). The assay lyses any mycoplasma present in 
cell culture supernatant, releasing enzymes that react with the MycoAlert substrate and convert 
adenosine diphosphate (ADP) to adenosine triphosphate (ATP). The ratio of ATP before and 
after the addition of substrate is then calculated. A ratio of <0.8 is considered mycoplasma-free 
while >1.2 shows mycoplasma contamination.  
2.3. Cell stimulation 
2.3.1. Positive and negative controls 
LPS is a known TLR4 ligand and therefore TLR4-specific LPS (from E.coli serotype J5, Alexis 
Biochemicals, California, USA) was used as a positive control throughout this study. This LPS 
does not contain TLR2 agonists, nor any protein or DNA contaminants known to activate TLRs. 
LPS was diluted in complete culture medium appropriate for each cell line and used at a range 
of concentrations up to 1000ng/ml. Untreated cells were incubated in complete media as a 
negative control. 
2.3.2. Metal ions 
Nickel chloride hexahydrate (NiCl2 6H2O) and cobalt chloride hexahydrate (CoCl2 6H2O) (both 
Sigma-Aldrich) were diluted in complete culture medium appropriate for each cell line. 
Complete media was selected as the metals ions precipitated in PBS and blank cell culture 
medium (previously optimised during MRes project). Metal salts were selected because nickel 
salts have previously been used to demonstrate nickel activation of human TLR4 (Schmidt et 
al., 2010).  
2.3.2.1. Metal ion concentrations 
Concentrations of NiCl2 and CoCl2 used for in vitro cell stimulation in previous studies vary 
considerably. The concentrations used in this study were selected based on research in similar 
cell lines and refined following consideration of metal ion levels surrounding failed MoM joints 
observed in clinical studies (De Smet et al., 2008, Davda et al., 2011). This will be discussed in 
more detail in section 4.4. 
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2.4. TLR4 inhibition 
2.4.1. CLI-095 
CLI-095 (Invivogen, San Diego, USA) is a small molecule TLR4 antagonist. It is also known 
as TAK-242 or resatorvid and has been shown to block LPS-mediated TLR4 signalling by 
binding to Cys747 in the intracellular domain of TLR4 (Takashima et al., 2009). This prevents 
recruitment of adaptor proteins such as MyD88 and TRIF to the activated receptor (Matsunaga 
et al., 2011) and inhibits subsequent downstream signalling (Error! Reference source not 
found.A). CLI-095 was reconstituted in DMSO and diluted in complete cell culture medium 
according to the manufacturer’s protocol. Cells were pre-incubated with CLI-095 for 6h prior 
to stimulation with a TLR4 ligand.  
2.4.2. PAb-hTLR4 
PAb-hTLR4 (Invivogen) is a polyclonal rat IgG antibody against human TLR4. It is reported 
to inhibit TLR4-mediated signalling through receptor neutralisation and has been shown to be 
effective in MonoMac 6 cells (Ekaney et al., 2014) (Error! Reference source not found.B).  
2.4.3. MAb2-hTLR4 
MAb2-hTLR4 (Invivogen) is a monoclonal mouse IgG1 antibody (clone 3C3) against human 
TLR4. The exact antibody binding site is unknown (Figure 2.1C) but like PAb-hTLR4 it is 
reported to neutralise human TLR4 activation and prevent subsequent intracellular signalling 
(Scarpa et al., 2015).  
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Figure 2.1: Mechanism of action of TLR4 inhibitors 
A. CLI-095 binds to Cys747 in the intracellular domain of TLR4, preventing the 
recruitment of adaptor proteins including MyD88, TIRAP, TRIF and TRAM which are 
required for downstream signalling. B. PAb-hTLR4 is a polyclonal anti-TLR4 
neutralising antibody and therefore binds multiple epitopes. C. MAb2-hTLR4 is a 
monoclonal anti-TLR4 neutralising antibody. Its exact binding site is unknown.  
A. CLI-095
B. PAb-hTLR4
C. MAb2-hTLR4
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2.5. Cytotoxicity 
Cytotoxicity was assessed by trypan blue staining. 10μl trypan blue dye (Logos Biosystems, 
Anyang-City, South Korea) was mixed with 10μl cell suspension and the number of live and 
dead cells was counted using a Luna II automated cell counter (Logos Biosystems). The cell 
counter determines cell viability by detecting trypan blue uptake; cells with disrupted 
membranes and reduced viability cannot exclude the dye and appear blue, while healthy cells 
can exclude the dye and appear white/clear. However during the optimisation of this assay it 
was noted that the automated counts being generated were not accurate as healthy cells were 
falsely detected as nonviable. An example of this is shown in Figure 2.2; cells circled in red 
are classed as unviable (tagged image) but analysis of the raw image indicates that the cells are 
clear of trypan blue and therefore viable. To combat this issue the same staining process was 
used but the raw images collected using the Luna II cell counter were counted manually.   
 
Figure 2.2: Cytotoxicity assay optimisation 
Unstimulated MonoMac 6 cells were stained with trypan blue dye and counted using a 
Luna II automated cell counter. In some experiments it was noted that during the counting 
process viable cells were mistakenly being classified as nonviable (circled in red in tagged 
image but appear viable in raw image). Green circles indicate viable cells.  
2.6. Gene expression analysis 
2.6.1. RNA extraction 
Total RNA was extracted from cells using an RNeasy Mini kit (Qiagen, Venlo, Netherlands) 
following the manufacturer’s protocol. Briefly, cells were collected in a 1.5ml microcentrifuge 
tube and lysed in Buffer RLT containing 1% v/v β-mercaptoethanol to inhibit RNase activity. 
The lysed solution was further homogenised using a needle and syringe before the addition of 
70% v/v ethanol and transfer to the spin column assembly. A series of washing and 
centrifugation steps were performed followed by incubation of the spin column membrane with 
DNase I for 15 minutes. Several further washing and centrifugation steps were performed 
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before elution of the purified RNA in 50μl nuclease-free water. RNA quantity and quality was 
measured by Nanodrop ND-1000 spectrophotometer at wavelengths of 260nm and 280nm. A 
260/280 ratio of between 1.8 and 2.2 indicates good quality RNA.  Isolated RNA was stored at 
-80oC if required.  
Integrity of isolated RNA was confirmed by gel electrophoresis on a 1.2% w/v agarose gel. 
Two distinct bands should be seen representing the 28S and 18S ribosomal RNA subunits 
indicating intact RNA (Figure 2.3). 
 
Figure 2.3: RNA gel electrophoresis 
Isolated RNA was separated by electrophoresis on a 1.2% w/v agarose gel. The 28S and 
18S bands are the two ribosomal subunits and show intact RNA. The two samples shown 
are for reference only. 
2.6.2. Reverse transcription  
cDNA was synthesised from total RNA using either Superscript III reverse transcriptase or a 
Maxima First Strand cDNA Synthesis kit (both ThermoFisher Scientific, Waltham, USA). The 
Superscript III method uses oligodT primers while the Maxima method includes oligodT 
primers and random hexamers, and this has been shown to produce increased amounts of cDNA 
from the same starting amount of RNA (Dr Alison Tyson-Capper, personal communication).  
2.6.2.1. Superscript III reverse transcriptase 
Each Superscript III reverse transcription reaction contained 1μg total RNA, 10μl 5X First 
Strand Buffer, 2μl 10mM dNTP mix, 1μl oligo(dT)20 (50μM), 1μl DTT (0.1M), 1μl RNase 
OUT (40 units/μl) (all ThermoFisher Scientific) and nuclease-free H2O to a final volume of 
49μl. As the final step 1μl Superscript III reverse transcriptase was added to each reaction and 
stirred with a pipette tip. The reverse transcription reactions were incubated in a G-Storm 
thermal cycler for 50 minutes at 50oC followed by 5 minutes at 85oC. This method was 
optimised by previous members of the laboratory.  
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2.6.2.2. Maxima First Strand cDNA synthesis 
Each Maxima First Strand cDNA Synthesis Reaction contained 1μg total RNA, 4μl 5X 
Reaction Mix, 2μl Maxima Enzyme Mix (all ThermoFisher Scientific) and nuclease-free H2O 
to a final volume of 20μl. Reactions were incubated in a G-Storm thermal cycler for 10 minutes 
at 25oC, 15 minutes at 50oC and finally 5 minutes at 85oC. Synthesised cDNA was stored on 
ice for immediate use or at -20oC for long-term storage. If required cDNA was diluted in H2O 
before further assays were conducted.  
2.6.3. Quantitative real-time polymerase chain reaction 
Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted using TaqMan 
gene expression probes (Table 2.2). The TaqMan-based method was selected for its high 
specificity compared to SYBR Green (Figure 2.4) and, aside from the arrays described in 
chapter 3, all qRT-PCR conducted in this study used TaqMan assays. Each reaction contained 
1μl 20X TaqMan gene expression assay (containing primer pair and gene-specific probe) 
(ThermoFisher Scientific), 10μl 2X TaqMan Universal MasterMix II (ThermoFisher 
Scientific), 4μl diluted cDNA template and 5μl nuclease-free water. No template controls 
(NTC) were included for each primer and contained nuclease-free H2O instead of cDNA. 
Unless otherwise stated gene expression was normalised to GAPDH as a housekeeping gene.  
20μl reaction was added in triplicate to each well of a 96-well reaction plate. qRT-PCR was 
performed using a StepOnePlus real-time PCR thermal cycler (Applied Biosystems, 
Massachusetts, USA). Reactions were incubated at 50oC for 2 minutes and 95oC for 10 minutes 
followed by 40 cycles of 95oC for 15 seconds and 60oC for 1 minute.  
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Target gene Abbreviation Species RefSeq Assay ID 
Exon 
boundary 
Beta actin ACTB Human NM_001101.3 Hs01060665_g1 2-3 
Beta actin Actb Mouse - Mm00607939_s1 6-6 
Chemokine (C-C motif) ligand 2 CCL2 Human NM_002982.3 Hs00234140_m1 1-2 
Chemokine (C-C motif) ligand 20 CCL20 Human NM_001130046.1 Hs00355476_m1 2-3 
Chemokine (C-C motif) ligand 25 CCL25 Human NM_001201359.1 Hs00608373_m1 5-6 
Chemokine (C-X-C motif) ligand 1 Cxcl1 Mouse NM_008176.3 Mm04207460_m1 3-4 
Chemokine (C-X-C motif) ligand 10 CXCL10 Human NM_001565.3 Hs01124251_g1 2-3 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH Human NM_002046.4 Hs99999905_m1 3-3 
Hypoxia-inducible factor 1α HIF1A Human NM_001243084.1 Hs00153153_m1 4-5 
High mobility group box protein 1 HMGB1 Human NM_002128.4 Hs01590761_g1 1-2 
Heat shock protein A1A HSPA1A Human NM_005345.5 Hs00359163_s1 1-1 
Intracellular adhesion molecule-1 ICAM1 Human NM_000201.2 Hs00164932_m1 2-3 
Interleukin-1α IL1A Human NM_000575.3 Hs00174092_m1 6-7 
Interleukin-6 IL6 Human NM_000600.3 Hs00985639_m1 2-3 
Interleukin-8 IL8 Human NM_000584.3 Hs00174103_m1 1-2 
Interleukin-1 receptor-associated kinase 2 IRAK2 Human NM_001570.3 Hs00176394_m1 11-12 
Integrin alpha 4 ITGA4 (CD49D) Human NM_000885.4 Hs00168433_m1 2-3 
Integrin alpha L ITGAL (CD11a) Human NM_001114380.1 Hs00158218_m1 13-14 
Vascular adhesion molecule-1 VCAM1 Human NM_001078.3 Hs00365480_g1 1-2 
Table 2.2: TaqMan gene expression assays 
TaqMan gene expression assays were purchased from ThermoFisher Scientific. Table shows the target genes investigated in this study, the relevant assay 
IDs (identification numbers used by the manufacturer) and the reference sequences used for primer and probe design (taken from the NCBI RefSeq 
database). Most TaqMan probes bind across exon boundaries because this ensures that the assay only detects genes that have been correctly spliced. 
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Figure 2.4: TaqMan versus SYBR Green chemistry in qRT-PCR 
A. TaqMan gene expression assays contain forward (FP) and reverse (RP) primers and a 
gene-specific probe. i. The probe has a fluorescent reporter dye (R) and quencher (Q) 
attached and binds to the target gene. ii. During primer extension DNA polymerase 
cleaves the probe, releasing the reporter dye from the quencher and increasing 
fluorescence. iii. Cleavage of the probe by DNA polymerase allows the primer to continue 
extension without affecting binding. B. i. SYBR Green dye binds to all double-stranded 
DNA. ii. As DNA is denatured during qRT-PCR, SYBR Green is released and 
fluorescence is decreased. iii. When qRT-PCR is complete the dye binds to all double-
stranded DNA. Figure adapted from https://www.thermofisher.com/uk/en/home/life-
science/pcr/real-time-pcr/qpcr-education/taqman-assays-vs-sybr-green-dye-for-
qpcr.html 
.
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2.7. Protein analysis 
2.7.1. Enzyme-linked immunosorbent assay  
Supernatant from stimulated cells was collected in a 1.5ml microcentrifuge tube and centrifuged 
at 179g for 5 minutes to pellet cells. The supernatant was then stored at -80oC prior to further 
assays.  
Enzyme-linked immunosorbent assays (ELISA) were used to detect cellular cytokine secretion. 
IL-6, IL-8, CXCL10 and sICAM-1 ELISA kits (Peprotech, London, UK) were used according 
to the manufacturer’s protocol with minor modifications for the assay development step, as 
optimised by Dr Jem Palmer. Unless otherwise stated all steps were followed by aspiration of 
the plate and 2 wash cycles using an automated plate washer (ThermoFisher Scientific) and 
wash buffer (1X PBS and 0.01% v/v Tween).  
An Immulon 4HBX 96-well plate (ThermoFisher Scientific) was coated with capture antibody 
at 4oC overnight. The plate was blocked for 1h at room temperature (RT) using 5% w/v bovine 
serum albumin (BSA) in PBS. The block buffer was diluted 1:10 in wash buffer to give the 
reagent diluent. Samples were diluted in reagent diluent as appropriate and a seven-point 
standard curve was generated before standards and samples were added to the plate in triplicate 
and incubated for 3h at 4oC. Reagent diluent was included to give a blank reading for 
normalisation. The detection antibody was added to the plate and incubated at RT for 2h. 
Instead of using the avidin provided in the kit, streptavidin-HRP (horseradish peroxidise) 
conjugate (ThermoFisher Scientific) was diluted 1:5000 in reagent diluent before addition to 
the plate and incubation for 30 minutes at RT. The detection solution was composed of 200µl 
o-phenylenediamine dihydrochloride (OPD), 5µl hydrogen peroxide and 12.5 ml citrate buffer 
and incubated at RT until colour had fully developed. No aspiration and wash step was 
performed at this point. The reaction was stopped with 2M sulphuric acid (H2SO4). Absorbance 
was read at 490nm on a BioTek Synergy HT plate reader (BioTek, Vermont, USA). The 
Peprotech ELISA protocol is summarised in Table 2.3 and reagent concentrations are shown 
in Table 2.4.  
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Step Diluent 
Volume 
(µl) 
Time (h) 
Temperature 
(oC) 
Capture antibody PBS 100 Overnight 4 
Block buffer (5% w/v 
BSA) 
PBS 150 1 RT 
Samples and standards 
Reagent 
diluent 
100 3h 4 
Detection antibody 
Reagent 
diluent 
100 2 RT 
Streptavidin-HRP 
conjugate 
Reagent 
diluent 
100 0.5 RT 
OPD detection solution N/A 100 N/A RT 
Table 2.3: Peprotech ELISA protocol 
All volumes are per well of a 96 well plate. ‘RT’ indicates room temperature. The 
detection solution in the final step was incubated for approximately 3 minutes or until 
colour had fully developed. 
 
CCL20 secretion was quantified by DuoSet ELISA (R&D Systems, Minneapolis, USA) 
according to the manufacturer’s protocol. The protocol was similar to the Peprotech ELISA 
procedure with some minor differences. The capture antibody coating step was performed at 
RT and the plate was blocked in 1% w/v BSA in PBS. The plate was developed using a substrate 
solution with tetramethylbenzidine (R&D Systems) and absorbance was read at 450nm. 
Reagent concentrations for the CCL20 ELISA are shown in Table 2.4.   
 IL-6 IL-8 sICAM-1 CXCL10 CCL20 
Capture antibody (μg/ml) 1 0.5 1 0.5 2 
BSA in block buffer (%) 5 5 5 5 1 
Maximum standard (pg/ml) 2000 1000 3000 1000 1000 
Detection antibody (μg/ml) 0.5 0.5 0.5 0.25 0.02 
Table 2.4: ELISA reagent concentrations 
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2.7.2. ELISA data analysis 
Blank (reagent diluent) values were subtracted from all other standards and samples. A standard 
curve was generated (Figure 2.5) and used to calculate the sample concentrations. Values were 
multiplied by the appropriate dilution factor.  
 
Figure 2.5: Representative IL-6 ELISA standard curve 
2.8. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software Inc., San 
Diego, USA). All error bars show the standard error of the mean (SEM) unless otherwise stated. 
The analysis method is described for each individual experiment. Statistical significance is 
shown as follows *=p<0.05, **=p<0.01, ***=p<0.001.  
2.9. Graphs and images 
All graphs were generated using GraphPad Prism 6.0. Unless otherwise stated diagrams were 
created in Microsoft Powerpoint 2013 using Servier Medical Art images, available online at 
http://www.servier.com/Powerpoint-image-bank.  
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Chapter 3. Medium-throughput study to investigate the effect of cobalt 
ions 
3.1. Introduction 
Cobalt ions activate human TLR4 but it is not known how they regulate other TLR4 signalling 
factors including MyD88, TRIF, IRAK1 and IRAK3 (IRAKM). It is important to improve our 
understanding in this regard because these factors influence the inflammatory outcome of TLR4 
activation. Consequently, one of the initial aims of the study was to determine the effect of 
cobalt ions on a broad range of TLR4 signalling factors, inflammatory cytokines, chemokines, 
and their receptors, with the subsequent goal of identifying a marker of cobalt-mediated TLR4 
activation that can be used to further define the immunological effects of cobalt ions.  
3.1.1. MonoMac 6 cells 
A human cell line was required for this study because, as described in section 1.5.1, murine 
TLR4 is not activated by cobalt ions. Further sequence analysis of this region of TLR4 revealed 
that the histidine pocket is only present in humans and other primates, precluding the use of 
conventional small animal models (Figure 3.1). Although humanised mouse models represent 
a realistic option for future research, one of the aims of the present study was to develop an in 
vitro model to test the effects of cobalt and other metal ions, and therefore a human cell line 
was considered appropriate. Macrophages are highly relevant to ARMD as they often dominate 
the inflammatory infiltrate of MoM peri-implant tissues (Natu et al., 2012) and their presence 
in synovial fluid makes them primary responders to wear debris. MonoMac 6 cells were chosen 
for this study because they are responsive to LPS through their expression of TLR4 (Lee and 
Sullivan, 2001).  
 
Figure 3.1: Presence of TLR4 histidine pocket in different species 
The histidine pocket (red box) present at positions 456 and 458 in the human TLR4 
sequence is also present in other primates such as the baboon (‘PAPAN’) and chimpanzee 
(‘PANPA’). However it is not found in the mouse, rat or Chinese hamster (‘CRIGR’) 
TLR4 sequences, nor in larger animals including the pig. Analysis was performed using 
the UniProt alignment tool available online at 
http://www.uniprot.org/align/A201601082M3UUO3L42.  
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3.2. Objectives 
 To investigate the effect of cobalt ions on expression of a range of inflammatory 
cytokine and TLR signalling genes using qRT-PCR arrays 
 To validate any notable findings from the arrays using TaqMan-based gene expression 
assays for individual target genes  
 To investigate the effect of cobalt ions on secretion of pro-inflammatory cytokines using 
Proteome Profiler (dot blot) arrays 
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3.3. Specific materials and methods 
3.3.1. RT2 Profiler qRT-PCR arrays  
MonoMac 6 cells were seeded at 0.2x106 cells per well in a 6-well plate and treated with 
0.75mM CoCl2 or left untreated for 4h. The CoCl2 concentration was selected based on previous 
in vitro studies on cobalt and TLR4 (Raghavan et al., 2012), as well as the MRes project 
preceding this work, and will be discussed in more detail in chapter 4. RNA was isolated using 
an RNeasy Mini Kit (Qiagen, Venlo, Netherlands) as described in section 2.6.1. cDNA was 
reverse transcribed from 1µg RNA using an RT2 First Strand Kit (Qiagen) following the 
manufacturer’s protocol, which included a genomic DNA elimination step. cDNA was then 
used for SYBR Green-based RT2 Profiler PCR arrays (Qiagen). The arrays used were 
Inflammatory Cytokines and Receptors (PAHS-011C) and Toll-like Receptor Signalling 
Pathway (PAHS-018Z), and were performed according to manufacturer’s protocol. Briefly, 
102µl cDNA was mixed with 1350µl 2x RT2 SYBR Green Mastermix (Qiagen) and 1248µl 
RNase-free H2O before 25µl of the reaction was added to each well of the array plate. Each 
array included a series of housekeeping gene controls and human genomic DNA contamination 
controls. qRT-PCR was conducted using a StepOnePlus thermal cycler and the reactions were 
heated to 95oC for 10 minutes before 40 cycles of 15 seconds at 95oC and 1 minute at 60oC. 
Three independent CoCl2 stimulation experiments were performed meaning that six arrays 
(three each for stimulated and unstimulated) were conducted in total.  
3.3.2. qRT-PCR array data analysis 
Data obtained from the qRT-PCR arrays was analysed using Qiagen’s RT2 Profiler PCR Array 
Data Analysis program Version 3.5 (available online at 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) and the Excel analysis 
spreadsheet (available via the same website). All three pairs of arrays were analysed together. 
p values of <0.05 were considered significant, together with a fold change in gene expression 
of greater than 2.  
Any genes in which the average Ct value for both treated and untreated samples was >35 were 
excluded from the analysis as very low Ct values can affect results. In addition, genes in which 
one sample (e.g. unstimulated) had an average Ct value of >35 were noted and this is taken into 
consideration in the analysis.  
3.3.3. Proteome Profiler human cytokine array 
Proteome Profiler Human Cytokine Arrays (R&D Systems, Minneapolis, USA) detect 
inflammatory cytokines in cell culture supernatant using a principle similar to an ELISA. 
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Capture antibodies are bound to a nitrocellulose membrane and after incubation with cell 
culture supernatant a cocktail of biotinylated detection antibodies is added. The signal is 
detected using streptavidin-HRP and chemiluminescence meaning that it is proportional to the 
amount of cytokine present. Arrays were conducted according to the manufacturer’s protocol 
using conditioned media (supernatant) from MonoMac 6 cells stimulated with 0.75mM CoCl2, 
1000ng/ml LPS or left unstimulated for 24h. This longer timepoint was chosen to allow for 
protein expression changes compared to the shorter 4h stimulation used for gene expression.
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3.4. Results 
3.4.1. Effect of cobalt ions on MonoMac 6 cell viability 
Cobalt is known to be cytotoxic in both its ionic and particulate forms (Kwon et al., 2009). 
Before the qRT-PCR arrays were conducted it was important to determine whether or not CoCl2 
caused cytotoxicity in MonoMac 6 cells as this could influence the assay outcome. MonoMac 
6 cells were stimulated for 4h with 0.75mM CoCl2 and a cytotoxicity assay was conducted 
(Figure 3.2A&B) using trypan blue staining. Images were taken using a Luna II automated cell 
counter and counted manually for the reasons detailed in section 2.5. Viability in untreated 
MonoMac 6 cells was normalised to 100%. CoCl2 stimulation caused cell viability to decrease 
to 94% (p<0.0059) (Figure 3.2C) showing that CoCl2 does cause a degree of cytotoxicity in 
MonoMac 6 cells.  
 
Figure 3.2: Effect of CoCl2 on MonoMac 6 cell viability 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h and cytotoxicity was 
assessed by trypan blue staining. Images were taken on a Luna II automated cell counter 
and counted manually. A. Luna cell counter image of unstimulated cells. B. Luna cell 
counter image of CoCl2-stimulated cells. C. Percentage cell viability of MonoMac 6 cells 
following CoCl2 stimulation. Data was normalised to 100% viability in untreated cells. 
Graph shows combined results from two independent experiments. Statistical 
significance was calculated by unpaired Student’s t test. 
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3.4.2. Effect of cobalt ions on TLR4 expression 
Many studies report that TLR4 ligands such as LPS exert their effects in part through 
upregulation of TLR4 expression (Bosisio et al., 2002, Yokota et al., 2010, Guzzo et al., 2012). 
TLR4 expression was investigated to determine whether or not this might be the case for cobalt 
ions, which could contribute to any observed changes. Analysis by qRT-PCR using TaqMan 
gene expression assays revealed that 4h stimulation of MonoMac 6 cells with 0.75mM CoCl2 
did not cause any changes in TLR4 expression compared to the unstimulated control (p=0.1018) 
(Figure 3.3). 
 
Figure 3.3: Effect of CoCl2 on TLR4 expression 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h. RNA was collected and 
cDNA synthesised by reverse transcription. TLR4 expression was analysed by qRT-PCR 
(TaqMan gene expression assay). Data is representative of three independent experiments 
and statistical significance was calculated using a Student’s t test (p=0.1018).  
3.4.3. Effect of cobalt ions on TLR signalling genes 
qRT-PCR arrays were used to determine the effect of cobalt ions on genes related to TLR 
signalling, and inflammatory cytokine and receptor genes. The arrays were specifically selected 
to give an overview of the inflammatory response to cobalt in relation to TLR signalling as 
cobalt ions activate human TLR4.  
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h before RNA was isolated and 
cDNA synthesised from 1µg RNA by reverse transcription. TLR Signalling qRT-PCR arrays 
(PAHS-018Z) were then performed. Genes with a fold upregulation greater than 2 are shown 
in Table 3.1 while those showing a fold downregulation greater than 2 are detailed in Table 
3.2. Overall 23 genes were upregulated by CoCl2 treatment and 23 were downregulated. An 
initial overview of the affected genes shows the widespread effects of cobalt as it regulated the 
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expression of genes encoding PRRs, signalling factors, transcription factors, adaptor proteins, 
and cytokines. The full gene list along with detected fold changes and p values is shown in 
Appendix A.   
There was no change in TLR4 expression which supports the results of the TaqMan-based 
analysis in Figure 3.3. However, expression of other TLRs (TLR1, TLR3, TLR5, TLR6, TLR8 
and TLR9) was downregulated following cobalt stimulation, most notably TLR1 which 
decreased more than 30-fold. Downregulation of TLR6 reached statistical significance 
(p=0.0251). 
TLR4 and other TLRs recruit adaptor proteins to their intracellular domains to initiate 
downstream signalling pathways. The MyD88-dependent and TICAM1 (TRIF)-dependent 
pathways can both be activated when LPS binds TLR4 (Kawai et al., 2001, Weighardt et al., 
2004). The arrays showed a significant increase in TICAM1 expression (p=0.0393) following 
cobalt stimulation and TICAM2 (TRAM) was also upregulated. In contrast MYD88 expression 
was decreased 3-fold by cobalt ions (Table 3.2), although other components of the MyD88-
dependent pathway were upregulated, including interleukin receptor-associated kinase 2 
(IRAK2) (p=0.0133).  
The expression of genes encoding transcription factors was also regulated by cobalt ions, 
particularly members of the NFκB family. NFKB1 was upregulated 7-fold and an inhibitor of 
NFκB, NFKBIA, was similarly increased (Table 3.1). However signalling factors involved in 
activation of other transcription factors were also upregulated, including Jun proto-oncogene 
(JUN) (p=0.0159) which is part of the JNK/p38 pathway and results in AP-1 transcription factor 
activation.  
The gene showing the largest fold upregulation in the TLR signalling arrays was HSPA1A 
which encodes heat shock 70kDa protein 1A (an Hsp70 family member); its expression was 
upregulated more than 200-fold by CoCl2 (Table 3.1). Two pro-inflammatory cytokine genes, 
interleukin-8 (IL8) and interleukin-1A (IL1A) were significantly upregulated (p<0.001 and 
p=0.0255 respectively). A second gene encoding heat shock 60kDa protein, HSPD1, was also 
upregulated, although this was not statistically significant. In addition to the very large 
expression changes detected for these genes, smaller fold changes were observed for other 
cytokines and chemokines, including interleukin-1B (IL1B), chemokine (C-X-C motif) ligand 
10 (CXCL10) and colony stimulating factor 2 (CSF2). In contrast other pro-inflammatory 
cytokines were downregulated, including interferon gamma (IFNG) and interleukin-2 (IL2). 
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CCL2 showed the largest downregulation (over 400-fold) of all genes on the TLR signalling 
arrays (Table 3.2). 
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Gene RefSeq Gene name Fold change  
HSPA1A NM_005345 Heat shock 70kDa protein 1A 202.39 
IL8 NM_000584 Interleukin 8 40.91 
HSPD1 NM_002156 Heat shock 60kDa protein 1 28.04 
IL1A NM_000575 Interleukin 1 alpha 17.11 
NFKBIA NM_020529 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor, alpha 
7.81 
NFKB1 NM_003998 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1 
7.62 
UBE2N NM_003348 Ubiquitin-conjugating enzyme E2N 5.03 
TICAM2 NM_021649 Toll-like receptor adaptor molecule 2 4.92 
JUN NM_002228 Jun proto-oncogene 4.47 
PELI1 NM_020651 Pellino homologue 1 4.42 
IL1B NM_000576 Interleukin 1 beta 4.32 
TICAM1 NM_182919 Toll-like receptor adaptor molecule 1 3.68 
TIRAP NM_001039661 
Toll-interleukin 1 domain-containing 
adaptor protein 
3.47 
CXCL10 NM_001565 Chemokine (C-X-C motif) ligand 10 3.28 
TLR10 NM_030956 Toll-like receptor 10 3.2 
IRAK2 NM_001570 
Interleukin-1 receptor-associated kinase 
2 
3.17 
CSF2 NM_000758 
Colony stimulating factor 2 (granulocyte-
macrophage) 
2.42 
CHUK NM_001278 
Conserved helix-loop-helix ubiquitous 
kinase 
2.35 
REL NM_002908 
V-rel reticuloendotheliosis viral 
oncogene homologue (avian) 
2.32 
TBK1 NM_013254 TANK-binding kinase 1 2.28 
RIPK2 NM_003821 
Receptor-interacting serine-threonine 
kinase 2 
2.25 
CASP8 NM_001228 
Caspase 8, apoptosis-related cysteine 
peptidase 
2.06 
CLEC4E NM_014358 C-type lectin domain family 4, member E 2.01 
 
Table 3.1: Upregulated TLR signalling genes following cobalt stimulation 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h before RNA was isolated 
and cDNA synthesised by reverse transcription. Gene expression was assessed by TLR 
Signalling qRT-PCR array (PAHS-018Z). Table shows genes that were upregulated more 
than 2-fold. Significant (p<0.05) changes are shown in bold. Analysis was performed 
using Qiagen’s online array analysis software (see section 3.3.2) using three pairs of 
arrays (stimulated versus unstimulated). The full array analysis results are shown in 
Appendix A. 
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Gene RefSeq Gene name Fold change 
CCL2 NM_002982 Chemokine (C-C motif) ligand 2 -410.75 
TLR1 NM_003263 Toll-like receptor 1 -33.91 
IL2 NM_000586 Interleukin 2 -32.56 
TLR8 NM_138636 Toll-like receptor 8 -12.88 
IFNG NM_000619 Interferon gamma -10.96 
CD180 NM_005582 CD180 molecule -9.00 
CD14 NM_000591 Cluster of differentiation 14 -8.76 
IL12A NM_000882 Interleukin 12A -5.46 
FADD NM_003824 
Fas (TNFRSF6)-associated via death 
domain 
-3.70 
TLR3 NM_003265 Toll-like receptor 3 -3.45 
MYD88 NM_002468 
Myeloid differentiation primary response 
gene (88) 
-3.36 
TLR5 NM_003268 Toll-like receptor 5 -3.23 
IFNB1 NM_002176 Interferon beta 1 -3.21 
NFKBIL1 NM_005007 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor-like 1 
-3.18 
HRAS NM_005343 
V-Ha-ras Harvey rat sarcoma viral 
oncogene homologue 
-3.05 
TAB1 NM_006116 TGF-beta activated kinase 1 -3.01 
TLR6 NM_006068 Toll-like receptor 6 -2.75 
ELK1 NM_005229 ELK1, member of ETS oncogene family -2.67 
TLR9 NM_017442 Toll-like receptor 9 -2.41 
SIGIRR NM_021805 
Single immunoglobulin and toll-interleukin 
1 receptor (TIR) domain 
-2.39 
CD86 NM_006889 CD86 molecule -2.22 
IRAK4 NM_016123 
Interleukin-1 receptor-associated kinase 
4 
-2.18 
MAP2K4 NM_003010 Mitogen-activated protein kinase kinase 4 -2.02 
 
Table 3.2: Downregulated TLR signalling genes following cobalt stimulation 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h before RNA was collected, 
cDNA synthesised by reverse transcription and gene expression assessed by TLR 
Signalling qRT-PCR arrays (PAHS-018Z). Table shows genes that were downregulated 
more than 2-fold. Significant (p<0.05) changes are shown in bold. Analysis was 
performed using Qiagen’s online array analysis software (see section 3.3.2) using three 
pairs of arrays (stimulated versus unstimulated). The full array analysis results are shown 
in Appendix A. 
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3.4.4. Effect of cobalt ions on inflammatory cytokine genes 
Using the same method as described earlier (4h stimulation of MonoMac 6 cells with 0.75mM 
CoCl2), cobalt-mediated gene expression changes were analysed using Inflammatory Cytokine 
and Receptor qRT-PCR arrays (PAHS-011C). As seen in the TLR arrays, cobalt regulated 
expression of a broad ranges of genes including chemokines, cytokines, and their receptors. 
Fourteen genes were upregulated more than 2-fold (Table 3.3) while 32 were downregulated 
by the same factor (Table 3.4). The full gene list along with detected fold changes and p values 
is shown in Appendix B. 
Upregulated expression of 8 chemokines was observed (Table 3.3). Two of these changes were 
found to be significant, the 35-fold upregulation of chemokine (C-C motif) ligand 20 (CCL20) 
(p=0.0020) and the 14.53-fold upregulation in IL8 expression (p=0.0236). Other upregulated 
chemokine genes included chemokine (C-X-C motif) ligand 2, 3 and 14 (CXCL2, CXCL3 and 
CXCL14) as well as chemokine (C-C motif) ligand 3, 4 and 25 (CCL3, CCL4 and CCL25) but 
none of the changes reached statistical significance. Downregulation of 9 chemokine genes was 
noted; CCL7, CCL2, CCL8, CCL13, CCL11, CXCL12, CXCL13 CXCL6 and CCL23 were all 
downregulated by more than 2-fold but none were statistically significant.  
Interleukin-36 gamma (IL36G), lymphotoxin alpha (LTA) and interleukin-1 beta (IL1B) 
expression was upregulated following cobalt stimulation (Table 3.3). However as with 
chemokine expression there was not a uniform upregulation of cytokine expression, with 
downregulation observed in expression of interleukin-36 alpha (IL36A), interleukin-10 (IL10) 
and interleukin-5 (IL5) (Table 3.4).   
Only one cytokine or chemokine receptor, interleukin-1 receptor 1 (IL1R1), was upregulated 
following cobalt treatment (Table 3.3). Several receptor genes were downregulated, including 
chemokine (C-C motif) receptor 2 (CCR2), chemokine (C-X-C motif) receptor 1 and 2 (CXCR1 
and CXCR2), interleukin-10 receptor beta (IL10RB) and interleukin-13 receptor alpha 1 
(IL13RA1). Of these IL10RB was significantly decreased (p<0.001) by cobalt ions (Table 3.4).  
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Gene RefSeq Gene name Fold change 
CCL20 NM_004591 Chemokine (C-C motif) ligand 20 34.96 
CXCL3 NM_002090 Chemokine (C-X-C motif) ligand 3 15.13 
IL8 NM_000584 Interleukin 8 14.53 
CXCL2 NM_002089 Chemokine (C-X-C motif) ligand 2 11.21 
CCL4 NM_002984 Chemokine (C-C motif) ligand 4 10.27 
CCL25 NM_005624 Chemokine (C-C motif) ligand 25 7.71 
C3 NM_000064 Complement component 3 7.20 
IL13 NM_002188 Interleukin 13 2.97 
CXCL14 NM_004887 Chemokine (C-X-C motif) ligand 14 2.96 
IL1R1 NM_000877 Interleukin 1 receptor type 1 2.76 
IL36G NM_019618 Interleukin 36 gamma 2.73 
LTA NM_000595 Lymphotoxin alpha 2.53 
CCL3 NM_002983 Chemokine (C-C motif) ligand 3 2.21 
IL1B NM_000576 Interleukin 1 beta 2.11 
 
Table 3.3: Upregulated inflammatory cytokine and receptor genes following cobalt 
stimulation 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h before RNA was isolated 
and cDNA synthesised by reverse transcription. Gene expression changes were assessed 
by Inflammatory Cytokine and Receptor qRT-PCR arrays (PAHS-011C). Table shows 
all genes that were upregulated more than 2-fold. Significant changes (p<0.05) are shown 
in bold. Analysis was performed using Qiagen’s Excel-based software using three pairs 
of arrays (stimulated versus unstimulated). Full results of the array analysis are shown in 
Appendix B. 
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Gene RefSeq Gene name Fold change 
CCR2 NM_001123396 Chemokine (C-C motif) receptor 2 -77.1 
CD40LG NM_000074 CD40 ligand -11.78 
LTB4R NM_181657 Leukotriene B4 receptor -11.04 
CCR1 NM_001295 Chemokine (C-C motif) receptor 1 -9.43 
CCL7 NM_006273 Chemokine (C-C motif) ligand 7 -9.11 
CCL2 NM_002982 Chemokine (C-C motif) ligand 2 -6.81 
IL36A NM_014440 Interleukin 36 alpha -6.25 
LTB NM_002341 Lymphotoxin beta -5.91 
IL10 NM_000572 Interleukin 10 -5.50 
IL1F10 NM_173161 Interleukin 1 family member 10 (theta) -5.47 
CARD18 NM_021571 
Caspase recruitment domain family member 
18 
-4.42 
CCR6 NM_004367 Chemokine (C-C) motif receptor 6 -4.35 
CCL8 NM_005623 Chemokine (C-C motif) ligand 8 -4.10 
CCL13 NM_005408 Chemokine (C-C motif) ligand 13 -3.96 
CCL11 NM_002986 Chemokine (C-C motif) ligand 11 -3.82 
IL36B NM_173178 Interleukin 36 beta -3.60 
TNF NM_000594 Tumour necrosis factor -3.25 
CXCL12 NM_000609 Chemokine (C-X-C motif) ligand 12 -3.03 
IL1RN NM_000577 Interleukin 1 receptor antagonist -2.86 
IL5 NM_000879 Interleukin 5 -2.82 
CXCL13 NM_006419 Chemokine (C-X-C motif) ligand 13 -2.66 
AIMP1 NM_004757 Aminoacyl tRNA synthetase -2.58 
ABCF1 NM_001090 ATP-binding cassette sub-family 4 -2.57 
TOLLIP NM_019009 Toll interacting protein -2.54 
CXCL6 NM_002993 Chemokine (C-X-C) motif ligand 6 -2.53 
CXCR2 NM_001557 Chemokine (C-X-C motif) receptor 2 -2.50 
CCR5 NM_000579 Chemokine (C-C motif) receptor 5 -2.33 
C5 NM_001735 Complement component 5 -2.12 
IL10RB NM_000628 Interleukin 10 receptor beta -2.10 
CXCR1 NM_000634 Chemokine (C-X-C motif) receptor 1 -2.10 
CCL23 NM_005064 Chemokine (C-C motif) ligand 23 -2.05 
IL13RA1 NM_001560 Interleukin 13 receptor alpha 1 -2.02 
 
Table 3.4: Downregulated inflammatory cytokine and receptor genes following 
cobalt stimulation 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h before RNA was isolated 
and cDNA synthesised by reverse transcription. Gene expression changes were assessed 
by Inflammatory Cytokine and Receptor qRT-PCR arrays (PAHS-011C). Table shows 
all genes that were downregulated more than 2-fold. Significant changes (p<0.05) are 
shown in bold. Analysis was performed using Qiagen’s Excel-based software using three 
pairs of arrays (stimulated versus unstimulated). Full array analysis results are shown in 
Appendix B. 
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3.4.5. Validation of target genes by TaqMan-based qRT-PCR 
The qRT-PCR arrays use SYBR Green dye for gene expression quantification. TaqMan gene 
expression assays contain a probe specific for the target gene, providing a higher degree of 
specificity than the SYBR Green method (Figure 2.4). Selected results obtained from the qRT-
PCR arrays were therefore validated using TaqMan gene expression assays for individual 
genes. The chosen target genes and their reasons for selection are detailed in Table 3.5. They 
included genes that were significantly up- or downregulated following cobalt stimulation, those 
that showed inter-assay variability, and others that gave different results than predicted based 
on previous studies. 
Target gene 
Array fold 
change 
Reason for validation 
IL8 40.91 Significantly upregulated in arrays 
CCL20 34.96 Significantly upregulated in arrays 
CCL25 7.71 Upregulated in arrays 
CXCL10 3.28 
Upregulated in TLR array, no change detected in cytokine 
array 
IL1A 17.11 
Significantly upregulated in TLR array, no change detected 
in cytokine array 
IRAK2 3.17 
Significantly upregulated in arrays, key TLR4 signalling 
factor 
HMGB1 1.70 Known TLR4 ligand (Jong et al., 2006) 
HSPA1A 202.39 
Significantly upregulated in arrays, known TLR4 ligand 
(Klink et al., 2012) 
CCL2 -410.75 
Downregulated in arrays, literature suggests usually 
upregulated (Queally et al., 2009) 
Table 3.5: Target genes selected for further validation 
Table shows target gene expression fold changes detected by qRT-PCR arrays. IL8 and 
CCL2 were investigated on both sets of arrays; the fold changes shown in the table are 
the largest of the two detected.  
 
cDNA was synthesised using the Superscript III kit (section 2.6.2.1) and the RNA collected for 
the qRT-PCR arrays. TaqMan-based qRT-PCR analysis confirmed upregulation of IL8 
(p<0.001), CCL20 (p<0.001), CCL25 (p=0.0074), CXCL10 (p=0.0114), IL1A (p<0.001), 
IRAK2 (p<0.001) and HSPA1A (p<0.001) by MonoMac 6 cells in response to CoCl2 (Figure 
3.4A-G). There was no change in HMGB1 expression (p=0.9188) (Figure 3.4H) and a 
significant downregulation of CCL2 following cobalt stimulation (p<0.001) (Figure 3.4I), both 
of which were consistent with the SYBR Green array results. The fold change values were 
different from those obtained using the arrays and this will be discussed later in the chapter. 
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Figure 3.4: Validation of target gene expression by TaqMan-based qRT-PCR 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 4h before RNA was isolated 
and cDNA synthesised by reverse transcription. qRT-PCR was performed using TaqMan 
probes specific for the target genes. All data is representative of at least two independent 
experiments and statistical significance was calculated by an unpaired Student’s t test. 
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3.4.6. Effect of cobalt ions on inflammatory cytokine secretion 
Human Cytokine Proteome Profiler (dot blot) arrays (R&D Systems) were used to investigate 
the effect of cobalt ions on cytokine secretion by MonoMac 6 cells. Cells were treated with 
0.75mM CoCl2, 1000ng/ml LPS or left untreated for 24h. Conditioned media was then collected 
and incubated with the array membranes as per the manufacturer’s protocol. Relative dot 
intensity was calculated by densitometry using Photoshop as shown below: 
(Mean intensity of sample dot x number of pixels)/ 
(Mean intensity of control dot x number of pixels) 
Using this method the cytokine showing the largest change in secretion following CoCl2 
stimulation was IL-8, which was upregulated (Figure 3.5A). Other notable CoCl2-mediated 
increases were observed for interleukin-1 receptor antagonist (IL-1ra), macrophage migration 
inhibitory factor (MIF), serpin E1 and chemokine (C-X-C motif) ligand (CXCL1). Very small 
changes were observed in soluble intracellular adhesion molecule 1 (sICAM-1), CCL5 and 
CXCL10 secretion (Figure 3.5A).  
Following LPS stimulation MonoMac 6 cells considerably increased secretion of CCL2, CCL4, 
CXCL1, CXCL10 and IL-1ra. Elevated secretion of IL-1β, IL-8, sICAM-1, MIF and CCL3 was 
also observed (Figure 3.5). There were significant differences between the CoCl2 and LPS-
induced cytokine profiles, including in CXCL10 (p<0.001), CXCL1 (p=0.0026) and IL-1β 
(p<0.001) secretion (Figure 3.6). In all of these cases LPS caused a larger increase in cytokine 
secretion than CoCl2. These differences will be discussed in more detail in section 3.5. 
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Coordinate Cytokine Coordinate Cytokine Coordinate Cytokine 
A1 Reference B9 Serpin E1 D7 IL-5 
A2 CCL5 B10 - D8 IL-6 
A3 CXCL12 C1 - D9 IL-8 
A4 TNFα C2 IL-10 D10 - 
A5 sTREM-1 C3 IL-12 p70 E1 Reference 
A6 - C4 IL-13 E2 C5/C5a 
A7 - C5 IL-16 E3 CD40 
ligand 
A8 - C6 IL-17 E4 G-CSF 
A9 - C7 IL-17E E5 GM-CSF 
A10 Negative C8 IL-23 E6 CXCL1 
B1 - C9 IL-27 E7 CCL1 
B2 IL-32α C10 - E8 sICAM-1 
B3 CXCL10 D1 - E9 IFN-γ 
B4 CXCL11 D2 IL-1α E10 Reference 
B5 CCL2 D3 IL-1β  
B6 MIF D4 IL-1ra 
B7 CCL3 D5 IL-2 
B8 CCL4 D6 IL-4 
 
Figure 3.5: Proteome Profiler human cytokine arrays 
MonoMac 6 cells were treated with 0.75mM CoCl2, 1000ng/ml LPS or left untreated for 
24h. Supernatant was collected and used for Proteome Profiler human cytokine arrays 
(R&D Systems). A. Dot blot showing changes in cytokine secretion following CoCl2 and 
LPS stimulation. B. Coordinates of antibodies on dot blot arrays. Dashes indicate that 
there was no antibody present.  
A. 
B. 
71 
 
 
 
Figure 3.6: Densitometric analysis of Proteome Profiler arrays 
Proteome Profiler human cytokine arrays were conducted using supernatant from MonoMac 6 cells stimulated with either 0.75mM CoCl2 or 
1000ng/ml LPS for 24h. Relative intensity of membrane dots was calculated and normalised to the untreated control (set to 0). Graph shows all 
upregulated cytokines and compares secretion of each cytokine in response to CoCl2 (light bars) and LPS (dark bars). n=1. Statistical significance 
was calculated by unpaired Student’s t test. p values: CXCL10 (p<0.001), IL-1ra (p=0.9139), MIF (p=0.0014), CXCL1 (p=0.0026), sICAM-1 
(p=0.0011), Serpin E1 (p=0.0158), IL-8 (p=0.0011), C5/C5a (p=0.0824), IL-1β (p<0.001), CCL2 (p<0.001), CCL3 (p=0.0015), CCL4 (p<0.001), 
CCL5 (p=0.3422), G-CSF (p=0.0321). 
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3.5. Discussion 
MonoMac 6 cells were chosen for this aspect of the study because as a cell line they should 
provide a consistent and reproducible response to stimuli. They have also previously been 
shown to express TLR4 and respond to LPS by increasing their secretion of cytokines including 
IL-8 (Dr Jem Palmer, Newcastle University, personal communication). Although primary blood 
mononuclear cells (PBMC) would be interesting to study, they introduce an element of 
variability (e.g. TLR4 expression levels) that was not desirable at this point in the investigation.  
Initial observations of the qRT-PCR array analysis shows that cobalt ions have a broad effect 
on inflammatory genes, regulating cytokine, chemokine, and receptor expression, as well as 
that of PRRs and signalling factors from different pathways, including the MyD88-dependent 
and TRIF-dependent arms of TLR signalling. Most previous studies have focused on the 
outcome of inflammatory signalling (i.e. cytokine secretion or macrophage activation) rather 
than on the activated signalling pathways and how their components may be regulated. This 
section will discuss the results obtained from the qRT-PCR arrays in signalling pathway order 
from immune receptors (e.g. TLRs) through to cytokines, chemokines, and other inflammatory 
mediators.   
Toll-like receptor expression 
The TLR signalling arrays detected downregulation of TLR1, TLR3, TLR5, TLR6, TLR8 and 
TLR9 expression following cobalt treatment, while TLR4 expression was unaffected. This is 
largely consistent with the results of tissue analysis by Takagi et al who observed decreased 
expression of all TLRs (except TLR4 and TLR9) in tissues surrounding aseptically-loosened 
hip implants compared to controls (Takagi et al., 2007). The same study showed that TLR4 
expression around these joints is largely due to infiltrating macrophages and thus highlights the 
benefit of using MonoMac 6 cells as a model in this study. The absence of cobalt-mediated 
changes in TLR4 expression is interesting because TLR4 is often upregulated following LPS 
stimulation, which enhances the inflammatory response (Guzzo et al., 2012). It suggests that 
other gene expression changes, such as upregulation of IL8, are a consequence of downstream 
signalling pathway activation and effector molecule expression rather than increased TLR4 
expression and activation. Attempts were made during this study to investigate the effect of 
cobalt ions on TLR4 cell surface expression using flow cytometry. However optimisation of 
the TLR4 antibody proved challenging and given the timeframe of the project analysis by this 
method was not possible. Further investigation into TLR4 protein expression would therefore 
be required to fully validate the conclusions drawn in this section of the study.   
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TLR10 was the only TLR gene upregulated by CoCl2. The reasons for this are unclear as the 
ligand for TLR10 has not yet been identified. It has been suggested that TLR10 recognises viral 
PAMPs (Lee et al., 2014) but a recent study has also indicated that it is able to dampen 
inflammatory cytokine secretion and therefore may be the only TLR to inhibit inflammation 
(Oosting et al., 2014). Given this conflicting information it is difficult to interpret cobalt-
mediated TLR10 upregulation.  
Co-receptors, adaptor proteins and co-stimulatory molecules 
LPS activation of TLR4 requires co-receptors LBP, CD14 and MD2 (also known as lymphocyte 
antigen 96 or LY96) but the effect of cobalt on these proteins is not yet clear. No change in 
MD2 expression was detected after CoCl2 stimulation but CD14 expression was downregulated. 
CD14 only becomes involved in TLR4 pathogen recognition once LPS has bound to LBP and 
as cobalt binds directly to TLR4, the downregulation of CD14 may indicate that it is not part of 
the signalling complex required for cobalt activation of the receptor.  
Downregulation of CD180 expression was detected by the arrays. CD180 forms a complex with 
myeloid differentiation protein 1 (MD1, also known as lymphocyte antigen 86 or LY86) and 
works with TLR4 to promote B cell proliferation and differentiation in response to LPS. LY86 
expression was unaffected by cobalt ions. Expression of another co-stimulatory molecule, 
CD86, was also downregulated, although to a lesser degree than CD180 (2-fold compared to 9-
fold). CD86 is expressed by antigen-presenting cells and engagement with its ligand CD80 
stimulates T cell activation, as well as maturation of the antigen-presenting cell. Decreased 
expression of co-stimulatory molecules is surprising as previous studies have shown that they 
can be upregulated in response to TLR4 activation by LPS (Hoebe et al., 2003). Caicedo et al 
also reported increased CD80 and CD86 expression in cobalt-stimulated macrophages (Caicedo 
et al., 2007), although these changes were detected at 48h post-stimulation which may account 
for the differences between the studies. It must be acknowledged that the in vitro approach used 
in the present study does not model the cell-cell interactions that take place in vivo and a co-
culture system (e.g. of endothelial cells with macrophages) would perhaps reveal different 
results; this method would better replicate the in vivo environment in which cell behaviour is 
influenced by factors (growth factors, cytokines, hormones etc) released by neighbouring cells, 
as well as by engagement with cell surface molecules. It may also be the case that at this very 
early timepoint cobalt does not induce effects that would result in activation of the adaptive 
immune system.  
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MyD88 and TRIF are the major intracellular adaptor proteins involved in LPS-mediated TLR4 
activation (Kawai et al., 1999, Yamamoto et al., 2003). Their recruitment to the activated 
receptor complex results in diverse but overlapping stimulation of inflammatory signalling 
pathways. MyD88-dependent signalling leads to upregulation of the transcription factors NFκB 
and AP-1 while TRIF-dependent signalling promotes IRF-mediated transcription (Figure 
1.10). 
. As a result there are differences in the cytokine profile resulting from activation of each 
pathway; MyD88/NFκB signalling leads to increases in cytokines like IL-6 and IL-8 (He et al., 
2013a, Morandini et al., 2013) while TRIF promotes release of type I interferons and CXCL10 
(Weighardt et al., 2004).  
Cobalt activation of TLR4 has previously been shown to activate the MyD88-dependent 
pathway (Potnis et al., 2013) so it was surprising to find a 3-fold downregulation of MYD88 
expression in this study. However Toll-interleukin 1 domain-containing adaptor protein 
(TIRAP) was upregulated; TIRAP binds to MyD88 to promote signalling pathway activation, 
indicating that downstream components of the MyD88 pathway can be activated by CoCl2. 
TRIF (referred to in the arrays as Toll-like receptor adaptor molecule 1 or TICAM1) and TRAM 
(Toll-like receptor adaptor molecule 2 or TICAM2) were both upregulated, suggesting increased 
activation of TRIF-dependent signalling by CoCl2. The clearest indication of MyD88 and TRIF 
pathway activation is given by the cytokine and chemokine profile generated in response to 
cobalt ions which will be discussed in more detail later in this section.  
As well as upregulation of positive regulators of TLR4 signalling, downregulation of inhibitory 
single immunoglobulin and toll-interleukin 1 receptor domain (SIGIRR) was detected. SIGIRR 
has a TIR domain that can engage with the homologous domain in TLR4 and prevent 
recruitment of MyD88 and TRIF, thus inhibiting downstream TLR4 signalling. Its reduced 
expression may indicate that MyD88 and TRIF are free to bind TLR4 and mediate activation 
of intracellular signalling cascades.  
Intermediate Toll-like receptor signalling factors 
Intracellular signalling pathways determine the outcome of cell stimulation, and are themselves 
dependent on the activity of the adaptor proteins and co-receptors described above. The TLR4 
signalling pathway is complex and there is considerable cross-talk between different pathways, 
as well as modulation or inhibition of the pathway by endogenous factors such as interleukin 1 
receptor-associated kinase 3 (IRAK3, IRAKM).  
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The IRAK proteins are essential to the MyD88 pathway of TLR4 signalling. IRAK2, 
upregulated by CoCl2, interacts with MyD88 and then with TRAF6 to mediate NFκB activation. 
A second IRAK, IRAK4, was slightly (2.18-fold) downregulated by CoCl2; IRAK4 is recruited 
to MyD88 when TLR4 is activated. TGF-beta activated kinase 1 binding protein 1 (TAB1) 
which forms part of the TRAF6 protein complex in the MyD88-dependent pathway was also 
downregulated. In the clinical context of this study it is interesting to note that TAB1 
downregulation is associated with increased activity of matrix metalloproteases (MMPs) which 
degrade collagen (Ciechomska et al., 2014). CoCl2 regulation of the TLR signalling pathway 
may therefore have broader effects aside from direct stimulation of cytokine secretion.  
Pellino homologue 1 (PELI1) was upregulated 4-fold by cobalt ions while ubiquitin-
conjugating enzyme E2N (UBE2N) expression was increased 5-fold. These two proteins may 
function together as Pellino-1 mediates the Lys-63 ubiquitination of IRAK1 which leads to 
NFκB activation while UBE2N is responsible for generating Lys-63 ubiquitin chains. A recent 
study has also shown that LPS stimulation upregulates Pellino-1 activity in MonoMac 6 cells, 
resulting in increased polyubiquitination of IRAK1, TBK1, and TAK1, and subsequent 
enhanced NFκB activity and IL-8 release (Murphy et al., 2015). The increased PELI1 
expression observed in the present study may contribute to potentiation of TLR4 activation and 
the increased IL8 expression also observed.   
The mitogen-activated protein (MAP) kinases control cell proliferation and differentation. 
Seven MAPK genes were investigated using the qRT-PCR arrays and of these only one, MAP 
kinase kinase 4 (MAP2K4), was affected by CoCl2. As this was a fold downregulation of just 
2.01 and there was no change in any of the other MAP kinase genes, it does not appear that 
MAP kinases play a significant role in the cellular response to cobalt at this early timepoint. It 
is important to acknowledge that no change in gene expression does not necessarily mean that 
there is no change in enzyme activity so inhibitors targeting MAP kinase function would be 
required to define their role in the response.  
Transcription factors 
The outcome of TLR signalling results in activation of one or more transcription factors 
including NFκB, AP-1 and interferon regulator factor 3 (IRF3). Array analysis showed that 
cobalt has a considerable impact on NFκB signalling. NFκB is present in most eukaryotic cells 
and is involved in the regulation of many inflammatory genes that express an NFκB binding 
site in their promoter region. NFκB itself is sequestered in the cytoplasm as part of a protein 
complex that prevents its activity. For NFκB-mediated gene transcription the inhibitor proteins 
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in the complex are phosphorylated and targeted for degradation. NFκB is then released and 
translocates to the nucleus to regulate gene transcription. Two of the kinases involved in the 
phosphorylation process were upregulated following cobalt stimulation; these were conserved 
helix-loop-helix ubiquitous kinase (CHUK), also known as IκB kinase-α (IKK-α, IKK1) and 
TANK-binding kinase 1 (TBK1). This supports the results of a previous study demonstrating 
that cobalt particles can induce degradation of inhibitors of κB (IκB) (Rachmawati et al., 2013), 
resulting in increased NFκB activity. In addition to upregulation of the NFκB-activating kinases 
there was a 7-fold increase in NFKB1 expression, which encodes a subunit of NFκB, again 
suggesting promotion of NFκB-mediated transcription by cobalt ions. There was also 
downregulation of NFκB inhibitor-like 1 (NFKBIL1). Although its function is not completely 
clear, NFκBIL1 is thought to inhibit inflammatory responses to LPS by preventing NFκB 
activation (Atzei et al., 2010) and consequently its downregulation following cobalt stimulation 
suggests a drive towards NFκB-mediated gene transcription.  
It is important to note that in addition to the increased expression of promoters of NFκB 
signalling, NFκB inhibitor alpha (NFKBIA) was upregulated by a similar fold change to 
NFKB1. This could potentially inhibit activity of the transcription factor, thus having a 
modulatory effect on immune responses. NFκBIα has also recently been implicated in carbon 
nanoparticle-induced cell death (Periasamy et al., 2016) and may therefore be a sign of cobalt 
cytotoxicity, although only a small cytotoxic effect was observed following 4h CoCl2 
stimulation.   
NFκB is a key regulator of immune responses, and chronic inflammatory diseases such as 
irritable bowel syndrome are associated with persistent NFκB-mediated inflammation (Asquith 
and Powrie, 2010). LPS induces the expression of NFκB-dependent genes such as IL-8 via a 
TLR4-dependent mechanism (Chow et al., 1999). NFκB activation through TLR4 requires the 
MyD88-dependent and TRIF-dependent pathways; MyD88-deficient mice display impaired 
cytokine production upon LPS exposure but although there is a time delay NFκB is still 
activated, which shows involvement of the TRIF pathway (Kawai et al., 1999). TRIF-deficient 
cells also show decreased LPS-mediated cytokine secretion but near normal NFκB activation 
because MyD88 compensates for the absence of TRIF (Yamamoto et al., 2003).  However when 
both adaptor proteins are inhibited there is no NFκB activation following LPS challenge 
(Yamamoto et al., 2003). This information suggests that the NFκB-mediated cytokine secretion 
observed here could therefore be the result of activation by either arm of the TLR4 signalling 
pathway.  
77 
 
Although NFκB signalling dominated the results of the arrays, signalling to other transcription 
factors was affected by CoCl2. Jun proto-oncogene (JUN) encodes c-Jun and complexes with 
other proteins to form the transcription factor AP-1. AP-1 regulates transcription of genes 
associated with bacterial and viral responses such as cytokines, and can also contribute to cell 
differentiation and apoptosis. Cobalt has previously been shown to induce apoptosis via 
activation of AP-1 at comparable concentrations (0.2-1mM) but this was at longer timepoints 
(36h) to those used for the arrays (Zou et al., 2001). Upregulation of JUN may contribute to 
AP-1 formation and subsequent apoptosis, which could in turn account for the cytotoxic effects 
of cobalt ions. These results show that the effects of cobalt are not limited to NFκB signalling.  
Cytokines and secreted factors 
The factor with the largest upregulation detected across all arrays was heat shock 70kDa protein 
1A (HSPA1A) followed by heat shock 60kDa protein 1A (HSPD1). Heat shock proteins (Hsps) 
are released as a response to cell stress and damage, and modulate inflammation by assisting in 
the refolding of proteins damaged during these processes. The increased expression of Hsps 
here is likely due to cobalt causing cytotoxicity, although as mentioned previously there was 
only a small decrease in cell viability in the presence of cobalt. Hsps and particularly HSPA1A 
will be discussed in more detail in chapter 4. 
The pleiotropy of cytokines makes analysing the potential inflammatory outcome of their up- 
or downregulation more complex. For example IL-13 is released during Th2 responses to 
modulate and dampen inflammation but it also increases the activity of matrix metalloproteases 
which promotes collagen deposition and fibrosis (Kaviratne et al., 2004). In this section 
cytokines will be discussed based on their dominant or most well-described function but it is 
acknowledged that their effects can be multifactorial and depend considerably on other factors 
such as receptor expression and the activity of other cytokines. 
The up- and downregulated cytokines detected in both sets of arrays were categorised as 
predominantly pro- or anti-inflammatory (Table 3.6). Of the five upregulated cytokines, four 
were pro-inflammatory (IL1A, IL1B, CSF2 and IL36G). For example IL1A encodes IL-1α which 
promotes inflammatory cell proliferation and increases activity of the transcription factors 
NFκB and AP-1 to drive further inflammatory cytokine secretion (Wolf et al., 2001). IL-1β, 
encoded by IL1B, is induced by NFκB-mediated transcription and is released when TLRs are 
activated by DAMPs (Eltom et al., 2014). However there was also increased expression of IL13 
which is a Th2-associated cytokine and can inhibit Th1 pro-inflammatory responses. 
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Downregulation of seven pro-inflammatory cytokines was observed (Table 3.6), including two 
interferons, IFNG (IFNγ) and IFNB1 (IFNβ). IFNγ is associated with decreased receptor 
activator of NFκB (RANK) expression (Ji et al., 2009) and therefore confers protection against 
osteoclastogenesis and subsequent osteolysis (Xu et al., 2009). In this case IFNγ 
downregulation could affect the balance between osteoblast and osteoclast formation and drive 
osteoclastogenesis. IFNβ promotes release of additional inflammatory cytokines and 
chemokines, as well as apoptosis. There was also a downregulation in TNFα expression, which 
is surprising because TNFα is usually upregulated in response to TLR4 stimulation by LPS and 
is often released early in inflammatory responses. However it is possible that using the array 
method (i.e. only studying one timepoint) means that any upregulation in TNFα expression is 
missed as changes in TNFα expression are often very transient. Additional dose response curves 
would be required to more fully investigate the effect of cobalt ions on TNFα expression and 
secretion.  
Interestingly, aside from IL13, the anti-inflammatory cytokines (IL2, IL10 and IL1F10) 
regulated by CoCl2 were all downregulated (Table 3.6). IL-2 contributes to lymphocyte 
proliferation, including regulatory T cells, and as such is considered anti-inflammatory or 
immunomodulatory. IL2 expression may be decreased here because the early timepoint used is 
unlikely to involve the adaptive immune system. Consequently, any of the cobalt-mediated 
inflammatory responses observed in this and other studies may not only be the result of 
increased pro-inflammatory cytokine secretion but also a decrease in the expression and activity 
of immunomodulatory cytokines.        
Pro-inflammatory Anti-inflammatory 
Upregulated cytokines 
IL1A    CSF2 
IL1B    IL36G 
IL13 
Downregulated cytokines 
IFNG    IL36B 
IL12A    TNF 
IFNB1    IL5 
IL36A 
IL10 
IL2 
IL1F10 (IL38) 
Table 3.6: Regulation of pro- and anti-inflammatory cytokines by cobalt ions 
Chemokine expression 
The expression of many chemokines was altered in response to CoCl2. IL8 expression was 
significantly upregulated in both sets of arrays although with different fold changes (40-fold in 
the TLR signalling arrays and 14.5-fold in the cytokine arrays). IL-8 promotes neutrophil 
migration, and other neutrophil chemotactic cytokines were upregulated including CCL20, 
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CXCL3, CXCL2 and CCL3 (Table 3.7). This is interesting as neutrophils are not present at high 
levels in failed MoM peri-implant tissues (Lähdeoja et al., 2009). However they do have a very 
short half-life and if they are indeed being recruited by these chemokines neutrophils may 
initiate recruitment of other inflammatory cells through secretion of cytokines such as CXCL10 
(chemotactic for lymphocytes). 
The arrays also detected increased expression of several monocyte/macrophage chemokines. 
These were CXCL10, CCL4, CCL25 and CXCL14 (Figure 3.7). Macrophages are often found 
in large numbers in ARMD tissues and these chemokines may be responsible for their 
recruitment. The only lymphocyte-specific upregulated chemokines were CXCL10 and CCL20. 
This could be because the adaptive immune response occurs over time and 4h post-CoCl2 
stimulation is too early to see any changes related to adaptive immunity.  
 
Chemokine 
Target cell 
Monocyte/macrophage Neutrophil T 
lymphocyte 
IL-8  ++  
CXCL10 ++  ++ 
CCL20  + ++ 
CXCL3  ++  
CXCL2  ++  
CCL4 ++   
CCL25 ++   
CXCL14 ++   
CCL3  ++  
Table 3.7: Target cells for chemokines upregulated by CoCl2 
Table shows the immune cells attracted by particular chemokines. ‘++’ indicates that a 
chemokine is strongly chemotactic for that particular cell, while ‘+’ indicates that the 
effect is weaker, or less well-described in the literature.  
 
Expression of several of the CCL chemokines was downregulated. However in some cases (e.g. 
CCL11) the change in expression was less than one Ct value but because their expression levels 
were low (Ct >30) this was amplified to give a large fold change. The exception to this is 
chemokine C-C motif ligand 2 (CCL2). CCL2 expression was higher (Ct<30) than that of the 
other CCL chemokines, although there was still a large downregulation in expression following 
CoCl2 stimulation. This is a very interesting observation as other studies have reported CCL2 
upregulation by cobalt-stimulated cells (Queally et al., 2009). However it is conceivable that 
the observed effect is a result of cobalt-mediated hypoxia as similar hypoxic effects have been 
reported (Bosco et al., 2004). Downregulation of CCL2 will be discussed in more detail later in 
this chapter and in chapter 6. .  
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Cytokine and chemokine receptor expression 
Of all the cytokine and chemokine receptor genes found to have a fold change >2, only 
interleukin-1 receptor type 1 (IL1R1) was upregulated. The encoded protein, IL-1R1, is very 
closely related to TLR family and receptor activation leads to recruitment of MyD88, activation 
of the MyD88-dependent pathway, and increased NFκB-mediated gene transcription (Muzio et 
al., 1997). Unlike TLRs IL-1R1 is activated by the endogenous cytokines IL-1α, IL-1β and IL-
1ra rather than PAMPs. Interestingly, IL1A expression was upregulated following cobalt 
stimulation, suggesting that this signalling pathway may be involved in the cellular response to 
cobalt ions.  
Downregulation of several other cytokine receptors was observed; these were chemokine (C-C 
motif) receptor 1 (CCR1) and 2 (CCR2), leukotriene B4 receptor (LTB4R), chemokine (C-X-
C) motif receptor 2 (CXCR2), interleukin-10 receptor beta (IL10RB) and interleukin-13 receptor 
alpha 1 (IL13RA1). The ligands for these receptors are shown in Table 3.8. IL10RB expression 
was significantly downregulated and is the receptor for members of the IL-10 family. Cytokines 
belonging to this family, including IL-9, IL-10 and IL-26, are primarily associated with 
inhibition of inflammatory responses and a drive towards a Th2 response. Downregulation of 
IL10RB following cobalt stimulation could indicate a decrease in the activity of 
immunomodulatory cytokines such as IL-10 and a Th1-dominated immune response. 
Receptor 
gene 
Ligands 
IL1R1 IL-1α, IL-1β, IL-1ra 
CCR2 CCL2, CCL7, CCL13 
LTB4R Leukotriene B4 
CCR1 CCL3, RANTES (CCL5), CCL7 
CXCR2 IL-8 
CXCR1 IL-8, CXCL6 
IL10RB IL-10, IL-22, IL-26, IL-28, IL-
29 
IL13RA1 IL-13 
Table 3.8: Cytokine and chemokine receptors and their ligands 
Table shows cytokine and chemokine receptor genes affected by cobalt ions and their 
ligands. IL1R1 was the only receptor found to be upregulated and expression of all others 
shown in the table was downregulated.  
 
The downregulation of so many cytokine and chemokine receptors following cobalt stimulation 
at first seems to suggest that the effect of cytokines may be inhibited, which could be aimed at 
protecting the cell from an overwhelming inflammatory response. However the downregulation 
may also be a direct result of increased cytokine and chemokine release. This is particularly the 
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case for expression of the IL-8 receptors CXCR1 and CXCR2 which were both downregulated 
by cobalt treatment. IL-8 can dose-dependently downregulate CXCR1 and CXCR2 expression 
by neutrophils which inhibits further neutrophil migration and allows increased cell adhesion, 
thus promoting localised inflammation (Hu et al., 2011). CXCR1 and CXCR2 expression can 
also be downregulated as a consequence of TLR4 activation by pathogens like LPS (Alves-
Filho et al., 2010). The impaired neutrophil migration causes inflammation at the neutrophil 
site and increased sepsis susceptibility (Rios-Santos et al., 2007). The change in CXCR1 and 
CXCR2 expression detected by the arrays may therefore be the result of increased IL-8 
expression and secretion, cobalt activation of TLR4, or a combination of the two.    
When assessing the impact of cobalt ions on inflammatory factors it is important to consider 
the redundancy of cytokines, chemokines, and their receptors, as well as cross-talk between 
pathways. Chemokines can activate multiple receptors and the receptors themselves often have 
multiple ligands. For example CCL4 binds to CCR1, CCR5 and CCR8. CCR1 and CCR5 
expression was downregulated by cobalt ions whilst CCR8 expression was unaffected, meaning 
that even in the absence of two of its receptors CCL4 could still induce inflammatory effects. 
There is also evidence of compensatory mechanisms and cross-talk within the chemokine 
system whereby knockdown of a chemokine receptor results in upregulation of chemokines 
with similar functions (Yanaba et al., 2004). Furthermore, factors such as CXCL4 have been 
shown to reduce chemokine receptor expression (Schwartzkopff et al., 2012) to modulate 
inflammation. Functional studies such as migration assays would provide insights into the 
overall effects of the cytokine, chemokine, and receptor changes revealed by the arrays.       
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Figure 3.7: Cobalt-regulated cytokines, chemokines and receptors 
Figure shows cytokines, chemokines, and their receptors as regulated by cobalt ions in 
the qRT-PCR arrays. Upregulated genes are shown in green and downregulated genes are 
shown in red. Those unaffected by cobalt (fold change<2) are shown in black. Genes in 
grey were not included in the arrays. Image created using information from Balkwill et 
al (Balkwill, 2004). 
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Apoptosis mediators 
There is evidence that cobalt can cause cytotoxicity from preliminary experiments in this study 
and from the literature (Kwon et al., 2009). Consequently it was interesting to observe that Fas 
(TNFRSF6)-associated via death domain (FADD), a key receptor in apoptosis, was 
downregulated following cobalt stimulation, although there was a very small (2.06-fold) 
upregulation in expression of the FADD ligand caspase 8 apoptosis-related cysteine peptidase 
(CASP8). Aminoacyl tRNA synthetase (AIMP1) is a cytokine released under apoptotic 
conditions and was also downregulated by cobalt ions, which suggests that any cell death 
occurring may not be due to apoptosis. This supports a previous study showing that high cobalt 
concentrations can induce necrosis rather than apoptosis (Huk et al., 2004).  
Taken together the data obtained from the arrays suggests that cobalt ions can activate 
inflammatory signalling pathways, particularly through increased NFκB activity. There are 
many similarities between CoCl2 responses and LPS-induced responses reported in previous 
studies, such as increased expression of IL8 and CCL20. However there are also some striking 
differences, including downregulation of CCL2 and decreased expression of co-stimulatory 
molecules following cobalt treatment. These factors are often upregulated by LPS (Hoebe et 
al., 2003, Guijarro-Muñoz et al., 2014). 
Array validation 
Following analysis of the SYBR Green qRT-PCR arrays, nine genes were selected for further 
validation using qRT-PCR with TaqMan gene expression probes. TaqMan assays were used 
because they contain a gene-specific fluorescent probe alongside primers. This gives improved 
specificity in comparison to SYBR Green chemistry where a fluorescent dye binds to all double-
stranded DNA and increases the likelihood of false positive results (Figure 2.4).  
TaqMan-based qRT-PCR analysis revealed gene expression changes comparable to those of 
the SYBR Green arrays in terms of the overall trend (i.e. upregulation, downregulation or no 
change) in gene expression. There were however some notable differences in the fold change 
values obtained for each individual gene. For example CCL20 showed a 35-fold upregulation 
in the arrays but more than a 200-fold increase using the TaqMan probe method. These 
discrepancies may arise through differences in the chemistry of TaqMan and SYBR Green 
assays, differences in the analysis process, or be the result of in vitro assay variability.  
The validated genes were selected for their relevance to the clinical context of this study. Their 
general function is discussed below and their potential significance in ARMD and MoM hip 
failure will be discussed in more detail in chapter 4.  
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IL8 
IL8 was significantly upregulated by cobalt ions at gene level in both sets of arrays, as well as 
in the validation TaqMan-based qRT-PCR assays. The encoded IL-8 protein is a pro-
inflammatory chemokine that targets neutrophils (Baggiolini et al., 1989) and recruits them to 
the site of inflammation through activation of the CXCR1 and CXCR2 receptors. The role of 
IL-8 in TLR4 signalling and ARMD will be discussed in full in later chapters. 
CCL20 
CCL20 (also known as macrophage inflammatory protein 3 alpha or MIP3α) acts on its target 
cell via the CCR6 receptor (Liao et al., 1999). CCR6 is expressed on T and B lymphocytes 
(Kondo et al., 2007, Wiede et al., 2013) and therefore CCL20 induces the migration of these 
cells (Liao et al., 2002, Cook et al., 2014). The elevated CCL20 expression observed in this 
study supports the findings of Raghavan et al who demonstrated that cobalt increased CCL20 
expression by human endothelial cells (Raghavan et al., 2012).  
CXCL10 
CXCL10 is secreted via the TRIF-dependent arm of TLR4 signalling (Bandow et al., 2012). It 
recruits T lymphocytes (Stanford and Issekutz, 2003) and monocytes (Petrovic-Djergovic et al., 
2015) to the site of inflammation. Upregulation of CXCL10 along with that of MyD88-
dependent chemokines such as IL8 suggests that cobalt activates both the MyD88 and TRIF-
dependent arms of the TLR4 signalling pathway. This hypothesis was recently supported by 
Oblak et al who showed that cobalt increases activation of the IFN-β (MyD88-dependent) and 
CXCL10 (TRIF-dependent) promoters (Oblak et al., 2015).  
CCL25 
CCL25 is chemotactic for macrophages and dendritic cells and acts via CCR9 (Youn et al., 
1999). Although a very large fold upregulation in CCL25 was detected using the qRT-PCR 
arrays, validation by TaqMan-based assays showed only a 2-fold change in gene expression.  
IL1A 
IL1A expression was upregulated following cobalt stimulation and its encoded protein IL-1α is 
a pro-inflammatory cytokine that is associated with cell damage and apoptosis. In the context 
of this study it is interesting to note that IL-1α promotes osteoclast formation and subsequent 
bone resorption (Lader and Flanagan, 1998). MoM implants are associated with higher rates of 
aseptic loosening compared to ceramic-on-polyethylene and metal-on-polyethylene implants 
and this is due to bone resorption (Abu-Amer et al., 2007).  
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HMGB1  
HMGB1 is a DNA-binding protein that stabilises DNA structure. It is also involved in 
inflammation as it is released from necrotic and apoptotic cells (Scaffidi et al., 2002, Bell et al., 
2006), as well as in response to PAMPs like LPS (El Gazzar, 2007). Despite the lack of change 
detected by the arrays HMGB1 expression was validated because it can bind and activate TLR4 
(Jong et al., 2006). It was important to consider that other TLR4 ligands may be secreted via an 
alternative pathway and then feedback to activate TLR4, perpetuating inflammation 
independently of cobalt. However there was no change in HMGB1 expression suggesting that 
it is not having an inflammatory effect in this case.  
HSPA1A 
HSPA1A expression was also investigated as it was shown to be significantly upregulated 
following cobalt treatment in the TLR arrays. HSPA1A encodes Hsp70 which activates TLR4 
(Klink et al., 2012). qRT-PCR using TaqMan probes confirmed upregulation of HSPA1A 
expression in the presence of cobalt, although there were considerable differences in the 
detected fold changes (202-fold in the arrays compared to 12-fold with the TaqMan method). 
The observed upregulation raises the question of whether Hsp70 may be contributing to cobalt-
mediated inflammation by activating TLR4. However a 4h cobalt stimulation was used for the 
qRT-PCR arrays and this is a very short time for HSPA1A to be upregulated, translated into 
Hsp70, secreted from the cell, and then feedback to activate TLR4, causing the changes in other 
genes such as IL8. Hsp70 is purported to decrease IL-8 secretion (Malago et al., 2005) which 
suggests that it is not responsible for all of the gene expression changes detected by the qRT-
PCR arrays.  
CCL2 
CCL2 secretion is known to occur upon LPS activation of TLR4 (Guijarro-Muñoz et al., 2014). 
Its release has also been observed in response to nickel particles (Glista-Baker et al., 2012), as 
well as following cobalt ion stimulation of osteoblasts and epithelial cells (Queally et al., 2009, 
Devitt et al., 2010). The CoCl2-induced downregulation of CCL2 is therefore one of the most 
surprising results from the qRT-PCR arrays. CCL2 protein secretion can be increased by IL-6 
(Biswas et al., 1998, Ekhlassi et al., 2008) and as there was no change in IL-6 expression in 
either the qRT-PCR arrays or protein arrays, it may be that this contributes to the change in 
CCL2. Interestingly, other studies have shown that CCL2 can be downregulated by using cobalt 
as a hypoxia mimetic (Negus et al., 1998, Safronova et al., 2003) which may also have 
influenced the observed response. 
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Proteome Profiler cytokine arrays 
Cytokine secretion by CoCl2 and LPS-stimulated MonoMac 6 cells was assessed by Proteome 
Profiler array. An initial visual assessment of the arrays shows clear differences not only 
between the CoCl2 and untreated arrays, but also between CoCl2 and LPS. The differing 
cytokine profiles suggest that cobalt ions and LPS do not activate identical signalling pathways. 
This may be due to the different mechanisms of receptor activation; cobalt binds directly to 
TLR4 while LPS requires transfer across adaptor molecules prior to TLR4 activation. It is not 
known how the binding of the ligands, particularly cobalt, may affect receptor structure or the 
recruitment and binding of downstream signalling factors like MyD88. Additionally, as LPS 
and cobalt are very different ligands it is impossible to directly compare the agonist 
concentrations. Consequently, although the effect on a particular cytokine may seem more 
potent with LPS (for example), it does not necessarily mean that LPS has a greater pro-
inflammatory effect than CoCl2. 
The array analysis revealed several cytokines that were increased in response to LPS or CoCl2 
and others that were affected by only one ligand (Figure 3.8). Serpin E1 was the only cytokine 
increased by CoCl2 but not by LPS while CCL2, CCL3, CCL4 and IL-1β were increased 
following LPS stimulation but not CoCl2.  
 
Figure 3.8: Differential regulation of cytokine secretion by LPS and CoCl2 
Figure shows upregulated cytokines from the cytokine profiler arrays and whether they 
were upregulated by LPS (blue), CoCl2 (red) or both.  
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Cytokines and chemokines that were regulated by CoCl2 in the Proteome Profiler arrays are 
discussed below: 
IL-8 
IL-8 is a pro-inflammatory chemokine that recruits neutrophils and mediates other 
inflammatory functions such as adhesion. It is discussed in more detail earlier in this chapter as 
well as in section 4.4.  
IL-1ra 
Interleukin-1 receptor antagonist (IL-1ra) binds to the interleukin-1 receptor (IL-1R1) and is 
able to block the action of IL-1 family members including IL-1α and IL-1β. Caicedo et al 
demonstrated that IL-1ra can prevent lymphocyte reactivity in patients who show nickel or 
cobalt hypersensitivity (Caicedo et al., 2010), which suggests that the observed upregulation in 
this study could have an immunomodulatory effect if similar effects occur in vivo.  
MIF  
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that inhibits the 
anti-inflammatory action of glucocorticoids on factors such as IL-6 and IL-8 (Calandra and 
Bucala, 1997), and as such is considered an immunoregulatory molecule. It is released by LPS-
stimulated macrophages and induces further secretion of pro-inflammatory cytokines by 
macrophages and activated T cells. MIF inhibition can protect against an exaggerated immune 
response in bacterial sepsis (Calandra et al., 2000). This suggests that the increased MIF release 
following cobalt stimulation may promote further inflammation.   
Serpin E1 
Serine protease inhibitor E1 (serpin E1, also known as plasminogen activator inhibitor-1 or 
PAI-1) is an inhibitor of fibrolysis, the process of blood clot formation. Its secretion was 
increased in response to CoCl2 stimulation but not in response to LPS. This is surprising as a 
previous study has shown that LPS can regulate serpin E1 expression through TLR4 activation 
(Ren et al., 2014). The same study showed that serpin E1 knockdown inhibits TLR4-mediated 
inflammatory responses including TNFα secretion. It is therefore possible that its upregulation 
in response to CoCl2 may promote release of other cytokines.    
CXCL1 
Chemokine (C-X-C motif) Ligand 1 is chemotactic for neutrophils. CXCL1 has recently been 
implicated in osteoclast formation by binding to its receptor CXCR2. Activation of CXCR2 is 
associated with increased osteoclastogenesis (Hardaway et al., 2015), which is interesting 
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because several chemokines that bind CXCR2, including IL-8, are also upregulated by cobalt 
ions. It is therefore possible that a small upregulation of several different chemokines could still 
have an inflammatory effect because many act via the same receptor.  
sICAM-1 
Soluble intercellular adhesion molecule-1 (sICAM-1) is a secreted form of the membrane-
bound adhesion molecule ICAM-1. The exact function of sICAM-1 is unclear but it has been 
linked to angiogenesis and tumour progression. sICAM-1 function and its potential significance 
in ARMD will be discussed in more detail in section 5.5. 
CCL5 
Chemokine (C-C motif) ligand 5, also known as regulated on activation, normal T cell 
expressed and secreted (RANTES), is chemotactic for monocytes and T cells. It is surprising 
that LPS had little effect on CCL5 release in this assay because previous studies have shown 
that LPS activation of TLR4 results in significantly increased CCL5 secretion (Fitzgerald et al., 
2003). However a previous study has shown that CoCl2 can downregulate both CCL5 and CCL2 
release (Oh et al., 2014).   
CXCL10 
CXCL10 release was slightly increased following CoCl2 stimulation, which correlates with the 
increased gene expression detected by qRT-PCR array. CXCL10 function is discussed earlier 
in this chapter and in section 4.4.  
CCL2, CCL3 and CCL4 
It is particularly interesting to observe that CCL2, CCL3 and CCL4 secretion was increased in 
LPS-stimulated MonoMac 6 cells but not in those treated with CoCl2 (Figure 3.8). The effect 
of CoCl2 on CCL2 is consistent with the qRT-PCR array data. A possible mechanism 
underlying this inhibition could involve suppressor of cytokine signalling (SOCS) molecules 
as SOCS-3 has been shown to attenuate CCL chemokine secretion as a protective response (Qin 
et al., 2007, Qin et al., 2008). However other inflammatory factors (such as prostaglandins) can 
result in chemokine inhibition (Jing et al., 2004), and from the assays conducted in this study it 
is not clear which mechanisms are responsible.  
3.5.1. Future work 
Data presented here clearly shows that cobalt ions can regulate inflammatory responses in 
human MonoMac 6 macrophages. However the nature of the qRT-PCR arrays meant that only 
a limited number of timepoints and cobalt concentrations could be used. Further work could be 
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conducted to determine the effect of cobalt ions at different concentrations and also at longer 
timepoints (e.g. 12 or 24h). In addition, a number of genes were not expressed at high levels by 
MonoMac 6 cells and although there was some evidence of expression changes following cobalt 
treatment, their levels remained too low for informed analysis (examples include CCL8 and 
CXCL9). The qRT-PCR arrays could therefore be performed on a second cell line to validate 
the results obtained in MonoMac 6 cells and assess the effect of cobalt on genes that were not 
highly expressed by these cells.  
It is important to acknowledge that cytokines can be regulated via multiple signalling pathways. 
For example, CCL2 can be upregulated via JAK/STAT signalling (Lee et al., 2011) but NFκB 
may also be involved in the regulation of CCL2 expression as its promoter contains an NFκB 
binding element (Deng et al., 2013). siRNA knockdown could be performed to target 
JAK/STAT or NFκB signalling components, followed by quantification of CCL2 expression or 
secretion. This would provide greater insight into which signalling factors contribute to 
secretion and expression of individual cytokines.   
The Proteome Profiler arrays provide an excellent starting point for studying the effects of 
cobalt ions on cellular cytokine secretion. As this was limited to investigating secreted 
inflammatory factors further work is required to validate the protein array work and assess 
expression of membrane-bound and intracellular signalling proteins following cobalt 
stimulation. Cell-based ELISA, Western immunoblotting, and flow cytometry would all be 
suitable techniques for analysis.   
3.5.2. Conclusion 
Overall the data obtained using the qRT-PCR and Proteome Profiler arrays indicates that cobalt 
ions can regulate expression of both pro- and anti-inflammatory cytokines and chemokines. For 
example, while pro-inflammatory IL8 was upregulated, there was also downregulation of other 
inflammatory chemokines, most notably CCL2. This was consistent across both gene 
expression and protein arrays. Expression of TLR signalling factors was also altered by cobalt 
ions although TLR4 itself was unaffected. While the NFκB pathway appeared to be upregulated 
overall, inhibitory NFKBIA expression was also upregulated and its effect on the subsequent 
cellular response is not clear. To determine the overall inflammatory effect of cobalt ions, 
functional studies are required and these will be discussed in later chapters.   
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Chapter 4. Role of the Toll-like receptor 4 signalling pathway in the 
inflammatory response to cobalt ions 
4.1. Introduction 
Chapter 3 describes an investigation into the cellular inflammatory response induced by cobalt 
ions in MonoMac 6 macrophages and shows that a wide range of signalling molecules and 
inflammatory factors are affected. However the overall aim of this study was to investigate the 
role of TLR4 in the immune response to cobalt ions, and subsequently a more focused approach 
was required. This necessitated selection of an appropriate marker of inflammatory responses 
to cobalt based on the qRT-PCR and Proteome Profiler arrays detailed in chapter 3. IL-8 was 
selected as a marker for cobalt-mediated inflammation because it was consistently and 
significantly upregulated by CoCl2 at both the gene expression and protein levels. IL-8 is also 
secreted when LPS activates TLR4, meaning that TLR4-specific LPS could be used to provide 
an effective positive control for receptor activation. Finally, the NFκB signalling pathway 
appears to be regulated by cobalt ions (chapter 3) and IL-8 is an NFκB-regulated chemokine 
making it an appropriate marker for further study.   
4.2. Objectives 
 To define the response of MonoMac 6 macrophages to cobalt ions, using IL-8 as a 
marker of inflammation 
 To investigate the potential of a small molecule TLR4 antagonist and anti-TLR4 
neutralising antibodies in prevention of the inflammatory response to cobalt ions 
 To further investigate cytotoxicity in response to cobalt ions 
 To investigate other inflammatory factors regulated by cobalt activation of TLR4 
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4.3. Results 
4.3.1. Development of an in vitro cell culture model for investigating cobalt-
mediated inflammatory responses 
The arrays detailed in chapter 3 offer insight into the inflammatory effects of cobalt but the 
nature of these assays meant that limited cobalt concentrations could be used. A series of 
additional assays was therefore utilised and optimised to further establish any dose-dependent 
effects of cobalt ions on IL-8 gene expression and secretion by MonoMac 6 cells.  
MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h (LPS 
concentration and timepoint previously optimised in MRes project) before RNA and 
supernatant were collected. IL8 gene expression was quantified by qRT-PCR at this timepoint 
to confirm that the changes observed in the arrays were still in effect. Analysis using TaqMan 
probes in qRT-PCR revealed that IL8 gene expression in MonoMac 6 cells is significantly 
upregulated following 24h treatment with CoCl2 and LPS (all p<0.001) (Figure 4.1A). A peak 
fold-change of approximately 70-fold occurred at 0.75mM CoCl2. GAPDH expression was 
consistent across the different treatment conditions (Appendix C). IL-8 secretion was measured 
by ELISA and a dose-dependent response was observed with significant increases in chemokine 
release across all CoCl2 concentrations (all p<0.001). Peak secretion of 7000pg/ml was reached 
at 1mM CoCl2 (Figure 4.1B). Both gene expression and protein secretion were very similar 
between cells stimulated with LPS and high CoCl2 concentrations (0.75mM and 1mM). LPS 
therefore provided an effective positive control for further assays.  
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Figure 4.1: Effect of CoCl2 on IL-8 gene expression and protein secretion 
MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h. A. 
RNA was collected, cDNA synthesised by reverse transcription, and qRT-PCR conducted 
to assess IL8 expression. B. IL-8 secretion was measured by ELISA. Data is 
representative of at least three independent experiments. Statistical significance was 
calculated by one-way ANOVA with Dunnett’s multiple comparisons test comparing 
treated samples to the untreated control. 
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4.3.2. Validation of IL-8 as a marker of inflammatory responses to cobalt 
To determine that induction of IL-8 secretion by cobalt ions was not unique to MonoMac 6 
cells, two other cell lines were investigated for their response to cobalt. They were THP-1, a 
monocyte cell line, and U2OS, an osteoblast cell line. Both cell lines were stimulated with 0.25-
1mM CoCl2 or 100ng/ml LPS for 24h before supernatant was collected and IL-8 secretion was 
measured by ELISA. THP-1 cells showed increased IL-8 release in response to CoCl2, with 
peak CoCl2-mediated secretion of 500pg/ml occurring at 0.75mM (p<0.001) (Figure 4.2A). 
The positive control LPS caused the maximum IL-8 release of approximately 600pg/ml 
(p<0.001).  
U2OS cells also increased IL-8 secretion following CoCl2 and LPS stimulation, although the 
pattern was different to that of THP-1 cells. IL-8 levels increased from 0.5mM CoCl2 
(p=0.0025) and peaked at 650pg/ml with 1mM CoCl2 treatment (p<0.001) (Figure 4.2B). LPS 
caused elevated IL-8 release (p<0.001) although at 400pg/ml this was less than the maximum 
CoCl2-induced secretion.  
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Figure 4.2: Effect of CoCl2 on IL-8 secretion by THP-1 and U2OS cells 
A. THP-1 and B. U2OS cells were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS 
for 24h before supernatant was collected and IL-8 secretion quantified by ELISA. Data 
is representative of at least three independent experiments and statistical significance was 
calculated by one-way ANOVA with Dunnett’s test for multiple comparisons comparing 
treated samples to the untreated control. 
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4.3.3. Selection of an optimal cobalt concentration 
The results described so far in this chapter were used to select an optimum cobalt concentration 
for use in further assays investigating the role of TLR4. In all of the assays cobalt ions had a 
dose-dependent effect with the peak response usually occurring at 0.75mM or 1mM CoCl2. The 
optimal concentration chosen for future use was 0.75mM CoCl2 because it induced the 
maximum response in several assays (for example IL8 expression) and is also closer to the 
clinically-relevant range than 1mM.  
4.3.4. Effect of cobalt ions on MonoMac 6 cell viability 
Cobalt ions can reduce cell viability (Kwon et al., 2009) and following selection of 0.75mM 
CoCl2 as the optimal concentration in MonoMac 6 cells, cytotoxicity at this concentration was 
investigated. MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 24h and cell viability 
was assessed by trypan blue staining and counted manually using images obtained from a Luna 
II automated cell counter. Viability in the untreated cells was normalised to 100% while cobalt 
caused cytotoxicity, reducing viability to approximately 75% (Figure 4.3).  
 
Figure 4.3: Effect of 24h CoCl2 stimulation on MonoMac 6 cell viability 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 or left untreated for 24h before 
cells were stained with trypan blue dye. Cell images were obtained using a Luna II 
automated cell counter and viability was assessed by manual counting due to the issues 
described in section 2.5. Viability in the untreated cells was normalised to 100% and 
CoCl2 stimulation reduced cell viability to 75%. Images are representative of four 
independent experiments. 
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4.3.5. Effect of cobalt ions on murine Cxcl1 expression 
Previous research has shown that cobalt ions cannot activate murine TLR4 due to the absence 
of the histidine residues to which cobalt binds (Raghavan et al., 2012, Tyson-Capper et al., 
2013a). To further validate this finding, J774 murine macrophages were assessed for Cxcl1 
(murine equivalent of IL8) expression in response to LPS and cobalt. J774 cells were treated 
for 4h with 1000ng/ml LPS or 0.75mM CoCl2, RNA was collected and Cxcl1 was quantified 
by qRT-PCR using Actb as a housekeeping gene. CoCl2 induced a 4-fold upregulation 
(p=0.0224) in Cxcl1 expression compared to a 550-fold change following LPS stimulation 
(p<0.001) (Figure 4.4).  
 
Figure 4.4: Cxcl1 expression in J774 macrophages 
J774 murine macrophages were stimulated with 0.75mM CoCl2 or 1000ng/ml LPS for 
4h. RNA was isolated and cDNA synthesised by reverse transcription. Cxcl1 expression 
was quantified by qRT-PCR using Actb as a housekeeping gene. Data is representative of 
three independent experiments and statistical significance was calculated by one-way 
ANOVA with Dunnett’s test for multiple comparisons comparing treated samples to the 
untreated control. 
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4.3.6. Optimisation of TLR4 antagonist CLI-095 
TLR4 activation is just one of many cellular processes that result in IL-8 secretion. It is therefore 
possible that the observed increases in IL-8 expression and secretion in response to CoCl2 are 
a non-specific inflammatory response to metal ion exposure, rather than a result of TLR4 
activation by cobalt ions. A small molecule TLR4 antagonist, CLI-095, was therefore used to 
elucidate the role of TLR4 in cobalt-mediated IL-8 release. CLI-095 binds to the intracellular 
domain of TLR4 to prevent recruitment of its adaptor proteins (e.g. MyD88, TRIF) and 
initiation of subsequent downstream signalling events. In previous studies CLI-095 has been 
shown to prevent LPS activation of TLR4 (Matsunaga et al., 2011). Consequently for this study 
an initial optimisation assay was performed using IL-8 as a marker to determine the inhibitory 
capacity of CLI-095. Following optimisation with CoCl2 all subsequent assays included LPS as 
a positive control. MonoMac 6 cells were treated with 0-10μg/ml CLI-095 for 6h prior to 
stimulation with 0.75mM CoCl2 for 24h and IL-8 secretion was measured by ELISA.  
Maximal IL-8 secretion in response to 0.75mM CoCl2 was approximately 4600pg/ml (Figure 
4.5). Using 2300pg/ml as 50% inhibition, the half maximal inhibitory concentration (IC50) was 
found to be approximately 2μg/ml. Near-complete inhibition of IL-8 secretion occurred at 
10μg/ml CLI-095 and so this concentration was selected for further assays.  
 
Figure 4.5: CLI-095 dose response curve 
The optimal concentration of the TLR4 antagonist CLI-095 was determined using IL-8 
as a marker of receptor activation by cobalt ions. MonoMac 6 cells were pre-incubated 
with 0-10μg/ml CLI-095 for 6h before 24h stimulation with 0.75mM CoCl2. IL-8 
secretion was measured by ELISA. The half maximal inhibitory concentration (IC50) was 
calculated at 1.5μg/ml. Maximal inhibition occurred at 10μg/ml CLI-095. n=1.
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4.3.7. Effect of cobalt ions on IL-8 and CXCL10 secretion 
The Proteome Profiler arrays described in chapter 3 showed an increase in CXCL10 secretion 
following cobalt stimulation. Although small, this change is interesting because CXCL10 
secretion can occur via activation of the TRIF-dependent pathway of TLR4 signalling as 
opposed to MyD88-dependent IL-8 release. To assess the role of TLR4 in the release of these 
cytokines MonoMac 6 cells were pre-treated with 10µg/ml CLI-095 for 6h before 24h 
stimulation with 0.75mM CoCl2 or 100ng/ml LPS. IL-8 and CXCL10 levels were quantified by 
ELISA. As expected given previous results, IL-8 secretion was significantly increased to 
approximately 4000pg/ml by CoCl2 and 7000pg/ml by LPS (both p<0.001). 10μg/ml CLI-095 
abrogated release of IL-8 in response to both ligands (p<0.001), suggesting that it is TLR4-
dependent (Figure 4.6A). CXCL10 secretion was increased by CoCl2 and LPS (1000pg/ml 
CXCL10 for CoCl2 and 1300pg/ml for LPS, both p<0.001) and significantly decreased in the 
presence of CLI-095 (both p<0.001) (Figure 4.6B). CXCL10 secretion was also decreased by 
the antagonist in untreated cells (p=0.0328) and the reasons for this will be discussed later in 
the chapter. 
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Figure 4.6: Effect of TLR4 inhibition on IL-8 and CXCL10 secretion 
MonoMac 6 cells were pre-incubated with 10µg/ml CLI-095 for 6h prior to 24h 
stimulation with 0.75mM CoCl2 or 100ng/ml LPS. A. IL-8 and B. CXCL10 secretion was 
measured by ELISA. Data is representative of three independent experiments and 
statistical significance was calculated by one-way ANOVA with Tukey’s test for multiple 
comparisons comparing all samples to each other. This data appears in Lawrence et al 
(Lawrence et al., 2014). 
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4.3.8. Effect of CLI-095 on expression of inflammatory genes 
To determine whether or not CLI-095 affected cobalt-mediated gene expression changes, IL8 
expression was used as a marker of TLR4 activation by cobalt ions. The same treatment method 
described in section 4.3.7 was used and IL8 expression was assessed by qRT-PCR. This 
revealed similar trends between gene and protein expression of IL-8; IL8 expression was 
significantly upregulated by 24h stimulation with CoCl2 and LPS (both p<0.001) and this was 
inhibited by CLI-095 (both p<0.001) (Figure 4.7). There was a slight decrease in IL8 
expression by untreated MonoMac 6 in the presence of CLI-095 but this was not statistically 
significant (p=0.6950).   
 
Figure 4.7: Effect of TLR4 inhibition on IL8 expression 
MonoMac 6 cells were pre-treated with 10μg/ml CLI-095 for 6h and then stimulated with 
0.75mM CoCl2 or100ng/ml LPS for 24h. RNA was isolated and cDNA synthesised by 
reverse transcription. IL8 expression was assessed by qRT-PCR. Data is representative of 
three independent experiments and statistical significance was calculated by one-way 
ANOVA with Tukey’s test for multiple comparisons comparing all samples to each other. 
This data appears in Lawrence et al (Lawrence et al., 2014). 
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4.3.9. Effect of CLI-095 on MonoMac 6 cell viability 
As CXCL10 secretion and IL8 expression were both decreased by 10μg/ml CLI-095 in 
untreated cells, a cytotoxicity assay was conducted to assess any potential toxic effects of the 
antagonist. Analysis by trypan blue staining revealed that >1μg/ml CLI-095 causes cytotoxicity 
in MonoMac 6 cells (Appendix D). As a result the optimal concentration was revised to 1μg/ml. 
As shown in Figure 4.8 this concentration still effectively inhibited CoCl2 and LPS-mediated 
IL-8 secretion, reducing IL-8 levels to approximately 2000pg/ml (both p<0.001). CLI-095 is 
reconstituted in DMSO and therefore an additional 1% v/v DMSO control was included to 
ensure that this did not have any effect on IL-8 secretion. There was no significant difference 
in IL-8 secretion by untreated cells and those challenged with DMSO (p=0.6422) (Figure 4.8). 
 
Figure 4.8: Effect of 1µg/ml CLI-095 on IL-8 secretion 
MonoMac 6 cells were pre-treated with 1μg/ml CLI-095 for 6h before stimulation with 
0.75mM CoCl2 or 100ng/ml LPS for 24h. A 1% v/v DMSO control was included as CLI-
095 is reconstituted in DMSO. Supernatant was collected and IL-8 secretion was 
measured by ELISA. Data is representative of three independent experiments and 
statistical significance was calculated by one-way ANOVA with Tukey’s test for multiple 
comparisons comparing all samples to each other. 
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4.3.10. Effect of TLR4 inhibition on cobalt-mediated cytokine release 
In addition to IL-8 and CXCL10 the secretion of two further inflammatory cytokines, CCL20 
and IL-6, was investigated. CCL20 was selected because of the upregulation in gene expression 
shown by the qRT-PCR arrays and subsequent validation in chapter 3. CCL20 can also be 
regulated via activation of TLR4 by LPS (Guijarro-Muñoz et al., 2014). IL-6 was chosen 
because its secretion following cobalt stimulation is variable, with some studies reporting an 
increase in release (Queally et al., 2009) while others suggest that it is unaffected or even 
downregulated by cobalt ions (Posada et al., 2015). 
MonoMac 6 cells were pre-treated with 1μg/ml CLI-095 for 6h followed by stimulation with 
0.75mM CoCl2 or 100ng/ml LPS for 24h. CCL20 and IL-6 levels were quantified by ELISA. 
CCL20 secretion was significantly increased to 300pg/ml (p<0.001) by CoCl2 while LPS 
induced a concentration of approximately 400pg/ml (p<0.001) (Figure 4.9A). CLI-095 
significantly inhibited CCL20 secretion in response to both ligands (p<0.001), reducing 
chemokine secretion to levels observed in untreated cells. LPS stimulation caused a significant 
upregulation in IL-6 secretion to 2000pg/ml (p<0.001) (Figure 4.9B) and in comparison CoCl2-
mediated IL-6 release was small at approximately 300pg/ml although it was still statistically 
significant (p=0.0450). CLI-095 pre-treatment inhibited IL-6 secretion in response to both 
CoCl2 and LPS. This was statistically significant for LPS (p<0.001) but not for CoCl2 
(p=0.0798) (Figure 4.9B). 
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Figure 4.9: Effect of TLR4 inhibition on CCL20 and IL-6 secretion 
MonoMac 6 cells were pre-treated with 1µg/ml CLI-095 for 6h before stimulation for 24h 
with 0.75mM CoCl2 or 100ng/ml LPS. A. CCL20 and B. IL-6 secretion was measured by 
ELISA. Data is representative of three independent experiments and statistical 
significance was calculated by one-way ANOVA with Tukey’s test for multiple 
comparisons comparing all samples to each other. 
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4.3.11.  Effect of anti-TLR4 neutralising antibodies on the inflammatory response 
to cobalt ions 
The data shown so far clearly demonstrates that cobalt regulates secretion and expression of 
cytokines and chemokines, and inhibition of TLR4 can prevent these responses. CLI-095 is a 
small molecule antagonist that requires intracellular access to successfully inhibit TLR4. 
Although its blockade of IL-8 and other inflammatory markers in response to cobalt 
demonstrates the potential of TLR4 as a therapeutic target in ARMD, CLI-095 itself is not a 
realistic therapeutic agent due to its mechanism of action. In contrast antibodies, particularly 
monoclonal antibodies, are constantly being developed for therapeutic use. This aspect of the 
study set out to investigate whether any commercially-available anti-TLR4 neutralising 
antibodies could prevent the inflammatory response to cobalt ions, again using IL-8 as a marker 
of cobalt-mediated TLR4 activation.  
Unlike CLI-095 which has been used in previous studies to prevent LPS activation of TLR4, 
no studies could be found in which PAb-hTLR4 or MAb2-hTLR4 inhibit the effect of LPS, 
although the manufacturer reports LPS antagonism by both antibodies. Furthermore, the exact 
mechanism by which cobalt activates TLR4 is unclear and thus potential mechanisms of 
inhibition are also unclear. Consequently all neutralising antibody assays included LPS as a 
positive control for TLR4 activation.   
4.3.12. Effect of PAb-hTLR4 on MonoMac 6 cell viability 
An initial cytotoxicity assay was conducted in which MonoMac 6 cells were pre-treated with 
5μg/ml PAb-hTLR4 (the highest concentration recommended by the manufacturer) for 16h. 
Cells were stained with trypan blue and cell viability assessed using a Luna II automated cell 
counter (Figure 4.10). Viability was normalised to 100% in untreated cells and was 94% for 
those incubated with PAb-hTLR4.    
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Figure 4.10: Effect of PAb-hTLR4 on MonoMac 6 cell viability.  
MonoMac 6 cells were incubated with 5μg/ml PAb-hTLR4 for 16h and cell viability was 
measured using trypan blue staining and manual counting using images obtained from a 
Luna II automated cell counter. Viability was normalised to 100% in untreated cells and 
was 94% for those incubated with PAb-hTLR4. Images on the right are a magnified 
section of those on the left. Data is representative of two independent experiments. This 
experiment was conducted in collaboration with MRes student Amy Mawdesley and is 
published in Lawrence et al (Lawrence et al., 2016). 
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4.3.13.  Effect of PAb-hTLR4 on cobalt-mediated IL-8 responses 
The ability of PAb-hTLR4 to inhibit cobalt activation of TLR4 was assessed using the pre-
treatment time (10 minutes) and ligand stimulation time (overnight or 16h) recommended by 
the antibody manufacturer. MonoMac 6 cells were incubated with 5μg/ml PAb-hTLR4 for 10 
minutes before stimulation with 100ng/ml LPS or 0.75mM CoCl2 for 16h. Changes in IL-8 
gene expression and protein secretion were assessed by qRT-PCR and ELISA. PAb-hTLR4 did 
not inhibit IL8 gene expression in response to cobalt ions and there was a slight increase in 
CoCl2-mediated IL8 expression in the presence of the antibody (p=0.6516) (Figure 4.11A). 
However LPS-induced IL8 expression was significantly decreased by PAb-hTLR4 (p<0.001). 
There was no significant difference in gene expression in untreated cells with and without the 
antibody (p=0.6516). IL-8 secretion showed a similar pattern to that of gene expression; PAb-
hTLR4 did not have any effect on IL-8 secretion by cobalt-stimulated cells (p>0.999) (Figure 
4.11B). There was a small decrease in IL-8 release for LPS treatment in the presence of the 
inhibitor but this was not statistically significant (p=0.4333). Interestingly, IL-8 production by 
unstimulated cells increased with PAb-hTLR4 although this was not statistically significant 
(p=0.0512). 
107 
 
 
Figure 4.11: Effect of PAb-hTLR4 on IL-8 gene expression and protein secretion 
MonoMac 6 cells were pre-treated with 5μg/ml PAb-hTLR4 for 10 minutes before 16h 
stimulation with 0.75mM CoCl2 or 100ng/ml LPS. RNA was isolated and supernatant 
collected. A. cDNA was synthesised by reverse transcription and IL8 expression 
measured by qRT-PCR. B. IL-8 secretion was quantified by ELISA. Data is 
representative of three independent experiments and statistical significance was 
calculated by one-way ANOVA with Tukey’s test for multiple comparisons comparing 
all samples to each other. These experiments were conducted in collaboration with MRes 
student Amy Mawdesley and are published in Lawrence et al (Lawrence et al., 2016).
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4.3.14. Optimisation of MAb2-hTLR4 
MAb2-hTLR4 is also reported to inhibit activation of TLR4 (Scarpa et al., 2015). However as 
with PAb-hTLR4 this required optimisation in MonoMac 6 cells prior to determining the 
antibody’s effect on cobalt-mediated activation. MonoMac 6 cells were incubated with 10μg/ml 
MAb2-hTLR4 for 16h and cytotoxicity was assessed by trypan blue staining and automated 
cell counting (Figure 4.12). Viability was normalised to 100% for untreated cells. Cells treated 
with MAb2-hTLR4 were also found to be 100% viable, showing that the monoclonal antibody 
does not cause cytotoxicity (Figure 4.12).  
 
Figure 4.12: Effect of MAb2-hTLR4 on MonoMac 6 cell viability 
MonoMac 6 cells were incubated with 10μg/ml MAb2-hTLR4 for 16h and cell viability 
was measured using trypan blue staining and an automated cell counter. Viability was 
100% for untreated cells and 100% for those incubated with the antibody. This 
experiment was conducted in collaboration with MRes student Amy Mawdesley and is 
published in Lawrence et al (Lawrence et al., 2016). 
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The ability of MAb2-hTLR4 to inhibit LPS-induced IL8 expression was investigated to 
determine the optimal antibody concentration for further assays. MonoMac 6 cells were pre-
incubated with 0.1-10μg/ml MAb2-hTLR4 for 1h prior to 16h stimulation with 100ng/ml LPS. 
Untreated cells were incubated with 10μg/ml MAb2-hTLR4 as a negative control. RNA was 
isolated and cDNA synthesised by reverse transcription before IL8 gene expression was 
quantified by qRT-PCR. There was a significant upregulation in IL8 expression following LPS 
stimulation for 16h (p<0.001) (Figure 4.13). Pre-incubation with 0.1μg/ml MAb2-hTLR4 did 
not cause a significant reduction in expression (p=0.6925) compared to the no antibody control 
(Figure 4.13). However 1μg/ml MAb2-hTLR4 caused a significant decrease in LPS-mediated 
IL8 expression (p<0.001) and this inhibitory effect was even greater following pre-incubation 
with 10μg/ml MAb2-hTLR4 (p<0.001). There was no difference in the response of untreated 
cells in the presence or absence of the antibody (p>0.999) (Figure 4.13). 10μg/ml MAb2-
hTLR4 was selected as the optimal concentration for inhibition of LPS-mediated TLR4 
activation and this was included as a positive control in subsequent experiments.  
 
Figure 4.13: Optimisation of MAb2-hTLR4 in LPS-stimulated MonoMac 6 cells 
MonoMac 6 cells were pre-treated with 0.1, 1 or 10μg/ml MAb2-hTLR4 for 1h before 
16h stimulation with 100ng/ml LPS. An untreated control was also included, with and 
without the maximum dose of antibody. IL8 gene expression was quantified by qRT-
PCR. Data is representative of three independent experiments and statistical significance 
was calculated by one-way ANOVA with Tukey’s test for multiple comparisons 
comparing all samples to each other. These experiments were conducted in collaboration 
with MRes student Amy Mawdesley.  
R
e
la
ti
v
e
 I
L
-8
 g
e
n
e
 e
x
p
r
e
s
s
io
n
 n
o
r
m
a
li
s
e
d
 t
o
 u
n
tr
e
a
te
d
 c
o
n
tr
o
l
0 1 0 0 0 .1 1 1 0
0
5 0
1 0 0
1 5 0
***
***
M A b 2 -h T L R 4  ( g /m l)
1 0 0 n g /m l L P S0
110 
 
4.3.15. Effect of MAb2-hTLR4 on cobalt-mediated IL-8 responses 
Following optimisation of MAb2-hTLR4 with LPS, the ability of the antibody to inhibit cobalt 
activation of TLR4 was assessed. 0.1µg/ml MAb2-hTLR4 was excluded from further assays as 
it had no inhibitory effect on LPS, but 1µg/ml and 10µg/ml were both included to investigate 
their effect on CoCl2. MonoMac 6 cells were pre-incubated with 1 or 10μg/ml MAb2-hTLR4 
for 1h followed by 16h stimulation with 0.75mM CoCl2. Positive control cells were pre-treated 
with 10μg/ml MAb2-hTLR4 and 100ng/ml LPS. RNA was isolated and cDNA synthesised for 
qRT-PCR while supernatant was collected for ELISA.  
IL8 gene expression was upregulated following cobalt stimulation and this effect was 
significantly inhibited by 1μg/ml and 10μg/ml MAb2-hTLR4 (both p<0.001) (Figure 4.14A). 
The most effective inhibition occurred with 10μg/ml MAb2-hTLR4, reducing the CoCl2-
induced IL8 expression change from 20-fold to 5-fold. IL-8 ELISA analysis revealed the same 
pattern as that of gene expression; there was a significant reduction in CoCl2-induced IL-8 
secretion with both concentrations of MAb2-hTLR4 (p=0.0375 for 1μg/ml and p<0.001 for 
10μg/ml) (Figure 4.14B). Inhibition was dose-dependent, with the greatest effect observed at 
10μg/ml MAb2-hTLR4. 
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Figure 4.14: Effect of MAb2-hTLR4 on IL-8 gene expression and protein secretion 
MonoMac 6 cells were pre-treated with a range of MAb2-hTLR4 concentrations for 1h 
and then stimulated with either 0.75mM CoCl2 or 100ng/ml LPS for 16h. RNA and 
supernatant were collected for IL-8 analysis. A. cDNA was synthesised by reverse 
transcription and IL8 expression was quantified by qRT-PCR. B. IL-8 secretion was 
measured by ELISA. Data is representative of three independent experiments and 
statistical significance was calculated by one-way ANOVA with Tukey’s multiple 
comparisons test comparing all samples to each other. These experiments were conducted 
in collaboration with MRes student Amy Mawdesley and are published in Lawrence et al 
(Lawrence et al., 2016). 
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4.3.16. Effect of PAb-hTLR4 on inflammatory gene expression 
The qRT-PCR arrays described in chapter 3 showed that as well as IL8 gene expression 
changes, cobalt ions increase expression of other cytokines and chemokines such as HSPA1A, 
IL1A and CCL20. To determine whether or not the inability of PAb-hTLR4 to inhibit cobalt 
responses was specific to IL-8, the antibody’s effect on these genes was assessed. As described 
previously, MonoMac 6 cells were pre-incubated with 5µg/ml PAb-hTLR4 for 10 minutes 
before 16h stimulation with 0.75mM CoCl2 or 100ng/ml LPS. qRT-PCR was performed to 
determine whether or not PAb-hTLR4 and MAb2-hTLR4 could inhibit cobalt-mediated 
upregulation of CCL20, IL1A and HSPA1A.  
CCL20 expression was significantly upregulated in response to both CoCl2 and LPS (both 
p<0.001) (Figure 4.15A). The effect of LPS was much larger than that of CoCl2 (40-fold 
compared to 10-fold). PAb-hTLR4 pre-treatment significantly decreased the change in CCL20 
expression induced by CoCl2 and LPS (p<0.001). IL1A expression was also upregulated by 
CoCl2 and LPS, although only the LPS response was statistically significant (p=0.1021 for 
CoCl2 and p<0.001 for LPS) (Figure 4.15B). PAb-hTLR4 significantly inhibited LPS-mediated 
IL1A expression (p=0.0044) but had no effect on the response to CoCl2 (p=0.8246). There was 
no change in HSPA1A expression in response to LPS (p=0.9979) (Figure 4.15C). HSPA1A 
expression was increased 10-fold in CoCl2-stimulated cells (p<0.001) but there was no change 
in response to LPS (Figure 4.15C). PAb-hTLR4 pre-treatment caused upregulation of HSPA1A 
expression in MonoMac 6 cells stimulated with CoCl2 (p<0.001).  
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Figure 4.15: Effect of PAb-hTLR4 on inflammatory gene expression 
MonoMac 6 cells were pre-incubated with 5µg/ml PAb-hTLR4 for 10 minutes before 
stimulation with 0.75mM CoCl2 or 100ng/ml LPS for 16h. RNA was isolated and cDNA 
synthesised by reverse transcription. A. CCL20 B. IL1A and C. HSPA1A expression was 
quantified by qRT-PCR. Data is representative of three independent experiments and 
statistical significance was calculated by one-way ANOVA with Tukey’s test for multiple 
comparisons comparing all samples to each other. This data appears in Lawrence et al 
(Lawrence et al., 2016). 
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4.3.17. Effect of MAb2-hTLR4 on inflammatory gene expression 
The effect of MAb2-hTLR4 on target genes CCL20, IL1A and HSPA1A was assessed. As 
previously, MonoMac 6 cells were pre-treated with 10μg/ml MAb2-hTLR4 for 1h before 16h 
stimulation with 0.75mM CoCl2 or 100ng/ml LPS. Analysis by qRT-PCR revealed that LPS 
induces a very large 130-fold increase in CCL20 expression (Figure 4.16A), which was 
significantly reduced by MAb2-hTLR4 (p<0.001). The size of the fold change masks the 
change induced by cobalt and therefore Figure 4.16B shows the effect of cobalt alone. There 
was a 10-fold increase in CCL20 expression following CoCl2 stimulation and this effect was 
significantly inhibited by MAb2-hTLR4 (p<0.001). Similarly to CCL20, LPS and CoCl2 caused 
upregulation of IL1A expression (both p<0.001), although the fold changes were more similar 
than for CCL20 (Figure 4.16C). MAb2-hTLR4 abrogated this increase in the case of both 
ligands (both p<0.001); the observed inhibition was greater for LPS than for CoCl2. 
Surprisingly, HSPA1A expression increased in the presence of the antibody in CoCl2-stimulated 
cells. LPS did not increase HSPA1A expression in cells with or without MAb2-hTLR4 
(p<0.001) (Figure 4.16D). 
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Figure 4.16: Effect of MAb2-hTLR4 on inflammatory gene expression 
MonoMac 6 cells were pre-treated with 10µg/ml MAb2-hTLR4 for 1h before 16h 
stimulation with 0.75mM CoCl2 or 100ng/ml LPS. RNA was isolated and cDNA 
synthesised by reverse transcription. qRT-PCR was performed to assess expression of 
A&B. CCL20, C. IL1A, and D. HSPA1A. Data is representative of three independent 
experiments and statistical significance was calculated by one-way ANOVA with 
Tukey’s test for multiple comparisons comparing all samples to each other. This data 
appears in Lawrence et al (Lawrence et al., 2016). 
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4.4. Discussion 
Selection of cobalt concentrations 
Studies into the inflammatory effects of cobalt ions differ considerably in the concentrations 
used for cell stimulation. This is likely to be a reflection of the broad range of metal ion levels 
detected in patient samples used in clinical investigations, which can vary significantly even 
within the same study (Rodríguez De La Flor et al., 2013). In some cases this is due to different 
tissues being investigated, for example synovial fluid cobalt levels are generally higher than 
those in serum because wear debris is released directly into the synovial fluid and tissues (Lass 
et al., 2014). However cobalt concentrations can also vary greatly from patient to patient 
making it difficult to define a clinically-relevant concentration. For example Macnair et al 
measured serum cobalt concentrations and found a range of 0.7-60.6µg/L (MacNair et al., 2013) 
whilst Newton et al detected cobalt concentrations from 2-10,759nmol/L in urine (Newton et 
al., 2012). The range of concentrations selected for the present study were chosen following 
consideration of the first study investigating nickel activation of TLR4 which used 1.5mM 
NiCl2 as the optimal concentration (Schmidt et al., 2010). This is a very high concentration 
when considering the results of most clinical studies and therefore 0.25-1mM CoCl2 was 
selected as an appropriate range when considering clinical concentrations, together with 
previous in vitro studies using cobalt ions (Raghavan et al., 2012, Ninomiya et al., 2013).    
Increased IL-8 secretion by MonoMac 6 cells was observed across all CoCl2 concentrations, 
suggesting that cobalt ions can be inflammatory even at lower levels. There was also an 
upregulation in IL8 gene expression by cobalt-stimulated MonoMac 6 cells, with peak 
expression occurring at 0.75mM CoCl2. The effect on IL-8 release was validated in two other 
cell lines relevant to this study; THP-1 monocytes and U2OS osteoblasts. Both cell lines 
increased IL-8 secretion following CoCl2 and LPS stimulation, showing the potential of cobalt 
to have widespread inflammatory effects. In all three cell lines studied 100ng/ml TLR4-specific 
LPS also caused increased IL-8 secretion (and gene expression in the case of MonoMac 6 cells), 
indicating that it is effective as a positive control for TLR4-dependent IL-8 secretion.  
Total IL-8 levels released by stimulated THP-1 and U2OS cells were lower than those secreted 
by MonoMac 6 macrophages, and therefore MonoMac 6 cells were used as a model in further 
assays. MonoMac 6 cells are also a useful in vitro model for this clinical scenario because 
macrophages are resident in the synovial fluid that lubricates joint implants and are 
consequently some of the first cells to encounter metal debris and ions released from the bearing 
surfaces.  
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Given that maximal IL8 gene expression occurred at 0.75mM CoCl2 and there was little 
difference in the IL-8 release between 0.75mM and 1mM CoCl2, 0.75mM was selected as the 
optimal cobalt concentration for further experiments. MonoMac 6, THP-1 and U2OS cells all 
released similar amounts of IL-8 when treated with 0.75mM CoCl2 as when they were 
stimulated with 100ng/ml LPS which further supports the use of 0.75mM CoCl2 as an optimal 
concentration, and LPS as a positive control.  
Cytotoxicity of cobalt ions 
Cobalt can cause cytotoxicity although previous studies have generated variable and conflicting 
results in this regard. Some have demonstrated no toxicity even with 1.5mM CoCl2 (Raghavan 
et al., 2012) while others have found 0.1mM CoCl2 to be toxic (Kanaji et al., 2014). It appears 
that cobalt-induced cytotoxicity is dependent on both cell type and the form of cobalt used (i.e. 
ions, nanoparticles, CoCrMo debris etc). To date no other studies have used MonoMac 6 cells 
to investigate the cellular response to cobalt ions. Consequently before any further assays were 
conducted the cytotoxic effect of CoCl2 on MonoMac 6 cells was investigated. The optimal 
concentration of 0.75mM CoCl2 was found to reduce cell viability from 100% (normalised 
value) in untreated cells to approximately 75% following 24h stimulation. Cytotoxicity is 
clearly a factor to consider in subsequent assays because it can influence cell responses but 
because 0.75mM CoCl2 was optimised based on previous studies and in vivo levels, it was 
decided to proceed with this concentration.  
Cytokine and chemokine expression and secretion 
Murine Cxcl1 expression was significantly increased by LPS stimulation whereas CoCl2 caused 
only a very small change in expression. In MonoMac 6 cells IL-8 expression and secretion was 
comparable between CoCl2 and LPS stimulation, suggesting that the effect in murine J774 cells 
is a TLR4-independent inflammatory response to CoCl2. This result supports previous studies 
showing that cobalt ions do not activate murine Tlr4 (Raghavan et al., 2012, Tyson-Capper et 
al., 2013a) and highlights the importance of focusing on human TLR4 for further work.   
This study clearly shows that cobalt can induce IL-8 release by MonoMac 6 macrophages and 
other cell lines. It was important to establish the role of TLR4 in the MonoMac 6 cell response 
to cobalt ions and this was done in the first instance using CLI-095, a small molecule TLR4 
antagonist. CLI-095 has already been widely used in the prevention of inflammatory responses 
to LPS (Glushkova et al., 2013, Hussey et al., 2013) and therefore optimisation was performed 
using 0.75mM CoCl2. This revealed that CLI-095 dose-dependently inhibits cobalt-mediated 
IL-8 secretion in MonoMac 6 cells and suggests a central role for TLR4 in the response. Similar 
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inhibitory effects were observed in IL8 expression, indicating that cobalt-mediated gene 
expression changes are also TLR4-dependent. CLI-095 inhibited the majority of IL-8 secretion 
following cobalt stimulation and also prevented LPS-mediated responses, showing that LPS is 
a good positive control for both receptor activation and inhibition. The Proteome Profiler arrays 
described in chapter 3 showed a small increase in CXCL10 secretion by cobalt-stimulated 
MonoMac 6 cells. The use of CLI-095 demonstrates that TLR4 is essential to CXCL10 
secretion in this case because pre-treatment with the inhibitor decreased CXCL10 release to 
that of untreated MonoMac 6 cells.     
As CLI-095 prevents the recruitment of all adaptor proteins to activated TLR4 it is not possible 
to identify which of these is responsible for the observed responses. However the cytokines 
released may provide insight into the signalling pathways that are activated by cobalt ions. As 
described in section 1.6.1, TLR4 activation by LPS results in the recruitment of adaptor proteins 
including MyD88 and TRIF to the intracellular domain of the receptor. Each adaptor protein 
signals via a different pathway, resulting in activation of different transcription factors and the 
production of diverse inflammatory cytokines and chemokines. Secretion of IL-8 following 
TLR4 activation is thought to be MyD88-dependent as mutation of MyD88 abrogates the LPS-
induced IL-8 response (He et al., 2013a). CXCL10 release can occur when the TRIF-dependent 
pathway is activated (Weighardt et al., 2004). TLR4-dependent secretion of both IL-8 and 
CXCL10 following cobalt stimulation therefore suggests that cobalt ions can activate both the 
MyD88 and TRIF-dependent arms of TLR4 signalling. Some caution is required here as 
CXCL10 can also be regulated by NFκB which in turn is modulated by MyD88 pathway 
activation. However a recent study has supported a role for the TRIF pathway in cobalt-
mediated inflammatory responses, demonstrating CXCL10 promoter activity following cobalt 
stimulation (Oblak et al., 2015), and others have previously suggested involvement of the 
MyD88-dependent pathway (Potnis et al., 2013).  
Untreated control cells with or without CLI-095 were included in all assays. This revealed a 
small but significant downregulation in CXCL10 secretion in the presence of the inhibitor. A 
similar effect was observed with IL-8 secretion and gene expression but this was not statistically 
significant. The effect may be due to release of endogenous TLR4 ligands such as HMGB1 by 
the cells, or a very low level of endotoxin contamination that activates TLR4. However the 
reduction in cytokine secretion may also be the result of cytotoxicity. The effect of the 
antagonist on cell viability was assessed because it is reconstituted in DMSO, a known 
cytotoxic agent. Treatment of MonoMac 6 cells with 10µg/ml CLI-095 reduced cell viability 
from 100% to approximately 80%. This is unlikely to be entirely responsible for the changes in 
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cobalt-mediated IL-8 and CXCL10 secretion because they are much larger changes than those 
observed in cell viability. However as cobalt can also cause toxicity the concentration of CLI-
095 was revised to 1µg/ml, which was found to inhibit IL-8 secretion without affecting cell 
viability and is in line with concentrations used in previous studies (Glushkova et al., 2013).  
The optimised concentration of CLI-095 was used to investigate the effect of cobalt ions on two 
additional inflammatory cytokines, CCL20 and IL-6. CCL20 was chosen for this aspect of the 
study because the qRT-PCR arrays showed that it was significantly upregulated by cobalt ions 
at gene level, and expression levels were high even at baseline, indicating that protein secretion 
would be detectable by ELISA. IL-6 was selected because there was no evidence of 
upregulation following cobalt stimulation in any of the arrays described in chapter 3 but there 
was an increase in response to LPS. There was a significant increase in CCL20 secretion by 
MonoMac 6 cells stimulated with CoCl2 or LPS. Pre-treatment with CLI-095 significantly 
decreased this effect suggesting that chemokine release is a result of TLR4 activation by cobalt 
ions. IL-6 secretion was also significantly upregulated by LPS but there was only a very small 
increase in response to cobalt ions. These low levels of IL-6 may also have been outside the 
detection range of the Proteome Profiler arrays in chapter 3 which would account for the lack 
of changes in secretion. As with IL-8, CXCL10 and CCL20, IL-6 release was prevented by 
CLI-095 (although not statistically significant), showing that even this small change in cytokine 
secretion is dependent on TLR4 activation.   
Cytokine and chemokine function: clinical significance in ARMD 
The cytokines and chemokines released following cobalt activation of TLR4 could potentially 
contribute to adverse reactions to metal debris through their immunological functions. IL-8 is 
a pro-inflammatory chemokine secreted in response to cellular stress and damage, pathogen 
phagocytosis and PRR activation. It is particularly chemotactic for neutrophils (Baggiolini et 
al., 1989) via activation of CXCR1 and CXCR2 receptors on target cells. IL-8 is also an 
angiogenic factor, promoting blood vessel formation through activation of CXCR2 (Heidemann 
et al., 2003). In a study by Ma et al using an endothelial cell and osteoblast co-culture system, 
TLR4 activation by LPS caused significant upregulation of IL-6 and IL-8 secretion, along with 
pro-angiogenic factors ICAM-1 and E-selectin (Ma et al., 2015). These changes were associated 
with increased microvessel formation (Ma et al., 2015). This is of importance to the present 
study because one of the leading indications for MoM implant failure is inflammatory 
pseudotumour growth, a process that requires vascularisation. It is therefore possible that 
cobalt/TLR4-mediated IL-8 secretion could promote angiogenesis and aid pseudotumour 
formation.   
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Another characteristic of ARMD is aseptic loosening of the joint implant caused by peri-
prosthetic osteolysis. Osteolysis is driven at least in part by inflammatory cytokines that 
promote the formation of osteoclasts (bone-resorbing cells) and prevent osteoblast activity. 
Bone metastasis in breast cancer requires osteolysis, and serum IL-8 levels correlate with the 
degree of metastasis in breast cancer patients (Bendre et al., 2002, Kamalakar et al., 2014). 
Furthermore, IL-8 stimulated the differentiation of peripheral blood mononuclear cells into 
osteoclasts and an anti-IL-8 antibody was able to prevent tumour osteolysis in an in vivo murine 
model (Kamalakar et al., 2014). Both IL-8 and CCL20 have been shown to have an indirect 
effect on osteoclast formation by increasing osteoblast secretion of IL-6 which in turn promotes 
osteoclastogenesis (Pathak et al., 2015). IL-8 levels in peri-implant tissues also correlate with 
incidences of aseptic loosening (Lassus et al., 2000, Tanaka et al., 2005).  Effects such as these 
are associated with CXCR1 and CXCR2 expression levels on IL-8 target cells (Bendre et al., 
2003) and cause variability from patient to patient. IL-8 therefore appears to play a key role in 
osteolysis and it could be speculated that if MoM patient cells secrete IL-8 in response to cobalt, 
an IL-8-mediated osteolytic response could develop, with the degree of osteolysis determined 
by CXCR1 and CXCR2 expression levels.   
Patients with ARMD (and specifically ALVAL) have elevated CXCL10 levels in their synovial 
fluid compared to those with a metal-on-polyethylene implant (Kolatat et al., 2015). Dapunt et 
al also showed the presence of CXCL10 in tissues from aseptically loosened MoM implants 
and this was associated with a small population of T lymphocytes (Dapunt et al., 2014). It is 
conceivable that TLR4-dependent CXCL10 secretion contributes to the lymphocyte infiltration 
around MoM implants, providing a link between innate and adaptive immune responses. 
CXCL10 can be produced by bone and in a murine model it recruits cancer cells that promote 
bone metastasis (Lee et al., 2012). The same study found that CXCL10 acts by increasing 
RANKL expression without altering OPG, which drives osteoclastogenesis (Lee et al., 2012). 
The effect was inhibited by Tlr4 knockdown indicating that the receptor is essential to the 
response. This suggests that TLR4 activation (e.g. by cobalt ions) may contribute to CXCL10-
induced osteoclastogenesis and osteolysis. 
CCL20 is a lymphocyte chemokine and promotes pro-inflammatory responses including B 
lymphocyte recruitment (Meissner et al., 2003). CCL20 is of interest to the present study 
because ALVAL, one of the features of ARMD, is characterised by lymphocyte infiltration of 
peri-implant tissues (Watters et al., 2010). If resident tissues macrophages secrete CCL20 it 
may contribute to the cellular infiltrate around failed MoM hip replacements by recruiting 
lymphocytes. Interestingly, CCL20 has been implicated in osteolysis as expression of CCL20 
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and CCR6 is elevated in leukaemia patients with osteolytic lesions compared to those with no 
bone breakdown (Giuliani et al., 2008). As a result CCL20 has been suggested as a biomarker 
of osteolysis (Palmer et al., 2015).  
The immunobiology of IL-6 is complex and there is often conflicting information regarding its 
potential inflammatory effects. For example Yoshitake et al showed inhibition of osteoclast 
formation by IL-6 (Yoshitake et al., 2008), while others have suggested that IL-6 promotes 
osteoclastogenesis (Kudo et al., 2003) and inhibition of the IL-6 receptor can prevent bone loss 
(Axmann et al., 2009). Of interest to this study is the ability of IL-6 to promote vascular 
endothelial growth factor (VEGF) expression; VEGF in turn leads to increased angiogenesis 
which aids tumour (and pseudotumour) formation (Huang et al., 2004). IL-6 is associated with 
ARMD as significantly higher concentrations were found in patients experiencing MoM 
implant failure compared to those with failed ceramic-on-polyethyleneimplants (Singh et al., 
2015).  
Anti-TLR4 neutralising antibodies 
Using IL-8 expression and secretion as a marker of TLR4 activation, the ability of anti-TLR4 
neutralising antibodies to prevent receptor activation by cobalt ions was assessed. A 
monoclonal anti-TLR4 neutralising antibody, MAb2-hTLR4, inhibited cobalt-mediated IL-8 
expression and secretion as well as expression of CCL20 and IL1A. In contrast a polyclonal 
anti-TLR4 neutralising antibody, PAb-hTLR4, failed to inhibit IL-8 secretion following either 
CoCl2 or LPS stimulation, while gene expression was marginally inhibited in LPS-stimulated 
cells. The polyclonal antibody inhibited CCL20 and IL1A expression following LPS treatment 
but in the case of cobalt it could only inhibit CCL20. With both MAb2-hTLR4 and PAb-hTLR4 
cobalt-mediated HSPA1A expression was further increased in the presence of the antibody.   
It is surprising that PAb-hTLR4 could not effectively inhibit cobalt-mediated inflammatory 
responses to the same extent as MAb2-hTLR4 because both antibodies are reported to inhibit 
TLR4 activation (Ekaney et al., 2014, Lima et al., 2015). The differences in efficacy are likely 
to arise through different antibody binding sites. As PAb-hTLR4 inhibited LPS activation better 
than CoCl2 it may bind to sites including those involved in the transfer of LPS from LBP to 
TLR4 itself. Cobalt binds directly to the receptor and consequently LBP is not required for 
TLR4 activation. The use of neutralising antibodies in this study supports the current 
understanding that cobalt and LPS bind and activate TLR4 by different mechanisms (Raghavan 
et al., 2012).   
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Another possible explanation for the lack of IL-8 and IL1A inhibition by PAb-hTLR4 is the 
presence of other TLR4 ligands such as Hsp70, as shown in the qRT-PCR arrays in chapter 3. 
It may be that cobalt ions cause increased secretion of inflammatory factors capable of 
activating TLR4 which feed back and perpetuate receptor activation. If these ligands bind to a 
site not targeted by PAb-hTLR4 they may be capable of promoting cellular responses even in 
the presence of the neutralising antibody. A third explanation could be that the increases in IL-
8 secretion following cobalt and LPS stimulation are too strong for the antibody to inhibit. 
Finally, as IL-1α is released during cell stress its secretion may not be entirely TLR4-dependent 
and may be the result of generalised inflammation.  
HSPA1A expression was increased in response to cobalt ions and this could not be prevented 
with either of the anti-TLR4 neutralising antibodies, indicating that it is not a TLR4-dependent 
effect. This is supported by the lack of change in HSPA1A expression following LPS 
stimulation; in all other assays LPS has been an effective positive control for TLR4 activation 
and inhibition by antagonists. Previous studies have shown that LPS can induce Hsp70 
(encoded by HSPA1A) but this appears to require synergy with other TLRs and their ligands, 
as well as specific physiological factors such as increased temperatures (Gupta et al., 2013, 
Tulapurkar et al., 2015). The elevated HSPA1A expression detected in the present study may 
well be a result of the cytotoxicity also described in this chapter as heat shock proteins are 
released during cell stress responses. HSPA1A expression increased further with both MAb2-
hTLR4 and PAb-hTLR4 pre-incubation and it is possible that some of the TLR4-dependent 
cytokines released have a protective effect on the cells which is abolished by TLR4 inhibition. 
However additional assays would be required to validate this theory. 
CLI-095, MAb2-hTLR4 and PAb-hTLR4 were all selected for use in this study because they 
have previously been shown to inhibit inflammatory responses to TLR4 ligands. In addition, 
TLR4 is an attractive therapeutic target because it is at the start of a cascade of intra- and 
intercellular signalling that may be implicated in ARMD. Its cell surface expression also makes 
it a more accessible target, as well as its involvement in a broad range of inflammatory response. 
Studies have highlighted the potential of targeting TLR4 in treatments for Gram negative septic 
shock, cardiovascular disease, and rheumatoid arthritis (Jia et al., 2014, Lima et al., 2015, 
Monnet et al., 2015). In the present study the inhibitor and antibodies’ blockade of LPS-
mediated TLR4 activation provided a good positive control when investigating their potential 
to inhibit cobalt activation of the receptor, but their therapeutic potential in ARMD requires 
careful consideration. For a TLR4 antibody to be a therapeutic option in the prevention of 
ARMD it must be capable of inhibiting cobalt activation of TLR4 without affecting a patient’s 
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ability to respond to LPS via the receptor; this is essential for mounting an immune response 
against Gram negative bacteria, as well as other PAMPs and DAMPs. As the LPS and cobalt 
binding sites within TLR4 are different, an antibody that specifically targets the histidine pocket 
may prevent cobalt (and nickel) activation of TLR4 while still conferring LPS responsiveness. 
The antibodies used in this study partially prevented LPS activation of TLR4 and therefore 
would not be suitable for ARMD prevention as they would block inflammatory responses to 
Gram negative bacteria as well as cobalt ions. However they clearly show that anti-TLR4 
neutralising antibodies have potential in ARMD therapeutics. There are a number of TLR4 
antibodies in clinical trials for inflammatory diseases, including NovImmune’s NI-0101, which 
has successfully completed Phase I for use in rheumatoid arthritis (Monnet et al., 2015) showing 
that TLR4 is a realistic clinical target despite its importance in the immune response to bacteria. 
Overall it is clear that cobalt activation of TLR4 results in increased secretion and expression 
of pro-inflammatory cytokines and chemokines. These factors (e.g. IL-6 and IL-8) have all 
previously been implicated in immune responses such as osteolysis and fibrosis. Persistent 
cytokine release appears central to the development of ARMD as it creates a pro-inflammatory 
environment that favours osteoclastogenesis and soft tissue necrosis (Gallo et al., 2013). 
However the mechanisms that lead to the release of these cytokines is not well understood. 
Based on the results of this study it is conceivable that the initial stimulus is cobalt-mediated 
TLR4 activation.   
Importance of TLR4 in inflammatory responses to cobalt 
From the data presented in this chapter it is clear that TLR4 plays a significant role in the 
cellular response to cobalt ions as the TLR4 antagonist and anti-TLR4 neutralising antibodies 
were able to prevent cobalt-mediated inflammatory cytokine secretion and gene expression. 
This raises the question of whether the immunological properties of cobalt in this in vitro cell 
culture model are entirely dependent on TLR4 activation, or whether other TLR4-independent 
responses also develop. CLI-095 was able to reduce IL-8 secretion to nearly the same level as 
in untreated cells suggesting that TLR4 significantly contributes to the inflammatory response.  
Many animal studies have been conducted to model the immunological response to wear debris 
and metal ions, and the majority have shown an inflammatory effect (Saini et al., 2010b, Akbar 
et al., 2012). Most of these studies use conventional small animal models such as mice and 
guinea pigs, which do not have the histidine pocket in TLR4 that is present in humans and 
primates (Figure 3.1). As an inflammatory response still develops, TLR4 activation cannot be 
fully responsible for the observed inflammation and therefore the reaction may be generalised 
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inflammation, or immune system activation via an as yet unidentified pathway. This also 
suggests that TLR4 activation alone is not responsible for the inflammatory responses in 
ARMD but may combine with other stimulatory signals (e.g. antigen presentation) to drive 
inflammation. The TLR4 signalling pathway itself is also regulated by endogenous and 
exogenous factors and they may influence the immunological outcome of receptor activation. 
Some of these factors will be discussed in more detail in chapter 6.    
4.4.1. Future work 
The data presented in chapter 3 clearly shows that cobalt ions affect the expression of 
inflammatory genes and TLR-related signalling factors. To further elucidate the role of TLR4 
in these responses, the same arrays could be performed using samples from MonoMac 6 cells 
pre-treated with CLI-095 or the anti-TLR4 neutralising antibodies before cobalt stimulation. 
This would give an improved overview of which changes are regulated by TLR4, as well as the 
efficacy of the TLR4 antagonists.  
An important aspect of further work in the study is to investigate the functional effects of the 
cytokines and chemokines secreted in response to cobalt ions. In addition it would be interesting 
to identify which factors may influence particular aspects of the inflammatory response (e.g. 
CCL2 is often responsible for macrophage recruitment). As well as providing greater insight 
into how they may influence ARMD, this would also allow a more targeted approach in the 
design of therapeutic agents for the inhibition of adverse reactions. As mentioned earlier, an 
antibody targeting cobalt-mediated responses would need to be carefully designed to ensure 
that the capacity of TLR4 to respond to LPS is preserved.    
The identification and optimisation of IL-8 as a biomarker for TLR4 activation by cobalt ions 
will be beneficial in further studies, including investigations into the specific downstream 
signalling factors involved in the response to cobalt. For example, siRNA knockdown of factors 
like IRAK2 could be performed, using IL-8 as a biomarker of the effect of cobalt ions. TLR4 
can also become tolerant or sensitised to its ligands and IL-8 could be used to assess cell 
responsiveness in appropriate assays.  
4.4.2. Conclusion 
The primary aim of this chapter was to use IL-8 as a biomarker of inflammation to investigate 
the effect of cobalt ions on TLR4 activation and subsequent cellular responses. Treatment with 
a clinically-relevant range of cobalt concentrations was found to increase IL-8 gene expression 
and protein secretion by MonoMac 6 cells. This was a TLR4-dependent effect as it was 
inhibited by CLI-095, a small molecule TLR4 antagonist. Similar patterns were observed in 
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cobalt-stimulated THP-1 monocytes and U2OS osteoblasts, as well as for CXCL10 expression, 
and CCL20 and IL-6 secretion by MonoMac 6 cells. A monoclonal anti-TLR4 neutralising 
antibody proved effective at inhibiting the majority of CoCl2-induced cytokine expression with 
the exception of HSPA1A. A polyclonal anti-TLR4 antibody was less successful in this regard. 
LPS provided an effective positive control for TLR4 activation in all experiments.  
From the data presented in this chapter it can be concluded that the TLR4 signalling pathway 
is central to the in vitro cellular inflammatory response to cobalt ions. It could therefore 
contribute to the inflammatory response seen in a proportion of MoM implant patients, perhaps 
as a co-stimulatory signal alongside other mechanisms of immune activation. As such, TLR4 
and its downstream signalling pathway are interesting targets both for further research into 
inflammatory responses to cobalt ions and as potential therapeutic options in the prevention of 
ARMD.  
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Chapter 5. Effect of cobalt ions on immune cell chemotaxis and binding 
5.1. Introduction 
Data presented in chapter 3 and 4 demonstrates that cobalt ions regulate expression and 
secretion of inflammatory cytokines and chemokines through direct activation of TLR4. 
Cytokines and chemokines in turn modulate numerous immunological functions including cell 
migration, adhesion, invasion, and proliferation. The overall outcome of cytokine signalling is 
determined by the cytokine profile released in response to a specific stimulus. The cumulative 
effect of the cobalt-induced cytokine profile is not yet clear.   
Histopathological studies have shown elevated immune cell infiltration of tissues around failed 
MoM hip implants. Whilst there has been considerable focus on ALVAL, the lymphocytic 
reaction frequently associated with MoM joint replacement failure, many studies have 
identified an innate immune cell infiltrate composed primarily of monocytes and macrophages 
but also containing low levels of neutrophils and eosinophils (Pandit et al., 2008, Mahendra et 
al., 2009). However the stimuli that lead to inflammatory cell recruitment around MoM 
implants are unknown.  
Cell adhesion and migration are critical steps in any inflammatory response and are particularly 
important for leukocyte extravasation. This is the process by which immune cells adhere to the 
vascular endothelial layer and then pass through the layer into the surrounding tissues where 
they can mount an inflammatory response against a pathogen. Extravasation (also known as 
diapedesis) requires interaction between adhesion molecules expressed on the leukocyte and 
endothelial cell for effective cell adhesion. Chemokine release is also essential to induce 
migration of target cells down a carefully coordinated chemokine concentration gradient. In the 
resting state these processes are tightly regulated to prevent unwanted inflammation but 
pathogen challenge results in upregulation of adhesion molecule and chemokine expression to 
drive leukocyte extravasation. 
5.1.1. Effect of metal ions and wear debris on cell adhesion 
Expression of adhesion molecules including intercellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1) and E-selectin by leukocytes such as 
macrophages promotes the cell-cell interaction required for effective cellular communication 
and coordination of inflammation (section 1.7.3). This includes involvement in processes like 
extravasation and vascularisation.   
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The expression of factors such as ICAM-1 and VCAM-1 is altered in tissues surrounding joint 
implants; for example ICAM-1 expression is increased in blood vessels near metal and 
UHMWPE implants (Al-Saffar et al., 1994). The effect of cobalt ions on cell adhesion was first 
studied in the 1990s by Goebeler et al who demonstrated that they upregulate ICAM-1 and 
VCAM-1 expression in human umbilical vein endothelial cells (HUVEC) (Goebeler et al., 
1993). More recently Ninomiya et al confirmed these findings and showed that the increase in 
adhesion molecule expression correlates with increased secretion of IL-8 and CCL2 by 
endothelial cells exposed to cobalt ions. These were functional changes as cobalt also increased 
lymphocyte binding to endothelial cells (Ninomiya et al., 2013). Interestingly, chromium, the 
second component of the CoCr alloy, did not have any effect on adhesion molecule expression 
and nor did molybdenum in work conducted by Caicedo et al (Caicedo et al., 2007, Ninomiya 
et al., 2013). As well as ions, cobalt nanoparticles have recently been shown to increase ICAM-
1 and VCAM-1 expression (Alinovi et al., 2015). Although it is clear from the studies described 
above that cobalt ions regulate adhesion molecule expression the role of TLR4 in the response 
is not known.  
5.1.2. Effect of metal ions and wear debris on cell migration 
One of the main stimuli for cell migration is the secretion of chemokines by cells exposed to a 
pathogen. Chemokines form a gradient and act via receptors expressed by their target cells 
(often leukocytes) to guide them to the site of inflammation, where they extravasate to access 
the tissues and carry out their effector functions for efficient pathogen eradication. 
A joint replacement causes an acute inflammatory response when it is first implanted into the 
body. In most patients this quickly subsides as the implant becomes integrated into the bone 
and the tissues heal from the initial surgical trauma. In a small number of patients the early 
acute inflammation is compounded by the presence of wear debris. In vitro studies have 
indicated that titanium-aluminium and cobalt-chromium wear debris can stimulate cells to 
release pro-inflammatory chemokines including CCL2 (MCP-1) and CCL3 (MIP-1α) (Jones et 
al., 2007, Kaufman et al., 2008). These chemokines recruit innate immune cells to the site of 
inflammation. However, as in the case of cell adhesion, the role of cytokines is not clear. 
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5.2.  Objectives 
 To identify an appropriate endothelial cell line for the study of cobalt and TLR4-
mediated inflammatory responses 
 To investigate the role of cobalt and TLR4 in adhesion molecule expression by 
endothelial cells and macrophages 
 To investigate the effect of cobalt activation of TLR4 on primary monocyte and 
neutrophil migration using a trans-well chemotaxis assay 
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5.3. Specific materials and methods 
5.3.1. Peripheral blood mononuclear cell transwell chemotaxis assay 
Human peripheral blood mononuclear cells (PBMC) were isolated from the whole blood of 
healthy volunteers using Lympholyte-H (Cedarlane, Ontario, Canada) according to the 
manufacturer’s protocol. Isolated PBMC were resuspended in pre-warmed RPMI-1640 
medium supplemented with 2mM L-glutamine and 10% v/v FBS.  
Conditioned media was generated by stimulating MonoMac 6 cells with CoCl2 or LPS as 
described in earlier chapters and centrifuging samples to remove cells. A 24-well companion 
plate (VWR International, Pennsylvania, USA) was blocked with 1% w/v BSA in media for 1h 
before 800µl conditioned media was added to each well. A cell culture insert with 3µm pores 
(VWR International) was placed in each well and 500,000 PBMC added to each filter. Cells 
were incubated at 37oC and 5% CO2 for 2 hours to allow migration. Excess media and cells 
were removed by pipetting and cleaning with a cotton bud. Filters were fixed overnight in ice-
cold methanol. 
Filters were stained with haematoxylin for 30 minutes and washed in Scott’s tap water for 10 
minutes followed by sequential rinsing in 50%, 75%, 90% and 100% v/v ethanol (2 minutes 
each). They were then air-dried for a minimum of 3h, excised, and mounted using DPX 
mountant. Monocytes adhered to the filter were counted by selecting five different visual fields 
at 40x magnification. The chemotaxis assay protocol is summarised in Figure 5.1. 
5.3.2. Neutrophil transwell chemotaxis assay 
Neutrophil chemotaxis was performed using neutrophils isolated from healthy volunteers by 
dextran sedimentation (Dextran T500, Pharmacosmos, Holbaek, Denmark) and centrifugation 
on Percoll gradients (GE Healthcare, Buckinghamshire, UK) as previously described 
(Dransfield et al., 1994). Neutrophils were resuspended in Hanks’ balanced salt solution 
(HBSS) supplemented with 10% v/v FBS prior to the assay. Following this step, the chemotaxis 
assay was conducted as described for PBMC chemotaxis (section 5.3.1) 
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Figure 5.1: Chemotaxis assay protocol overview 
1. MonoMac 6 cells in culture stimulated with cobalt ions. 2. PBMC isolated from whole 
human blood. 3. Conditioned media from cultured cells collected, centrifuged to remove 
cells and 800μl added to one well of a 24-well plate. 4. Cell culture insert with 3μm filter 
pores placed in the well and 500,000 PBMC added to the top of the filter. 5. PBMC 
incubated at 37oC and 5% CO2 for 2h to migrate. Migrated monocytes should adhere to 
the underside of the filter. 6. Filters stained with haematoxylin, excised, mounted on 
slides with DPX mountant, and monocytes counted.  
 
. 
131 
 
5.4. Results 
5.4.1. Effect of cobalt ions on human umbilical vein endothelial cells 
Previous research into the effect of nickel and cobalt ions on adhesion molecule expression has 
centred on human umbilical vein endothelial cells (HUVEC). As a result pooled HUVEC 
(PromoCell, Heidelberg, Germany) were assessed for their suitability for this study. One of the 
main aims of this chapter was to investigate the effect of cobalt-mediated TLR4 activation on 
adhesion molecule expression. It was therefore important to determine that the endothelial cells 
were stimulated by cobalt ions and LPS through TLR4 activation. A preliminary experiment 
was conducted using the metal ion concentrations optimised for MonoMac 6 cells in chapter 4, 
and IL-8 as a marker of TLR4 activation. HUVEC were stimulated with 0.25-1mM CoCl2 or 
100ng/ml LPS for 24h before supernatant was collected and analysed by ELISA. There was no 
significant difference in IL-8 secretion between untreated cells and those treated with 0.25-
0.75mM CoCl2 (Figure 5.2A). 1mM CoCl2 caused a small but significant increase in IL-8 
secretion from 550pg/ml to 650pg/ml (p=0.0245) while 100ng/ml LPS increased IL-8 levels to 
700pg/ml (p<0.001) (Figure 5.2A).  
A previous study investigating the effect of cobalt on endothelial cells has demonstrated that 
high cobalt concentrations (up to 4mM) can induce IL-8 secretion by HUVEC (Ninomiya et 
al., 2013).  Consequently HUVEC were treated with 1-4mM CoCl2 to establish whether or not 
these higher concentrations would have an effect. IL-8 secretion was again measured by ELISA. 
There was a significant decrease in IL-8 release across all CoCl2 concentrations compared to 
the untreated control (p<0.001 except 1mM where p=0.0312) (Figure 5.2B). The same study 
(Ninomiya et al., 2013) also used longer timepoints for cobalt stimulation and therefore 
HUVEC were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 48h after which IL-8 
secretion was measured by ELISA. There was a significant reduction in IL-8 secretion with 
0.25mM (p<0.001) and 1mM CoCl2 (p<0.001) while LPS caused a small increase in IL-8 
production (p=0.0042) (Figure 5.2C). Finally, IL-6 secretion was investigated as it has been 
shown to be upregulated in LPS and nickel-stimulated HUVEC (Goebeler et al., 1995). 
Following treatment with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h, IL-6 secretion by 
HUVEC was assessed by ELISA. Although there was a significant increase in IL-6 release in 
LPS-treated cells (p<0.001), there was no increase in IL-6 production by HUVEC stimulated 
with CoCl2 and a significant decrease was observed with 0.25mM (p=0.0088) and 0.5mM 
CoCl2 (p=0.0155) (Figure 5.2D). 
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Figure 5.2: Effect of CoCl2 on HUVEC 
A. HUVEC were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h and IL-8 
secretion was quantified. Data is representative of two independent experiments. B. 
HUVEC were stimulated with 1-4mM CoCl2 or 100ng/ml LPS and IL-8 secretion was 
quantified. Data is representative of two independent experiments. C. HUVEC were 
stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 48h and IL-8 secretion was 
quantified. n=1. D. HUVEC were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 
24h and IL-6 secretion was quantified. n=1. All cytokine quantification was performed 
by ELISA. Statistical significance was calculated by one-way ANOVA with Dunnett’s 
multiple comparisons test comparing treated samples to the untreated control.
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5.4.2. Effect of cobalt ions on human microvascular endothelial cells 
Given the lack of cytokine secretion by CoCl2 and LPS-stimulated HUVEC, a second 
endothelial cell line, HMEC-1, was assessed for its inflammatory response. As the HUVEC 
response to CoCl2 indicated cytotoxicity (i.e. decreased cytokine secretion by treated cells 
compared to controls), a cytotoxicity assay was conducted on HMEC-1 prior to any further 
assays. HMEC-1 were incubated with 0.75mM CoCl2 or left untreated for 24h before a 
cytotoxicity assay was performed using trypan blue staining and a Luna II automated cell 
counter. In contrast to the cytotoxicity observed in MonoMac 6 cells, there was no significant 
difference in HMEC-1 viability between CoCl2-stimulated and unstimulated cells (100% 
viability normalised to untreated cells).  
 
Figure 5.3: Effect of CoCl2 on HMEC-1 viability 
HMEC-1 cells were stimulated with 0.75mM CoCl2 or untreated for 24h before a 
cytotoxicity assay was conducted using trypan blue staining. Images were obtained on a 
Luna II automated cell counter and counted manually. n=1. Cell viability was normalised 
to 100% in control cells, and was found to be 100% in CoCl2-stimulated cells. 
 
HMEC-1 were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h. As well as being 
consistent with the concentrations used in MonoMac 6 cells, this CoCl2 dose range is 
comparable with other studies using cobalt in endothelial cells (Kim et al., 2006). Following 
cell treatment supernatant was collected and IL-8 secretion quantified by ELISA. In contrast to 
HUVEC, HMEC-1 displayed a significant upregulation in IL-8 production across all CoCl2 
concentrations, as well as with LPS stimulation (Figure 5.4A). Peak cobalt-mediated IL-8 
secretion of approximately 1200pg/ml occurred at 1mM CoCl2 (p<0.001) with LPS causing 
marginally higher secretion (p<0.001) (Figure 5.4A).  
Cobalt-mediated IL-8 secretion by MonoMac 6 cells is TLR4-dependent, as shown in chapter 
4. To further validate this data the small molecule TLR4 antagonist CLI-095 was used to 
134 
 
investigate HMEC-1 responses. In a preliminary assay HMEC-1 were pre-treated with a range 
of CLI-095 concentrations from 0.01-1µg/ml, followed by 24h stimulation with 0.75mM 
CoCl2. IL-8 secretion was quantified by ELISA. The antagonist was found to be inhibitory 
across all of the concentrations used (Appendix F). 1µg/ml CLI-095 was selected as the optimal 
concentration as it caused the largest inhibition of IL-8 secretion and is consistent with previous 
work conducted in MonoMac 6 cells. To confirm this initial result HMEC-1 were pre-treated 
with 1μg/ml CLI-095 for 6h and then stimulated with 0.75mM CoCl2 or 100ng/ml LPS for 24h. 
IL-8 secretion was measured by ELISA. In the presence of CLI-095 there was a significant 
reduction in IL-8 secretion in response to CoCl2 (p<0.001) and the positive control LPS 
(p<0.001) compared to when no inhibitor was used (Figure 5.4B). There was no significant 
difference in untreated samples with and without CLI-095 (p=0.4454).   
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Figure 5.4: Effect of CoCl2 and TLR4 inhibition on IL-8 secretion by HMEC-1 
A. HMEC-1 were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h before 
supernatant was collected and analysed by IL-8 ELISA. Statistical significance was 
calculated by one-way ANOVA with Dunnett’s test for multiple comparisons comparing 
all treated samples to the untreated contol. B. HMEC-1 were pre-treated with 1μg/ml CLI-
095 for 6h prior to 24h stimulation with 0.75mM CoCl2 or 100ng/ml LPS. IL-8 production 
was measured by ELISA. Statistical significance was calculated by one-way ANOVA 
with Tukey’s test for multiple comparisons comparing all samples to each other. All data 
is representative of three independent experiments. These experiments were conducted in 
collaboration with MRes students Sami Anjum and Amy Mawdesley. 
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Previous studies have demonstrated that cobalt ions induce secretion of IL-6 in different cell 
lines including keratinocytes and endothelial cells (Schmalz et al., 1998, Yang et al., 2015). 
However, as shown in Figure 5.2D, there was no increase in IL-6 release by HUVEC treated 
with CoCl2. IL-6 secretion by CoCl2-stimulated HMEC-1 cells was measured to establish 
whether or not this is a cell line-specific effect. HMEC-1 cells were stimulated with 0.25-1mM 
CoCl2 or 100ng/ml LPS for 24h before IL-6 levels were measured by ELISA. IL-6 secretion 
was significantly increased by CoCl2 across all concentrations (p<0.001 except for 0.25mM 
where p=0.0247) and by LPS (p<0.001) (Figure 5.5A). Peak IL-6 secretion reached 
approximately 1500pg/ml and was induced by 0.75mM CoCl2.   
To assess the role of TLR4 in IL-6 release by CoCl2-treated HMEC-1, cells were pre-treated 
with 1µg/ml CLI-095 for 6h followed by 24h treatment with 0.75mM CoCl2 or 100ng/ml LPS. 
CLI-095 significantly decreased IL-6 secretion in response to both CoCl2 and LPS to 
approximately 400pg/ml (both p<0.001). This is similar to IL-6 levels in untreated cells (Figure 
5.5B).  
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Figure 5.5: Effect of CoCl2 and TLR4 inhibition on IL-6 secretion by HMEC-1  
A. HMEC-1 were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h before 
supernatant was collected and IL-6 levels measured by ELISA. Statistical significance 
was calculated by one-way ANOVA with Dunnett’s multiple comparisons test comparing 
treated samples to the untreated control B. HMEC-1 were pre-treated with 1μg/ml CLI-
095 prior to 24h stimulation with 0.75mM CoCl2 or 100ng/ml LPS. IL-6 secretion was 
measured by ELISA. Statistical significance was calculated by one-way ANOVA with 
Tukey’s test for multiple comparisons comparing all samples to each other. All data is 
representative of three independent experiments. 
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5.4.3. Effect of cobalt ions on adhesion molecule expression 
HMEC-1 responded to CoCl2 and LPS by secreting inflammatory cytokines in a TLR4-
dependent manner and were therefore selected for further investigation into the effect of cobalt 
ions on adhesion molecule expression. Although ICAM-1 and VCAM-1 expression is most 
frequently studied in endothelial cells, monocytes and macrophages also express adhesion 
molecules to coordinate cell communication (Thornton and McDaniel, 2005). MonoMac 6 cells 
have previously been used for studying adhesion (Erl et al., 1995) and so they were investigated 
alongside HMEC-1 in this chapter.  
A preliminary assay was conducted to assess the effect of cobalt ions on expression of the 
adhesion molecules ICAM1 and VCAM1 in HMEC-1 and MonoMac 6 cells. Cells were treated 
with 0.75mM CoCl2 for 24h before RNA was isolated. cDNA was synthesised using the 
Maxima First Strand cDNA synthesis kit (Section 2.6.2.2) and ICAM1 and VCAM1 expression 
was analysed by qRT-PCR. VCAM1 expression could not be detected in untreated and CoCl2-
treated HMEC-1 and MonoMac 6 cells, and Ct values were >35 in CoCl2-stimulated samples 
(data not shown). 0.75mM CoCl2 caused a 15-fold upregulation in ICAM1 expression in 
MonoMac 6 cells (p=0.0010) (Figure 5.6A) and a 3-fold upregulation in HMEC-1 (p=0.0034) 
(Figure 5.6B). ICAM1 expression was considerably higher (Ct<30) than VCAM1 in 
unstimulated and stimulated samples from both cell lines and as a result further investigations 
focused on ICAM1.    
 
Figure 5.6: Effect of CoCl2 on ICAM1 expression 
A. MonoMac 6 and B. HMEC-1 cells were stimulated with 0.75mM CoCl2 for 24h before 
RNA was isolated and cDNA synthesised by reverse transcription. ICAM1 expression 
was quantified by qRT-PCR. Data is representative of at least two independent 
experiments and statistical significance was calculated by Student’s t-test comparing the 
treated sample to the untreated control. 
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5.4.4. Effect of TLR4 inhibition on adhesion molecule expression  
The role of TLR4 in cobalt upregulation of ICAM1 was investigated using CLI-095. MonoMac 
6 cells and HMEC-1 were pre-treated for 6h with 1µg/ml CLI-095 before stimulation with 
0.75mM CoCl2 or 100ng/ml LPS for 24h. As previously, ICAM1 expression was assessed by 
qRT-PCR. There was a significant increase in ICAM1 expression by cobalt-stimulated 
MonoMac 6 cells (p<0.001) although the 40-fold increase was larger than that observed in 
preliminary experiments (Figure 5.7A). In the presence of CLI-095 there was a significant 
reduction in ICAM1 expression (p<0.001), suggesting that the changes occur through cobalt 
activation of TLR4. As in previous assays LPS provided an effective positive control for TLR4 
activation because ICAM1 expression was also decreased in LPS-treated cells pre-incubated 
with CLI-095 (p=0.0185) (Figure 5.7A). Similar responses were observed in HMEC-1; ICAM1 
was upregulated 3-fold by CoCl2 (p=0.0132) and this was inhibited by CLI-095 (p<0.001) 
(Figure 5.7B). LPS again provided an effective positive control for TLR4 regulation of 
adhesion molecule expression; there was an 8-fold upregulation in expression by LPS-
stimulated HMEC-1 (p<0.001) and this was significantly inhibited by CLI-095 (p<0.001) 
(Figure 5.7B). Unlike in MonoMac 6 cells, untreated HMEC-1 cells downregulated ICAM1 in 
the presence of CLI-095 although this did not reach statistical significance (p=0.4707) (Figure 
5.7B).  
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Figure 5.7: Effect of TLR4 inhibition on ICAM1 expression 
A. MonoMac 6 cells or B. HMEC-1 were pre-treated with 1µg/ml CLI-095 for 6h 
followed by 24h stimulation with 0.75mM CoCl2 or 100ng/ml LPS. RNA was isolated 
and cDNA synthesised by reverse transcription. ICAM1 expression was assessed by qRT-
PCR. Data is representative of three independent experiments and statistical significance 
was calculated by one-way ANOVA with Tukey’s test for multiple comparisons 
comparing all samples to each other. 
R
e
la
ti
v
e
 g
e
n
e
 e
x
p
r
e
s
s
io
n
n
o
r
m
a
li
s
e
d
 t
o
 u
n
tr
e
a
te
d
 c
o
n
tr
o
l
0
1 0
2 0
3 0
4 0
5 0
***
*
1 g /m l C L I-0 9 5+ + +- - -
0 0 .7 5 m M
C o C l2
1 0 0 n g /m l
L P S
0 0 .7 5 m M
C o C l2
1 0 0 n g /m l
L P S
R
e
la
ti
v
e
 g
e
n
e
 e
x
p
r
e
s
s
io
n
n
o
r
m
a
li
s
e
d
 t
o
 u
n
tr
e
a
te
d
 c
o
n
tr
o
l
0
2
4
6
8
1 0
***
***
1 g /m l C L I-0 9 5+ + +- - -
A . M o n o M a c  6
B . H M E C -1
141 
 
5.4.5.  Effect of CoCl2 on soluble ICAM-1 secretion 
The data described so far in this chapter shows that cobalt ions can regulate ICAM1 gene 
expression through TLR4 activation, which has not previously been demonstrated. A number 
of other studies have shown that cobalt ions and wear debris can affect expression of membrane-
bound adhesion molecules (Ninomiya et al., 2013) but information regarding their effect on 
soluble forms of adhesion molecules is limited. The Proteome Profiler arrays described in 
chapter 3 showed a small increase in secretion of soluble ICAM-1 (sICAM-1), a secreted form 
of membrane-bound ICAM-1 (mICAM-1). Given this result together with the changes in 
ICAM1 expression following cobalt stimulation, sICAM-1 secretion by MonoMac 6 cells and 
HMEC-1 was investigated.  
MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h and sICAM-
1 secretion was measured by ELISA. There was a dose-dependent increase in sICAM-1 
secretion in response to CoCl2 (p<0.001 for all concentrations except for 1mM where p=0.0080) 
(Figure 5.8A). sICAM-1 release was also assessed in HMEC-1 using the same method; HMEC-
1 significantly increased sICAM-1 secretion following stimulation with 0.5, 0.75 and 1mM 
CoCl2 and 100ng/ml LPS (all p<0.001) but not with 0.25mM (p=0.6142) (Figure 5.8B). The 
trend of sICAM-1 secretion by HMEC-1 was slightly different from that of MonoMac 6 cells, 
with peak CoCl2-induced sICAM-1 secretion occurring at 0.5mM in MonoMac 6 cells 
(1000pg/ml) and 1mM in HMEC-1 (800pg/ml). In both cells lines LPS induced more sICAM-
1 secretion than CoCl2 stimulation. 
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Figure 5.8: Effect of CoCl2 on sICAM-1 secretion 
A. MonoMac 6 cells or B. HMEC-1 were stimulated with 0.25-1mM CoCl2 or 100ng/ml 
LPS for 24h before supernatant was collected. sICAM-1 secretion was measured by 
ELISA. Data is representative of three independent experiments and statistical 
significance was calculated by one-way ANOVA with Dunnett’s test for multiple 
comparisons comparing all samples to each other. These experiments were conducted in 
collaboration with MRes student Sami Anjum.  
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The role of TLR4 in CoCl2 and LPS-mediated sICAM-1 secretion was assessed using CLI-095. 
MonoMac 6 cells and HMEC-1 were pre-treated with 1µg/ml CLI-095 for 6h followed by 
stimulation with 0.75mM CoCl2 or 100ng/ml LPS for 24h. In MonoMac 6 cells CLI-095 
significantly decreased sICAM-1 secretion by CoCl2-stimulated cells from approximately 
900pg/ml to 400pg/ml (p<0.001) (Figure 5.9A), which is comparable to sICAM-1 release by 
untreated cells. In HMEC-1 sICAM-1 secretion following CoCl2 treatment was also 
significantly inhibited by CLI-095 (p<0.001), decreasing sICAM-1 release from 1200pg/ml to 
approximately 100pg/ml (Figure 5.9B). In this case sICAM-1 secretion by LPS-treated cells 
was lower than in CoCl2-stimulated cells but CLI-095 was still able to inhibit its production 
(p<0.001) (Figure 5.9B). Unlike ICAM1 expression, there was no difference in sICAM-1 
secretion by unstimulated HMEC-1 with or without the TLR4 inhibitor (p=0.9981) (Figure 
5.9B).
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Figure 5.9: Effect of TLR4 inhibition on sICAM-1 secretion 
A. MonoMac 6 cells or B. HMEC-1 were pre-treated with 1μg/ml CLI-095 for 6h 
followed by 24h stimulation with 0.75mM CoCl2 or 100ng/ml LPS. Supernatant was 
collected and sICAM-1 secretion was measured by ELISA. Data is representative of three 
independent experiments. Statistical significance was calculated by one-way ANOVA 
with Tukey’s multiple comparisons test comparing all samples to each other. These 
experiments were conducted in collaboration with MRes student Sami Anjum. 
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5.4.6. Effect of CoCl2 on CD11a and CD49d expression 
The effect of cobalt ions on subunits of LFA-1 and VLA-4 was investigated as they are ligands 
for ICAM-1 and VCAM-1 respectively. MonoMac 6 cells were chosen for this assay because 
as macrophages they express LFA-1 and VLA-4 (Erl et al., 1995) so that they can bind to 
endothelial cells expressing ICAM-1 or VCAM-1 for efficient extravasation. MonoMac 6 cells 
were treated with 0.75mM CoCl2 or 100ng/ml LPS for 24h before CD11a (LFA-1 subunit) and 
CD49d (VLA-4 subunit) expression was assessed by qRT-PCR. CD11a expression was 
significantly increased following LPS stimulation (p<0.001) although the fold-change was very 
small (1.2-fold). CD11a was downregulated in response to cobalt ions (p<0.001) (Figure 
5.10A). CD49a expression was significantly decreased in response to both CoCl2 and LPS (both 
p<0.001) (Figure 5.10B).  
 
Figure 5.10: Effect of cobalt and LPS on CD11a and CD49d expression 
MonoMac 6 cells were stimulated with 0.75mM CoCl2 or 100ng/ml LPS for 24h. RNA 
was isolated and cDNA synthesised by reverse transcription. A. CD11a and B. CD49a 
gene expression was measured by qRT-PCR. Data is representative of two independent 
experiments and statistical significance was calculated by one-way ANOVA with 
Dunnett’s test for multiple comparisons comparing treated samples to the untreated 
control. These experiments were conducted in collaboration with MRes student Sami 
Anjum. 
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5.4.7. Role of TLR4 in cobalt-mediated monocyte migration 
A transwell chemotaxis assay was undertaken to determine the effect of cobalt on immune cell 
migration. Monocytes were selected for this assay because monocyte and macrophage 
infiltration has been observed in tissues surrounding failed MoM joints (Jämsen et al., 2014). 
Previous studies have also reported elevated secretion of monocyte-specific chemokines such 
as CCL2 in response to MoM debris (Queally et al., 2009, Devitt et al., 2010).  
Data obtained in this study shows that chemokine release in response to cobalt ions can be 
blocked using a TLR4 antagonist. The same antagonist, CLI-095, was therefore used in the 
chemotaxis assays to assess its effect on monocyte migration. MonoMac 6 cells were pre-
treated with 1µg/ml CLI-095 for 6h followed by 24h stimulation with 0.75mM CoCl2 or 
100ng/ml LPS. A transwell migration assay was then conducted using monocytes isolated from 
the whole blood of a healthy volunteer. Migrated monocytes were stained with haematoxylin 
and counted at x40 magnification (Figure 5.11A). Monocyte chemotaxis was significantly 
increased in response to CoCl2 conditioned media (p=0.0290) but in the presence of the 
inhibitor was significantly reduced (p<0.001) (Figure 5.11B). Conditioned media from LPS-
treated MonoMac 6 cells (with and without CLI-095) provided an effective positive control for 
both TLR4 activation and the specificity of CLI-095 in blocking TLR4 (p<0.001) (Figure 
5.11B). There was no significant difference in the response to conditioned media from untreated 
cells with or without CLI-095 (p>0.99) showing that the inhibitor does not affect monocyte 
migration on its own. Two additional negative controls were included composed of complete 
media, and complete media with cobalt ions to ensure any migration was not due to a cobalt 
concentration gradient. There was no cell migration observed in either of these controls (data 
not shown).  
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Figure 5.11: Effect of CoCl2 and TLR4 inhibition on monocyte migration 
MonoMac 6 cells were pre-treated with 1μg/ml CLI-095 for 6h prior to stimulation with 
0.75mM CoCl2 or 100ng/ml LPS. A monocyte chemotaxis assay was conducted using 
conditioned media. A. Filters showing monocyte migration in response to each of the 
stimuli at x40 magnification. B. Migrated monocytes were counted at x40 magnification. 
>10 visual fields were counted for each treatment condition. Data is representative of four 
independent experiments each using a different cell donor. Statistical significance was 
calculated by one-way ANOVA with Tukey’s test for multiple comparisons comparing 
all samples to each other.   
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5.4.8. Role of TLR4 in cobalt-mediated neutrophil chemotaxis 
MonoMac 6 cells were pre-treated with 1µg/ml CLI-095 for 6h followed by stimulation with 
0.75mM CoCl2 or 100ng/ml LPS for 24h. Conditioned media was collected and its neutrophil 
chemotactic properties assessed by transwell neutrophil chemotaxis assay. Migrated 
neutrophils were stained on filters with haematoxylin and counted at x40 magnification (Figure 
5.12A). There was a significant increase in neutrophil chemotaxis in response to cobalt 
conditioned media compared to untreated controls (p<0.001). This was significantly abrogated 
when MonoMac 6 cells were pre-treated with CLI-095 (p<0.001) (Figure 5.12B), reducing 
neutrophil migration to levels similar to those in untreated samples. Conditioned media from 
LPS-stimulated MonoMac 6 cells provided a positive control. Neutrophil chemotaxis was 
increased in response to LPS conditioned media (p<0.001) and significantly decreased by CLI-
095 pre-treatment (p<0.001). Conditioned media from untreated cells did not affect neutrophil 
migration and there was no significant difference in the presence of CLI-095 (p>0.999). As for 
monocyte migration, additional negative controls were included containing HBSS or complete 
media with and without cobalt. No migration was observed in these controls (data not shown).  
A small preliminary study was also conducted using the method described above to determine 
the ability of anti-TLR4 neutralising antibodies MAb2-hTLR4 and PAb-hTLR4 (Error! 
Reference source not found.) to inhibit cobalt-mediated neutrophil migration. Both antibodies 
successfully inhibited migration with a greater effect observed for the monoclonal antibody 
than the polyclonal (Appendix G). 
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Figure 5.12: Effect of CoCl2 and TLR4 inhibition on neutrophil migration 
MonoMac 6 cells were pre-treated with 1μg/ml CLI-095 for 6h prior to stimulation with 
0.75mM CoCl2 or 100ng/ml LPS for 24h. A neutrophil chemotaxis assay was conducted 
using conditioned media. A. Haematoxylin-stained filters showing neutrophil migration 
in response to each of the stimuli at x40 magnification. B. Migrated neutrophils in >10 
different visual fields were counted at x40 magnification. Data is representative of three 
independent experiments each using a different cell donor. Statistical significance was 
calculated by one-way ANOVA with Tukey’s multiple comparisons test comparing all 
samples to each other.   
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5.5. Discussion 
Inflammatory cytokine secretion by endothelial cells 
This chapter aimed to investigate the effect of cobalt ions on inflammatory cell adhesion and 
migration, as well as on immune responses in endothelial cells. Cell adhesion and migration are 
of interest to the present study because they are both required for the immune cell infiltration 
of failed MoM peri-implant tissues. Furthermore, some of the cytokines and chemokines 
identified as being regulated by cobalt ions in earlier chapters contribute to cell adhesion and/or 
migration. For example, IL-8 is a potent neutrophil chemokine (Baggiolini et al., 1989) and is 
also associated with increased cell adhesion through its upregulation of ICAM-1 and VCAM-1 
(Kuai et al., 2012). IL-6 can upregulate ICAM-1 expression resulting in ICAM-1-dependent 
cell migration (Lin et al., 2013). Additionally, TLR4 positive cells have been identified in the 
vascular endothelium surrounding aseptically-loosened MoM hips, showing the potential for 
an immune response to TLR4 ligands (Pajarinen et al., 2010). Taken together this information 
made cell adhesion and migration relevant aspects for investigation in the present study.  
HUVEC are widely used as an endothelial cell model for studying the inflammatory effects of 
PAMPs, including LPS. Consequently they were selected as a potential model for investigating 
inflammatory and adhesion molecule responses to cobalt stimulation. Surprisingly, and in 
contrast to previous studies (Sultana et al., 1999, Ninomiya et al., 2013), there was only a small 
increase in IL-8 secretion with 24h of 1mM CoCl2 stimulation, and no increase in secretion 
with longer timepoints or increased CoCl2 concentrations. IL-6 secretion was also measured 
but no increases were noted in CoCl2-stimulated cells. The data suggests that the effect of cobalt 
ions is cell line-specific and supports the work of Raghavan et al who showed that cobalt 
stimulated inflammatory responses in dendritic cells but not in keratinocytes (Raghavan et al., 
2012).  
ELISA analysis revealed a decrease in IL-8 and IL-6 secretion by CoCl2-treated HUVEC 
compared to untreated cells. This suggests that cobalt may cause cytotoxicity in HUVEC, which 
contradicts the work of Ninomiya et al who did not observe any cytotoxic effects even at 4mM 
CoCl2, and also found increased cytokine secretion at these high concentrations (Ninomiya et 
al., 2013). The variation in cytokine secretion observed between studies may arise from 
different levels of TLR4 expression as HUVEC are primary cells and in this study they were 
pooled from multiple donors. Differences in cytokine release between endothelial cell lines and 
primary endothelial cells has previously been reported (Lidington et al., 1999). This is 
particularly likely to be the case in the present study because the HUVEC showed little response 
to LPS as a positive control, suggesting that expression of TLR4 itself or a component of the 
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signalling pathway is reduced in comparison to other cells. The variation in cytotoxic cobalt 
concentrations is less likely to arise from TLR4 expression and may be specific to the primary 
cells used in each study. As the focus of this study is on the role of TLR4 in cobalt-mediated 
inflammatory responses rather than the cell-specific nature of inflammation, HUVEC were not 
used in further analysis and an alternative endothelial cell line was sought.  
HMEC-1 were selected as an endothelial cell line model for this study because they express 
TLR4 and are responsive to LPS (J. Kirby, Institute of Cellular Medicine, Newcastle 
University, personal communication) (Faure et al., 2000). They are derived from the 
microvasculature and as cobalt is present in the blood of many MoM implant patients they are 
a good model for the study of ARMD. In contrast to HUVEC, HMEC-1 showed increased 
secretion of both IL-8 and IL-6 following CoCl2 and LPS stimulation. This could be prevented 
with CLI-095 showing that secretion occurs through cobalt activation of TLR4. The ability of 
cobalt to induce inflammation in microvasculature-derived cells is interesting in the clinical 
context of this study because soft tissue necrosis is a common feature of ARMD. Soft tissue 
necrosis occurs through vasculitis (blood vessel inflammation) restricting blood flow to the 
joint tissues. If cobalt can cause inflammation in blood vessels through TLR4 activation then it 
could potentially contribute to vasculitis, soft tissue necrosis, and ARMD.  
Adhesion molecule expression 
VCAM1 expression was not detected in untreated MonoMac 6 cells and HMEC-1, which 
supports previous studies showing that it is not constitutively expressed (Panés and Granger, 
1998). CoCl2 stimulation did not bring VCAM1 expression into the detection range of the qRT-
PCR assay and nor did LPS treatment (data not shown). More sensitive assays would be 
required to determine whether or not cobalt ions affect VCAM1 but its low expression levels 
raise questions of the physiological relevance for this study and therefore ICAM1 was the focus 
of further work.  
ICAM1 expression was increased by CoCl2 and LPS; this is a direct consequence of TLR4 
activation by the ligands because CLI-095 blocked the response. This supports similar work 
conducted using nickel ions; Tsou et al showed that up to 1.5mM NiCl2 upregulated IL-8 and 
ICAM-1 expression in HUVEC. Knockdown of MyD88 with siRNA and inhibition of NFκB 
through overexpression of IκBα both inhibited nickel-mediated ICAM-1 expression showing 
that they are both essential to the response(Tsou et al., 2013). ICAM-1 and IL-8 expression was 
also found to be TLR4-dependent because they could be inhibited by CLI-095. The results 
presented in the present study also suggest that changes in adhesion molecule expression 
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observed in previous studies could be a result of TLR4 activation by cobalt ions. This is 
particularly the case for the work of Ninomiya et al who showed that cobalt ions have an 
inflammatory effect, for example increasing the secretion of IL-8 and CCL2, and upregulating 
adhesion molecule expression (Ninomiya et al., 2013, Tyson-Capper et al., 2013b).  
As mentioned previously, adhesion molecules are regulated by cytokines such as IL-8, IL-6, 
IL-1β and TNFα. It is therefore conceivable that cobalt promotes adhesion molecule expression 
by stimulating TLR4-dependent cytokine release which then feedbacks to increase ICAM-1 
expression. For example, IL-1β upregulates ICAM-1 but has little effect on VCAM-1 
(Hosokawa et al., 2006). Interestingly, upregulated IL1B (gene encoding IL-1β) expression was 
detected by the qRT-PCR arrays and together with the increased IL-8 and IL-6 secretion it may 
contribute to the elevated ICAM1 expression described in this chapter.  
The CoCl2-mediated increase in ICAM1 shown in this chapter suggests that leukocyte adhesion 
can occur more readily in the presence of cobalt ions. This is similar to responses that develop 
during pathogen challenge and is indicative of a drive towards inflammation. Increased 
leukocyte adhesion favours extravasation and once inside the tissues leukocytes can perform 
inflammatory functions such as further cytokine secretion and activation of the adaptive 
immune system. The effect of cobalt on these processes could potentially contribute to ARMD 
development.   
sICAM-1 
This is the first study to show that cobalt and LPS upregulate sICAM-1 secretion in MonoMac 
6 cells and HMEC-1. As with ICAM-1 protein and gene expression, sICAM-1 release can be 
regulated by cytokines and chemokines; sICAM-1 has previously been reported to be induced 
by HMGB1 activation of TLR4 and its secretion may therefore be the result of feedback 
mechanisms (Bauer et al., 2012). However the effect is TLR4-dependent as secretion of 
sICAM-1 by both cell lines was prevented by the small molecule TLR4 antagonist CLI-095. 
Further work is required to establish whether this is a result of direct cobalt-mediated TLR4 
activation or an indirect result of feedback mechanisms.   
sICAM-1 is a soluble form of membrane-bound ICAM-1 (mICAM-1) and was first identified 
in patients with leukocyte adhesion deficiency (Rothlein et al., 1991). Although some studies 
have indicated that there is a direct correlation between mICAM-1 and sICAM-1 expression 
(Kjærgaard et al., 2013), others suggest that sICAM-1 does not always reflect levels of 
mICAM-1 (Giorelli et al., 2002). Despite these differences sICAM-1 has been proposed as a 
biomarker in several inflammatory diseases, including systemic inflammatory response 
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syndrome (De Pablo et al., 2013) and systemic sclerosis (Hasegawa et al., 2014). sICAM-1 is 
shed from endothelial cells following cell adhesion and this is an important step in the 
development of an immune response. It results in sICAM-1 accumulation in serum, thus making 
it a potential marker of inflammation. However the results of this study indicate that sICAM-1 
is not just a by-product of the adhesion process because even in the absence of cell-cell 
interactions in an in vitro cell culture assay there was still a TLR4-dependent increase in its 
release. Considerable further work is therefore required before sICAM-1 could be considered a 
marker of ARMD and MoM implant failure.  
sICAM-1 may be shed from the endothelial cell surface as a protective mechanism to dampen 
the inflammatory response, acting as a decoy molecule for the membrane-bound adhesion 
molecules (Garton et al., 2006). However there is increasing evidence that sICAM-1 can also 
be pro-inflammatory as mice overexpressing sICAM-1 have an exaggerated immune response 
and show increased monocyte and neutrophil recruitment to the site of inflammation (Mendez 
et al., 2011). Consequently the TLR4-dependent sICAM-1 release by MonoMac 6 cells may 
contribute to the monocyte and neutrophil migration described elsewhere in this chapter. In 
addition sICAM-1 can stimulate macrophage activation, increasing NFκB activity and pro-
inflammatory cytokine secretion (Schmal et al., 1998). This suggests that it could contribute to 
the cellular response to cobalt via feedback mechanisms that promote further cytokine release.   
sICAM-1 also plays a role in cell proliferation (Takahara et al., 2013), endothelial cell migration 
and angiogenesis (Gho et al., 1999). As such it is regarded as a key factor in cancer metastasis 
and tumour formation, which is of interest to the present study because of the pseudotumour 
development associated with ARMD. The increased expression of pro-angiogenic factors like 
sICAM-1 could promote blood vessel formation to support pseudotumour growth, making 
sICAM-1 an interesting factor for further investigation in ARMD.  
LFA-1 and VLA-4 
This study investigated the effects of cobalt and LPS on integrin subunits of LFA-1 and VLA-
4. Expression of CD11a, a subunit of LFA-1, showed a small but significant upregulation in 
response to LPS but was downregulated following cobalt stimulation. CD49d (VLA-4 subunit) 
expression was downregulated in response to both TLR4 agonists. This is surprising as a recent 
study has shown that both LFA-1 and VLA-4 can be upregulated via a TLR4-dependent 
mechanism (Liu et al., 2015). However the study did not investigate the effect of LPS on the 
individual subunits of LFA-1 and VLA-4 and it is possible that the subunits may be 
differentially regulated. It should also be acknowledged that cell adhesion is a rapid process 
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and molecules are up- or downregulated within a very short time frame to allow efficient 
extravasation. The decrease in subunits of LFA-1 and VLA-4 could therefore be a transient 
effect occurring as part of the complex adhesion process. It is interesting that LPS induced the 
same effect as CoCl2 for CD49a but the opposite for CD11a; this may highlight key differences 
in cellular responses to the two ligands. 
CD11 and CD18, both of which are subunits for ICAM-1 ligands, have recently been proposed 
as biomarkers of THR failure due to their correlation with aseptic loosening (Ovrenovits et al., 
2015). Interestingly, the study found that the markers were downregulated in patients with 
aseptically loosened hip implants compared to the healthy control and septic loosening groups. 
This shows the potential of integrins for future study in the pathology of MoM implant failure.  
Cell migration 
This study focused on monocyte and neutrophil chemotaxis because TLR4 is an innate immune 
receptor and both monocytes and neutrophils are involved in innate immunity. Furthermore, 
data presented in chapters 3 and 4 showed increased expression and/or secretion of monocyte 
and neutrophil chemotactic factors, including IL-8. Monocyte and neutrophil migration was 
significantly upregulated following CoCl2 and LPS stimulation of MonoMac 6 cells, showing 
that the cytokine and chemokine profile secreted by cobalt-stimulated cells favours immune 
cell migration. Monocyte migration was found to be TLR4-dependent as it was inhibited by 
CLI-095. A previous study has shown that cobalt induction of IL-8 results in neutrophil 
chemotaxis (Kim et al., 2006) but this is the first study to identify a role for TLR4 in the 
response. 
In both the monocyte and neutrophil assays there was considerably more cell migration in 
response to LPS than CoCl2. Data previously presented in this study shows that levels of 
cytokine and chemokine secretion are comparable between CoCl2 and LPS so this is a surprising 
observation. The effect is likely to be due to different combinations of chemokines secreted in 
response to each of the ligands, perhaps generating a more potent signal for LPS than for CoCl2.  
Monocyte and neutrophil chemotaxis assays were conducted using supernatant from cobalt-
treated cells. In vivo, a carefully coordinated chemokine gradient is established that directs 
migrating cells towards the site of inflammation. The in vitro assay method means that all of 
the chemokines are combined in each well and any potential gradient is lost. However this assay 
does demonstrate that the overall effect of the chemokine profile induced in response to cobalt 
is pro-migratory.   
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The results presented in this chapter may provide an explanation for the different inflammatory 
cell profiles observed in MoM peri-implant tissues. The reactions are often divided into two 
categories; ALVAL, i.e. a lymphocyte-dominated cellular infiltrate that resembles a type IV 
hypersensitivity response, and a monocyte/macrophage-dominated infiltrate that has been 
described as a ‘generalised’ inflammation and is sometimes attributed to cytotoxicity 
(Mahendra et al., 2009). It is possible that cobalt activation of TLR4 results in macrophage-
specific chemokines that guide cells to the peri-implant tissues where they identify cobalt as a 
pathogen and mount an inflammatory response. Macrophage recruitment is a key step in the 
development of osteolysis because migrated macrophages can be activated by cytokines and 
chemokines in the peri-implant environment, which can drive their differentiation into 
osteoclasts. Immunohistochemical studies into MoM implant failure report that the 
macrophage-dominated infiltrate can also contain fibroblasts and neutrophils. Neutrophils are 
much more common in septic loosening than aseptic (Pajarinen et al., 2010) and therefore it 
was interesting in this study to observe the ability of cobalt conditioned media to recruit 
neutrophils as well as monocytes. The low numbers of neutrophils around MoM implants may 
be due to their relatively short lifespan compared to macrophages (Summers et al., 2010) but 
they could aid in the recruitment of other immune cells to prolong the response. 
CCL2, a macrophage chemokine, has been the focus of many studies into adverse reactions to 
wear debris because of the high numbers of monocytes and macrophages seen around failed hip 
implants. Several studies have identified a central role for CCL2 in recruitment of macrophages 
to the site of wear particle-induced inflammation (Queally et al., 2009, Akbar et al., 2012) and 
as such CCL2 has recently been the target of therapies to prevent these adverse reactions (Yao 
et al., 2014). A mutant form of CCL2, known as 7ND, has been developed to block CCR2, the 
receptor for CCL2 (Yao et al., 2014). This in vitro study showed that 7ND blocked CCL2-
induced migration of THP-1 macrophages. In the present study it is particularly interesting to 
observe cobalt-mediated monocyte migration despite the downregulation of CCL2 expression 
described in earlier chapters, and its apparent central role in wear debris responses. However 
Huang et al found that CCL2 inhibition did not prevent macrophage migration following wear 
particle stimulation and concluded that other chemokines must be involved in the response 
(Huang et al., 2010); the data in the present study seems to support this theory. This highlights 
the redundancy of cytokines and chemokines and shows that it is their cumulative effect that is 
important to the overall inflammatory response. Functional studies such as migration assays are 
therefore particularly useful in the study of adverse responses to MoM implants. Cell migration 
is clearly a major aspect of ARMD development and work is ongoing to target macrophage 
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recruitment in ARMD prevention (Goodman et al., 2014). A better understanding of how 
recruitment is regulated could lead to improved therapeutic options. 
5.5.1. Future work 
ICAM1, CD11a and CD49d gene expression is altered by cobalt ions but it is not clear whether 
or not these changes also occur at the protein level. Analysis by flow cytometry, Western 
immunoblotting or immunohistochemistry would provide insight into this. It would also be 
interesting to investigate expression of these factors in tissue samples from MoM implant 
patients to see if it correlates with the in vitro data.  
To determine the functional consequences of ICAM1 gene expression changes, adhesion assays 
could be undertaken. This could include the use of a Cellix platform which can be used to 
investigate cell adhesion under flow conditions and represents shear stress along a blood vessel. 
Chips used in these assays can be coated either with recombinant adhesion molecules or with 
endothelial cells (stimulated or unstimulated) while immune cells (again stimulated or 
unstimulated) can be flowed across the chip and cell-cell adhesion is measured. Co-culture cell 
models could also be used to further investigate cell-cell interactions (e.g. macrophages and 
endothelial cells) and how this impacts upon adhesion molecule expression in the presence of 
cobalt ions.  
To test the effects of cytokines and TLR4 inhibitors on regulation of adhesion molecule 
responses, HMEC-1 could be incubated with conditioned media from cobalt-treated cells such 
as MonoMac 6. However this assay would require careful optimisation as in this study 
conditioned media from MonoMac 6 cells still contained the stimulus (e.g. CoCl2 or LPS). This 
would need to be removed before the assay could be performed.  
The chemotaxis assay data presented in this chapter clearly demonstrates the potential for cobalt 
ions to recruit immune cells across a porous membrane in response to a chemokine stimulus. 
To increase the physiological relevance of the assay and represent the endothelial cell barrier 
present in vivo, an endothelial cell layer could be grown across the filters. As described earlier 
the conditioned media generated in this study contains cobalt and as the cell-coated chemotaxis 
filters come into contact with the media optimisation would be required to determine how this 
could affect the cells.  
The use of primary monocytes and neutrophils means that there may be patient variability in 
the chemotaxis response to conditioned media because chemokine receptor expression differs 
between individuals as well as in different disease states (Henneken et al., 2005). As patient 
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variability increases the complexity of ARMD it would be interesting to correlate the extent of 
cell migration with levels of chemokine receptors such as CXCR2 (IL-8 receptor) to determine 
whether or not they influence the response. The use of antibodies against specific chemokine 
receptors would also provide further insight into the chemokines responsible for the effect (e.g. 
monocyte or neutrophil migration).  
5.5.2. Conclusion 
In summary the data presented in this chapter shows that there are differences in the endothelial 
cell response to cobalt ions; HMEC-1 secrete cytokines following cobalt treatment but HUVEC 
do not. HMEC-1 were chosen as an endothelial cell model and were found to upregulate 
expression of the adhesion molecule ICAM1 in a TLR4-dependent manner. A similar effect was 
observed in MonoMac 6 cells. Cobalt activation of TLR4 also increased secretion of a soluble 
adhesion molecule, sICAM-1, in both HMEC-1 and MonoMac 6 cells. Given the changes in 
ICAM1 expression it was surprising to find that expression of subunits of ICAM-1 and VCAM-
1 ligands (LFA-1 and VLA-4) was downregulated by cobalt ions.  Finally, conditioned media 
from cobalt-treated MonoMac 6 cells proved to be chemotactic for both primary monocytes 
and neutrophils, suggesting that the secreted chemokine profile is pro-migratory as well as 
TLR4-dependent.  
Overall this data indicates that cobalt ions could promote inflammatory cell adhesion and 
migration, and therefore inflammation, through upregulation of adhesion molecule and 
cytokine expression. TLR4 plays a central role in these responses because they were inhibited 
by CLI-095. Clinically the results presented here suggest that cobalt ions released into the joint 
space and blood by MoM bearing articulation could drive inflammatory responses via TLR4, 
and contribute to the inflammatory cell infiltrate observed in failed MoM peri-implant tissues.  
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Chapter 6. Patient variability: investigating cellular responses to cobalt 
ions 
6.1. Introduction 
Many previous MoM implant and ARMD investigations have focused on the biomechanics and 
biocompatibility of MoM implants to determine the events that lead to their failure. Some have 
concluded that there are links between high device wear rates or increased metal ion levels, and 
subsequent ARMD development (Glyn-Jones et al., 2011, Hailer et al., 2014). Despite such 
conclusions these factors cannot fully explain ARMD because implant wear rates and metal ion 
levels can be similar between two patients and yet one will develop ARMD while the other will 
not (Campbell et al., 2014). While it is clear from the data presented so far in this study that 
cobalt can induce inflammation by activating TLR4, it is also evident that this activation alone 
cannot be responsible for every ARMD case; all healthy individuals express functional TLR4 
as an essential component of the innate immune response and therefore have the potential to 
respond to cobalt ions. However ARMD does not develop in every patient with a MoM hip 
replacement (Meding et al., 2012), nor is the inflammatory response identical in those who 
ultimately progress to ARMD (Perino et al., 2014). Consequently other biological factors must 
be involved that contribute to promoting the inflammatory response in susceptible individuals, 
or inhibiting mechanisms that prevent the response in non-ARMD patients.   
There are numerous biological factors that could influence a patient’s susceptibility to ARMD. 
However the discovery of cobalt as a TLR4 ligand allows a more focused investigation into 
these factors as much is known about variables that influence the TLR4 signalling pathway.  
6.1.1. Genetic variation in ARMD 
Genetic variation has been investigated for its potential role in ARMD. Several studies have 
identified single nucleotide polymorphisms (SNPs) that may increase susceptibility to ARMD 
or adverse responses to other wear debris. These SNPs are mainly in genes encoding 
inflammatory signalling factors such as IL-6 and TNF (Gallo et al., 2009), as well as effector 
molecules like matrix metalloproteases (e.g. MMP-1) (Malik et al., 2007).   
Mutations within the TLR4 signalling pathway are known to inhibit receptor activation by 
nickel and cobalt ions; Oblak et al showed that mutant MD2 inhibits NFκB activation following 
metal ion stimulation (Oblak et al., 2015). The same study showed that mutations can have 
different effects on TLR4 ligands; mutation of the F440 residue in the TLR4 sequence 
significantly abrogated LPS activation of the receptor but had little impact on cobalt and nickel-
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mediated activation (Oblak et al., 2015). This indicates that genetic factors could potentially 
influence an individual’s response to metal ions.  
Two common TLR4 SNPs have been shown to affect the response to TLR4 ligands. Asp299G 
(referred to as D299G) and Thr399Ile (T399I) are both missense mutations. D299G is an 
aspartic acid to glycine change, while T399I is a threonine to isoleucine change. Both of these 
SNPs have a population prevalence of approximately 10% (Awomoyi et al., 2007). Guo et al 
found that murine hepatic stellate cells expressing D299G or T399I TLR4 exhibited 
hyporesponsiveness to LPS stimulation compared to wildtype TLR4 (Guo et al., 2009). The 
observed effects were not due to alterations in TLR4 expression levels in the D299G TLR4-
expressing cells and therefore are more likely to be a result of molecular or structural effects 
that lead to diminished LPS responses. Similarly, Figueroa et al demonstrated reduced LPS 
responsiveness in D299G TLR4-expressing HEK cells compared to wildtype TLR4-expressing 
cells (Figueroa et al., 2012). Using co-immunoprecipitation they showed that D299G TLR4 has 
a reduced ability to recruit the MyD88 and TRIF adaptor proteins compared to wildtype TLR4. 
LPS-mediated induction of MyD88-dependent IL8 expression was also inhibited in D299G 
TLR4-expressing cells (Figueroa et al., 2012). In contrast to the inhibitory effects of D299G, 
T399I-expressing cells did not show any reduction in MyD88 or TRIF-dependent responses to 
LPS. These effects occur despite the fact that LPS does not bind directly to the site of the 
mutation (Long et al., 2014). 
6.1.2. Role of other TLR4 ligands 
Receptor and ligand synergy can both affect the outcome of TLR4 signalling. For example 
activated TLR4 can synergise with TLR2 to promote inflammation (Sato et al., 2000). However 
for the purposes of this study it is the potential synergistic effects of TLR4 ligands that are of 
greatest interest.   
6.1.2.1. Bacterial endotoxin 
Aseptic loosening is the leading cause of joint implant failure but bacterial infection around a 
joint can also cause inflammation. If the infection is deep within the bone it may result in 
removal of the implant to allow treatment to take place (Haddad and Bridgens, 2008). Infection 
rates following THR with any implant material are generally low, at around 1% for primary 
THR and 2% for revision procedures (Blom et al., 2003), although infection is more common 
following MoM hip replacement or resurfacing (Wyles et al., 2014). The extent of the 
contribution of infection to joint implant failure is disputed. A recent study showed no 
association between bacterial infection and risk of revision in THR (Boot et al., 2015) but this 
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contradicts the results of many other studies that have shown that antibiotic prophylaxis can 
improve the longevity of a joint replacement (Espehaug et al., 1997, Engesæter et al., 2003). 
Infection can complicate ARMD diagnosis as the two conditions have very similar clinical 
presentations (Mikhael et al., 2009, Blumenfeld et al., 2010, Judd and Noiseux, 2011). It is also 
possible that infection and ARMD can occur at the same time and one may influence the 
biological and immunological response to the other. 
Infection is associated with bacterial endotoxin and is of interest to the present study because 
endotoxin (LPS) can activate TLR4. This is an important aspect of patient variability, 
particularly in the case of low-grade, sub-clinical levels of infection that can go undetected and 
untreated. It is estimated that up to 10% aseptic loosening cases could in fact have low-grade 
infection (Moojen et al., 2010). Bacterial endotoxin can also adhere to wear debris and promote 
inflammatory cytokine secretion and osteoclast differentiation through activation of pattern 
recognition receptors such as the TLRs (Bi et al., 2001, Brooks et al., 2002). Bacterial biofilms 
can form on the surface of orthopaedic implants (Heim et al., 2015) and may become detached 
during the wear process, allowing them to travel systemically and activate the immune system. 
For MoM implants understanding the true impact of infection is made more complex by the 
ability of cobalt and chromium ions to inhibit bacterial growth in some cases (Hosman et al., 
2009).  
TLR4 ligands can synergise to alter the inflammatory outcome of receptor activation. HMGB1 
and LPS combine to increase NFκB activation, cytokine secretion, and MMP activity in 
synovial fibroblasts (He et al., 2013b). Recent research has demonstrated that titanium particles 
enhance LPS-mediated nitric oxide, IL-6 and TNFα production by macrophages (Bianchi et al., 
2015). However despite the clinical relevance of LPS and cobalt to ARMD, no studies have 
shown whether there is a synergistic relationship between LPS and cobalt in terms of TLR4 
activation. 
6.1.2.2. Endotoxin tolerance 
Another mechanism that modulates TLR4 activation is repeated receptor exposure to a 
particular ligand which can result in tolerance. TLR4 tolerance to LPS is a well-documented 
effect and occurs through a range of mechanisms including increased IRAK-M expression 
(Escoll et al., 2003). This prevents formation of the IRAK complex that mediates the MyD88-
dependent pathway. As a result, cells that have already been exposed to LPS/endotoxin show 
reduced cytokine secretion when they are subsequently re-challenged with the ligand (Sun et 
al., 2014), a phenomenon that was first observed in sepsis patients and can result in 
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immunodeficiency (Ertel et al., 1995). In contrast, TLR4 can also become sensitised to ligands. 
For example, in murine macrophages pre-exposure to LPS resulted in an exaggerated 
inflammatory response to subsequent nickel challenge (Pestka and Zhou, 2006). This aspect of 
TLR4 signalling is a potential source of patient variability because other TLR4 ligands, such as 
LPS, could be present in the joint alongside cobalt ions.  
6.1.2.3. Nickel 
The National Joint Registry reports that women, particularly those under 55 years old, have a 
higher revision rate due to MoM implant failure than men (Powers-Freeling, 2015). Although 
the reasons behind this are not fully understood, several theories have been suggested including 
a smaller joint size leading to increased implant wear and resulting metal ion release (Reito et 
al., 2013). Other studies have suggested that women are more prone to metal sensitisation prior 
to receiving their hip implant, for example through wearing jewellery containing nickel (Pandit 
et al., 2008). This latter point is of particular interest to the current study as nickel also activates 
TLR4 (Schmidt et al., 2010). A recent study using a mouse model of metal allergy showed that 
nickel can act as an adjuvant during cobalt sensitisation, resulting in increased numbers of B 
and T lymphocytes and an enhanced inflammatory response (Bonefeld et al., 2015). This is 
unlikely to be a TLR4-specific effect because murine Tlr4 cannot be activated by nickel or 
cobalt (Tyson-Capper et al., 2013a), but it does demonstrate a potential interaction between 
metal ions in vivo. As in the case of LPS there is little known about synergy between nickel and 
cobalt in their activation of human TLR4. 
6.1.3. Inflammatory responses to other orthopaedic biomaterials 
The need for improvements in the biological and mechanical properties of hip replacements 
means that the materials used in implants are constantly evolving. New materials include 
bioactive glass which is considered less susceptible to biofilm formation than other orthopaedic 
materials (Rahaman et al., 2014). As well as preventing infection, a major aspect of 
biocompatibility is the successful integration of the hip implant into the bone without causing 
an inflammatory response. It is therefore important to investigate the inflammatory properties 
of all orthopaedic materials and not just those that are released from the bearing surfaces during 
implant wear.  
As well as nickel and cobalt, work has shown that palladium ions can activate TLR4 
(Rachmawati et al., 2013). Palladium is found in dental implants but is not usually present in 
MoM joints. However this raises the question of whether other orthopaedic metals may 
contribute to the inflammatory response to MoM implants. In orthopaedic devices cobalt is 
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usually found as an alloy with chromium and sometimes molybdenum. Although many studies 
have identified inflammation induced by CoCr debris, the use of the alloy makes it difficult to 
determine which metal is causing the immune response, or whether they are working in 
combination. Chromium concentrations can vary between implants depending on their design, 
as well as in tissue samples from individual patients (Rodríguez De La Flor et al., 2013), and 
therefore may influence inflammatory responses to MoM implants. Strontium is chemically 
similar to calcium and consequently is used in joint replacement cements and bearing surface 
to promote peri-implant bone growth and integration. As a relatively new orthopaedic material 
strontium is not universally used and research into its effectiveness is ongoing (Lu et al., 2015). 
This introduces an element of variability that is of interest in the context of the present study. . 
6.2. Objectives 
 To generate stable cell lines expressing wildtype and D299G forms of human TLR4 
 To evaluate the effect of these SNPs on the cellular response to cobalt ions using IL-8 
as a marker of TLR4 activation 
 To investigate the effect of LPS and nickel on cobalt-mediated cellular responses 
 To investigate the potential of chromium and strontium ions to activate human TLR4
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6.3. Specific materials and methods 
The methods described below are based on a study by Long et al investigating the effect of 
TLR4 SNPs on the downstream TLR4 signalling pathway (Long et al., 2014), and were adapted 
to suit the requirements of this study.  
6.3.1. 293-MD2-CD14 cells 
293-hMD2-CD14 cells (Invivogen) are human embryonic kidney (HEK) 293 cells transfected 
with human MD2 and CD14 genes but lacking TLR4 expression. Cells were cultured in DMEM 
4.5g/L glucose supplemented with 10% v/v FBS, 50U/ml penicillin, 50µg/ml streptomycin, 
2mM L-glutamine and 100µg/ml Normocin (Invivogen). Cells were passaged by washing in 
PBS followed by scraping as trypsin can affect cell activity. After 2 passages 50µg/ml 
HygroGold selection antibiotic (Invivogen) was added to growth medium to maintain the 
plasmid encoding MD2 and CD14.  
6.3.2. Plasmid preparation 
hu-TLR4 299 snp-flag pDEST40 and hu-TLR4 cDNA wt pDEST40 plasmids were gifts from 
Scott Friedman (Addgene plasmid #42647 and #42646 respectively). Full details of each 
plasmid are shown in Table 6.1. 
TLR4 
SNP 
ID Tag Vector 
backbone 
Bacterial 
resistance 
Selectable 
marker 
Laboratory 
source 
Wildtype 42646 Flag 
pcDNA 
DEST40 
Ampicillin Neomycin 
Scott Friedman 
(Mount Sinai 
School of 
Medicine, USA) 
Asp299Gly 
(D299G) 
42647 Flag 
pcDNA 
DEST40 
Ampicillin Neomycin Scott Friedman 
Table 6.1: TLR4 plasmids used in the transfection of 293-MD2-CD14 cells 
Wildtype and D299G TLR4 plasmids were a gift from Scott FriedmanThe Flag tag 
sequence encodes a protein tag that can be used for isolation or purification of proteins. 
The vector backbone refers to the main part of the vector, which contains gene promoters, 
selectable markers and bacterial resistance genes. 
 
Lysogeny broth (LB) agar plates were made using 35g/L LB agar dissolved in distilled H2O. 
LB media was made by dissolving the following in 1L distilled H2O; 10g tryptone/peptone, 5g 
yeast extract and 10g sodium chloride. E. coliwere cultured on agar overnight at 37oC and four 
individual colonies were selected followed by overnight incubation at 37oC in an orbital shaker 
at 200rpm. Plasmids were isolated from bacterial cultures using a PureYield Plasmid MiniPrep 
System (Promega, Madison, Wisconsin, USA) according to the manufacturer’s protocol.  
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6.3.3. Transfection procedure 
293-MD2-CD14 cells were transfected using GeneJuice (Novagen, Darmstadt, Germany) 
according to manufacturer’s protocol. Briefly, 3 days before transfection, cells were seeded at 
250,000 cells per well of a 6 well plate. Four transfections were performed using DNA isolated 
from the four different bacterial cultures and control cells were treated with either GeneJuice 
only or left untreated. The volumes of reagents and/or plasmid DNA used in each well are 
detailed in Table 6.2. Six hours after transfection 3% v/v FBS was added to each well to support 
cell growth. Twenty four hours following transfection the transfection media was removed and 
replaced with complete media.  
 Cells per 
well 
Growth 
medium (ml) 
OptiMEM 
(µl) 
GeneJuice 
(µl) 
Plasmid 
DNA (µg) 
Wildtype 
TLR4 
2.5 x 105 2 100 3 1 
D299G 
TLR4 
2.5 x 105 2 100 3 1 
Vehicle 2.5 x 105 2 100 3 0 
Untreated 2.5 x 105 2 100 0 0 
Table 6.2: Reagent volumes used for transfection of MD2-CD14 cells 
6.3.4. Selection of transfected cells 
Seventy two hours after transfection the media on cells transfected with wildtype TLR4 and 
D299G TLR4 was changed to complete media supplemented with 1mg/ml G418 (Sigma 
Aldrich). G418 is a neomycin analogue that kills untransfected cells that do not carry the 
neomycin selectable marker. Cells were maintained in G418-supplemented media throughout 
subsequent experiments. After four weeks the G418 concentration was reduced to 500μg/ml 
and after 6 weeks this was reduced again to 100μg/ml. The control cells (vehicle only and 
untreated) were not treated with G418. Media on all cells was changed every 2-3 days.  
6.3.5. Immunofluorescence 
293-MD2-CD14 cells were seeded in complete media on glass coverslips in 12-well culture 
plates and cultured to approximately 70% confluency. Coverslips were removed from the plate 
and fixed in ice-cold 100% methanol for 10 minutes. Coverslips were air-dried overnight at 
room temperature.  
To block non-specific binding 10% v/v normal goat serum in Tris-buffered saline (TBS) (0.1M 
Tris, 0.05M NaCl, at pH 7.6) was added to each coverslip and incubated at room temperature 
for 10 minutes. Following removal of the blocking agent, an anti-TLR4 rabbit primary antibody 
(Santa Cruz Biotechnology, Dallas, USA, catalogue number sc-10741) was diluted 1:100 in the 
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blocking agent, added to coverslips and incubated at 4oC overnight. The primary antibody was 
removed and coverslips were washed 3 times (2x 5 minutes washes and 1x 15 minutes) in TBS. 
A rhodamine-conjugated anti-rabbit secondary antibody diluted 1:40 in TBS was added to each 
coverslip and incubated in the dark at room temperature for 30 minutes. Coverslips were then 
stained with 4’,6-diamidino-2-phenylindole (DAPI) nuclear stain for 5 minutes and mounted 
using fluorescent mounting media (Dako, Cambridge, UK). Imaging was performed using a 
Zeiss Axio Imager II in the Bio-imaging Unit at Newcastle University.    
6.3.6. HEK-Blue-hTLR4 reporter cell assay 
HEK-Blue-hTLR4 cells (Invivogen, San Diego, USA) are human embryonic kidney (HEK) 293 
cells transfected with genes encoding human TLR4 and its co-receptors MD2 and CD14. In 
addition these cells contain a secreted alkaline phosphatase (SEAP) reporter gene controlled by 
NFκB. Consequently when TLR4 is activated, NFκB is also activated and secretion of SEAP is 
induced. HEK-Blue-hTLR4 cells were cultured in DMEM 4.5g/L glucose supplemented with 
2mM L-glutamine, 10% v/v FBS, 50U/ml penicillin and 50μg/ml streptomycin. 
HEK-Blue-hTLR4 reporter cells were used to determine activation of human TLR4 by different 
potential ligands. The assay has previously been optimised to demonstrate TLR4 activation by 
cobalt ions (Tyson-Capper et al., 2013a) and therefore the same method was used in this study. 
Cells were seeded at 20,000 cells per well of a 96-well plate and treated with chromium chloride 
hexahydrate (CrCl3) (Sigma-Aldrich) or strontium chloride hexahydrate (SrCl2) (Sigma-
Aldrich) in complete media for 24h. Supernatant was collected and SEAP secretion measured 
using QUANTI-Blue detection medium (Invivogen) according to the manufacturer’s protocol. 
Absorbance was read at 620nm. 
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6.4. Results 
6.4.1. Generation of stable TLR4 transfectants 
293-MD2-CD14 cells were transfected as described in section 6.3.3 and maintained in culture 
media supplemented with selection antibiotics. 1mg/ml G418 killed most cells in wells 
transfected with the wildtype (WT) TLR4 or D299G TLR4 plasmids, suggesting that 
transfection efficiency was low. However lower concentrations of G418 were ineffective at 
inducing cell death (data not shown). Cells were passaged as normal upon reaching confluency.  
Basic culture of the transfected cells proved challenging. One of the major problems with the 
293-MD2-CD14 cells line was that the cells clumped together as a sheet during passage and 
could not be separated by gentle pipetting. In similar cases trypsin would often be used for 
separation but it is not recommended by the manufacturer for these cells as it can alter their 
behaviour. Consequently the cells were difficult to count and seed. This made assessing TLR4 
expression more complex; flow cytometry was a possible method for analysis but the clumped 
cells would likely block the channels of the flow cytometer. To overcome this issue TLR4 
expression was assessed by immunofluorescence and qRT-PCR.  
Immunofluorescence analysis demonstrated TLR4 protein expression in both WT and D299G 
TLR4 transfected cells (Figure 6.1). The staining showed mainly surface receptor expression 
although some intracellular staining was also noted in both cell lines. qRT-PCR analysis 
demonstrated increased TLR4 expression by transfected cells compared to untransfected 
controls (Appendix H). In cases where all four replicate transfectants reached confluency and 
were suitable for analysis there were significant differences in TLR4 expression levels between 
the replicates (Appendix H). 
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Figure 6.1: Immunofluorescent staining of transfected 293-MD2-CD14 cells 
WT and D299G TLR4 transfected cells were assessed for TLR4 expression using immunofluorescent staining. A no primary antibody control was 
included for each assay. Images show separate DAPI and TLR4 staining and the merged images. Data is representative of two independent experiments 
in which four replicate transfections were performed for each SNP.   
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6.4.2. IL-8 expression and secretion by transfected and untransfected cells 
The main aim of this aspect of the study was to determine how SNPs affect the cellular response 
to cobalt ions. IL-8 secretion has been used as a marker of cobalt activation of TLR4 throughout 
this study and was therefore deemed an appropriate marker for investigation into 293-MD2-
CD14 cellular responses. As an initial control experiment untransfected 293-MD2-CD14 cells 
were stimulated with 0.5-1.5mM CoCl2 or 100ng/ml LPS for 24h before supernatant was 
collected and IL-8 release measured by ELISA. A broader range of CoCl2 concentrations was 
selected because no previous studies have investigated the effect of cobalt ions on 293-MD2-
CD14 cells. Interestingly, despite the lack of TLR4 expression by these cells there was a small 
but significant increase in IL-8 secretion to 500pg/ml with 0.5 and 1mM CoCl2 as well as with 
100ng/ml LPS (all p<0.001) (Figure 6.2). At 1.5mM CoCl2 there was no change in IL-8 
secretion compared to the untreated control (p=0.8351) (Figure 6.2). 
 
Figure 6.2: Effect of CoCl2 on IL-8 secretion by untransfected 293-MD2-CD14 cells 
Untransfected 293-MD2-CD14 cells were stimulated with 0.5-1.5mM CoCl2 or 100ng/ml 
LPS for 24h and IL-8 release was measured by ELISA. n=1. Statistical significance was 
calculated by one-way ANOVA with Dunnett’s test for multiple comparisons comparing 
stimulated samples to the unstimulated control. 
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6.4.3. IL-8 secretion and expression by TLR4 transfectants 
TLR4 function in the transfected cells was assessed using IL-8 as a marker of receptor 
activation. Unfortunately the wildtype TLR4 transfectants died before they could be analysed, 
although the reasons for this were unclear. The remaining assays were conducted using only 
the D299G TLR4 transfectants. As well as the LPS positive control assay, a second experiment 
was conducted to investigate the inflammatory effect of cobalt ions on the transfected cells. 
D299G TLR4 transfectants were stimulated with 0.75mM CoCl2 or 100ng/ml LPS for 24h 
before IL-8 secretion was measured by ELISA. Treatment with CoCl2 and LPS increased IL-8 
secretion by the D299G TLR4 transfectants to approximately 1000pg/ml (p<0.001) (Figure 
6.3). The variation in TLR4 expression by the four different cell lines did not correlate with IL-
8 secretion levels (Appendix H, Figures H.1 and H.2).  
 
Figure 6.3: Effect of CoCl2 on IL-8 secretion by D299G TLR4 transfectants 
D299G TLR4 cells were stimulated with 0.75mM CoCl2 or 100ng/ml LPS for 24h and 
IL-8 secretion was measured by ELISA. Four replicate experiments were conducted. 
Statistical significance was calculated by one-way ANOVA with Dunnett’s test for 
multiple comparisons comparing treated samples to the untreated control. 
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6.4.4. Effect of co-exposure to LPS and cobalt ions 
Another aim of this chapter was to identify how co-stimulation with cobalt ions and other TLR4 
ligands (i.e. LPS and nickel ions) affects cytokine secretion. IL-6 and IL-8 secretion were 
selected for investigation. IL-8 was chosen because it has been used as a marker of TLR4 
activation throughout this study. IL-6 was selected because its release is significantly increased 
following LPS activation of TLR4 but the response to CoCl2 is much smaller than that of IL-8, 
although it is still TLR4-dependent (Figure 4.9B). IL8 and IL6 expression was also assessed, 
together with CCL2 which is downregulated by CoCl2 in the MonoMac 6 cell line model 
(Chapter 3).   
MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 with 100ng/ml LPS (referred to as 
CoCl2-LPS) for 24h to investigate potential synergy between the two ligands. An LPS-only 
control was also included. RNA and supernatant were collected following stimulation. IL-6 and 
IL-8 secretion was measured by ELISA. IL-8 secretion was significantly upregulated to 
5000pg/ml with LPS stimulation alone (p<0.001) but there was no further increase in IL-8 
release when CoCl2 was added at any concentration (all p>0.9 compared to LPS-only control) 
(Figure 6.4A).  
Cellular secretion of IL-6 was upregulated to approximately 1600pg/ml following stimulation 
with 100ng/ml LPS (p<0.001) (Figure 6.4B). Co-stimulation with CoCl2-LPS caused a 
significant decrease in IL-6 secretion compared to the LPS-only control (all p<0.001). This was 
a dose-dependent effect, reducing IL-6 levels from 1000pg/ml with 0.25mM CoCl2-LPS to 
150pg/ml with 1mM CoCl2-LPS (Figure 6.4B). 
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Figure 6.4: Effect of CoCl2-LPS on IL-8 and IL-6 secretion 
MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 with or without 100ng/ml LPS 
for 24h. Supernatant was collected and analysed by ELISA for A. IL-8 and B. IL-6 
secretion. Data is representative of three independent experiments and statistical 
significance was calculated by one-way ANOVA with Tukey’s test for multiple 
comparisons comparing all samples to each other. Bars show statistical difference 
between untreated and LPS samples. Other asterisks indicate differences between LPS 
and CoCl2-LPS samples. 
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Expression of IL6, CCL2 and IL8 by CoCl2-LPS-stimulated MonoMac 6 cells was analysed 
by qRT-PCR. LPS upregulated IL6 expression by more than 3000-fold (p<0.001) but this 
was significantly abrogated by all concentrations of CoCl2 (all p<0.001) (Figure 6.5A), 
which reflects the pattern of IL-6 secretion shown in Figure 6.4B. A similar trend was 
observed for CCL2 expression, with a 12-fold upregulation in expression following LPS 
stimulation (p<0.001) (Figure 6.5B). This was significantly decreased by CoCl2 across all 
concentrations to expression levels lower than the untreated control (all p<0.001) (Figure 
6.5B). 
IL8 expression showed a different pattern to that of IL6 and CCL2. While LPS treatment 
alone still caused a significant 140-fold upregulation in IL8 expression (p<0.001) (Figure 
6.5C), the addition of CoCl2 had no synergistic effect at 0.25mM (p=0.2593) and 0.5mM 
(p=0.4028). At 0.75mM and 1mM CoCl2-LPS there was a significant decrease in IL8 
expression compared to the LPS only control (both p<0.001) (Figure 6.5C) which is a 
slightly different trend from the IL-8 secretion profile shown in Figure 6.4A. However the 
decrease was fairly small compared to that which was observed for IL6. IL8 expression 
decreased from 140-fold (LPS only) to 107-fold for 0.75mM CoCl2, and 70-fold for 1mM 
CoCl2. In contrast, IL6 expression decreased from 3000-fold (LPS only) to 80-fold with the 
addition of 0.25mM CoCl2.  
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Figure 6.5: Effect of CoCl2-LPS on inflammatory gene expression 
MonoMac 6 cells were stimulated with 100ng/ml LPS and 0.25-1mM CoCl2 in 
combination for 24h. RNA was isolated and cDNA synthesised by reverse transcription. 
qRT-PCR was performed for A. IL6 B. CCL2 and C. IL8. Data is representative of three 
independent experiments and statistical significance was calculated by one-way ANOVA 
with Tukey’s test for multiple comparisons comparing all samples to each other. Bars 
show significance between LPS only and untreated control. Other asterisks show CoCl2-
LPS samples compared to the LPS only sample.  
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In addition to the target gene expression changes observed following CoCl2-LPS stimulation, 
it was also noted that the combination of treatments caused a downregulation in expression 
of the housekeeping gene GAPDH (Figure 6.6A). GAPDH Ct values were approximately 
19 for untreated samples and increased significantly and dose-dependently with the addition 
of LPS and CoCl2 (all p<0.001), peaking at 21 with 1mM CoCl2-LPS. This was of concern 
because housekeeping gene expression should be consistent across all samples to provide an 
appropriate control for normalisation. Beta actin (ACTB) expression was also assessed to see 
if this effect occurred with other housekeeping genes and showed a very similar pattern to 
GAPDH (Figure 6.6B). Changes in housekeeping gene expression, particularly 
downregulation, can often be attributed to cell stress and RNA degradation (Hilmi et al., 
2003, Snider et al., 2011). To check RNA integrity in the CoCl2-LPS samples RNA was 
separated by agarose gel electrophoresis. There did not appear to be any loss of RNA 
integrity that may account for the decrease in GAPDH expression (Figure 6.7). RNA was 
not quantified prior to loading onto the gel which accounts for the differences in band 
intensity between the samples.  
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Figure 6.6: Effect of CoCl2-LPS on GAPDH and ACTB expression 
MonoMac 6 cells were stimulated with 100ng/ml LPS together with 0.25-1mM CoCl2 for 
24h. RNA was isolated and cDNA synthesised by reverse transcription. A. GAPDH and 
B. ACTB expression was analysed by qRT-PCR. Data is representative of three 
independent experiments and statistical significance was calculated by one-way ANOVA 
with Dunnett’s test for multiple comparisons comparing treated samples to the untreated 
control. 
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Figure 6.7: Effect of CoCl2-LPS on RNA integrity 
RNA integrity from CoCl2 and LPS-treated MonoMac 6 cells was assessed by 
electrophoresis separation on a 1.2% w/v agarose gel.  
6.4.5. Effect of co-exposure to cobalt and nickel ions 
MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 together with 0.75mM NiCl2 for 24h 
(referred to as CoCl2-NiCl2). Control cells were treated with 0.75mM NiCl2 only or left 
untreated. Following stimulation RNA was isolated and supernatant was collected. IL-6 and IL-
8 secretion was quantified by ELISA.  
In response to 0.75mM NiCl2 there was a significant increase in IL-8 secretion by MonoMac 6 
cells, reaching approximately 5000pg/ml (p<0.001) (Figure 6.8A). With the addition of 0.25, 
0.5 and 0.75mM CoCl2 there was no significant change in IL-8 secretion (p>0.2 in all cases) by 
co-stimulated cells. When cells were stimulated with 1mM CoCl2-NiCl2 there was a significant 
decrease in IL-8 release to approximately 3500pg/ml (p=0.0300) (Figure 6.8A). IL-6 secretion 
was significantly increased to just over 2000pg/ml by treatment with 0.75mM NiCl2 (p<0.001) 
(Figure 6.8B). CoCl2-NiCl2 co-stimulation resulted in abrogation of IL-6 release across all 
CoCl2 concentrations (all p<0.001), reducing IL-6 levels to approximately 100pg/ml (Figure 
6.8B).  
100ng/ml LPS- +           +          +          +          + 
0              0           0.25          0.5          0.75           1
28S
18S
CoCl2 (mM)
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Figure 6.8: Effect of CoCl2-NiCl2 on IL-8 and IL-6 secretion 
MonoMac 6 cells were stimulated with 0.75mM NiCl2 and 0.25-1mM CoCl2 in 
combination for 24h. Supernatant was collected and analysed by ELISA for A. IL-8 and 
B. IL-6 secretion. Data is representative of three independent experiments and statistical 
significance was calculated by one-way ANOVA with Tukey’s test for multiple 
comparisons comparing all samples to each other. Bars show statistical difference 
between untreated and NiCl2 only samples. Other asterisks indicate differences between 
NiCl2 and CoCl2-NiCl2 samples. 
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Following CoCl2-NiCl2 stimulation IL6, IL8 and CCL2 expression was assessed by qRT-PCR. 
IL6 secretion was significantly upregulated (more than 3000-fold) by NiCl2 compared to the 
untreated control (p<0.001) (Figure 6.9A). The addition of CoCl2 significantly decreased IL6 
expression in response to NiCl2 (all p<0.001 compared to NiCl2-only control) (Figure 6.9A). 
In contrast to the upregulation in IL6 expression there was a significant decrease in CCL2 
expression following NiCl2 stimulation (p<0.001 compared to untreated control) (Figure 6.9B). 
With the addition of 0.25mM CoCl2 there was a further reduction in CCL2 expression 
(p=0.0424 compared to NiCl2-only control) but it increased again with 0.75mM and 1mM 
CoCl2. Although this was a significant increase from the NiCl2 sample (both p<0.001) it did not 
reach the CCL2 expression levels detected in untreated cells. IL8 expression was upregulated 
approximately 150-fold by NiCl2 (p<0.001 compared to untreated control) (Figure 6.9C). 
When CoCl2 was added, IL8 expression decreased across all concentrations (all p<0.001 
compared to NiCl2-only control) although it was still upregulated 50-fold in these samples 
compared to the untreated control (all p<0.05). However there was no evidence of a dose-
dependent response (Figure 6.9C).  
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Figure 6.9: Effect of CoCl2-NiCl2 on inflammatory gene expression 
MonoMac 6 cells were stimulated with 0.75mM NiCl2 and 0.25-1mM CoCl2 in 
combination for 24h before RNA was isolated and cDNA synthesised by reverse 
transcription. A. IL6 B. CCL2 and C. IL8 gene expression was analysed by qRT-PCR. 
Data is representative of two independent experiments and statistical significance was 
calculated by one-way ANOVA with Tukey’s test for multiple comparisons comparing 
all samples to each other. Bars show statistical difference between NiCl2 only samples 
and the untreated control. Other asterisks show significance of CoCl2-NiCl2 samples 
compared to the NiCl2 only sample. 
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As with the CoCl2-LPS assays, closer analysis of the qRT-PCR data highlighted considerable 
changes in GAPDH expression between CoCl2-NiCl2-treated cells and untreated controls. The 
Ct value for GAPDH in untreated cells was approximately 19 and this increased dose-
dependently to 24 in 1mM CoCl2-NiCl2 samples (all p<0.001 compared to the untreated 
control) (Figure 6.10). In this case ACTB expression was not assessed because in the CoCl2-
LPS assays it showed a similar pattern to that of GAPDH (Figure 6.6).  
 
Figure 6.10: Effect of CoCl2-NiCl2 on GAPDH expression 
MonoMac 6 cells were stimulated with 0.25mM-1mM CoCl2 in combination with 
0.75mM CoCl2. RNA was isolated and cDNA synthesised by reverse transcription. 
GAPDH expression was quantified by qRT-PCR. Data is representative of two 
independent experiments and statistical significance was calculated by one-way ANOVA 
with Dunnett’s test for multiple comparisons comparing all samples to the untreated 
control.  
 
To determine whether or not the changes in GAPDH expression were due to RNA degradation 
induced by the CoCl2-NiCl2 cell stimulation, RNA was separated by electrophoresis on a 1.2% 
w/v agarose gel to assess integrity. There was no evidence of RNA degradation in any of the 
samples indicating that this is not the cause of downregulated GAPDH expression (Figure 
6.11).  
0 0 0 .2 5 0 .5 0 .7 5 1
0
1 0
2 0
3 0
C
t 
v
a
lu
e
- + + + + +
C o C l2 (m M )
0 .7 5 m M  N iC l2
*** *** ***
*** ***
181 
 
 
Figure 6.11: Effect of CoCl2-NiCl2 on RNA integrity 
RNA from MonoMac 6 cells stimulated with CoCl2-NiCl2 was separated by 
electrophoresis on a 1.2% w/v agarose gel to assess integrity.  
6.4.6. Chromium and strontium ions do not activate human TLR4 
Chromium and strontium are present in CoCr alloys and bone cement respectively, but their 
effect on TLR4 is unknown. HEK-Blue-hTLR4 cells were stimulated with 0.5-1.5mM CrCl3 or 
SrCl2 for 24h before TLR4 activation was assessed by SEAP reporter assay, as described 
previously (Tyson-Capper et al., 2013a). There was no increase in SEAP secretion by the cells 
following metal ion challenge (all p>0.3), indicating that neither chromium nor strontium 
activates TLR4 (Figure 6.12A&B). There was increased SEAP secretion in response to the 
positive control LPS which is indicative of TLR4 activation (p<0.001). To further support this 
data MonoMac 6 cells were incubated with 0.5-1.5mM CrCl3 or SrCl2 for 24h, and IL-6 and 
IL-8 secretion was measured by ELISA. No increase in IL-8 secretion was detected with either 
CrCl3 or SrCl2 stimulation (all p>0.6) (Figure 6.12C&D), nor was there any change in IL-6 
release (all p>0.9) (Figure 6.12E&F). LPS again provided an effective positive control by 
increasing both IL-8 and IL-6 secretion (all p<0.001).  
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Figure 6.12: Effect of chromium and strontium ions on TLR4 activation 
HEK-Blue-hTLR4 cells were stimulated with A. 0.5-1.5mM CrCl3 or B. 0.5-1.5mM 
SrCl2 and SEAP release was measured by reading absorbance at 620nm. MonoMac 6 
cells were then stimulated with the same concentrations of metal ions and LPS, and IL-8 
or IL-6 secretion was quantified by ELISA. C. IL-8 secretion following CrCl3 
stimulation. D. IL-8 secretion following SrCl2 stimulation. E. IL-6 secretion following 
CrCl3 stimulation. F. IL-6 secretion following SrCl2 stimulation. n=2 for reporter assays 
and n=1 for ELISAs. Statistical significance was calculated by one-way ANOVA with 
Dunnett’s test for multiple comparisons comparing stimulated samples to the 
unstimulated control. 
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6.5. Discussion 
Effect of TLR4 SNPs on cobalt response 
There are many polymorphisms that influence the outcome of TLR4 signalling pathway 
activation and contribute to its regulation of inflammation, including mutations in signalling 
factors and inflammatory cytokines. TLR4 SNPs were investigated in this study firstly because 
cobalt activates TLR4 and secondly because the SNPs can affect the response to other TLR4 
ligands including LPS (Figueroa et al., 2012, Long et al., 2014).  
293-MD2-CD14 cells were selected for this aspect of the study as they express the key TLR4 
co-receptors MD2 and CD14 but do not express TLR4 itself. A preliminary investigation was 
conducted to assess IL-8 secretion by untransfected 293-MD2-CD14 cells in response to CoCl2 
and LPS. There was a small (100pg/ml) but significant increase in IL-8 secretion following 
treatment with 0.5mM and 1mM CoCl2 as well as with 100ng/ml LPS. Given that the CoCl2-
mediated IL-8 release observed so far in this study has been attributed to TLR4 activation it is 
surprising that the cells released IL-8 when they do not express TLR4. However it is possible 
that this is the result of a generalised inflammation that occurs when cells are challenged with 
a pathogen. It would also provide an explanation for the cobalt-induced inflammatory responses 
detected in animal models (Masui et al., 2005, Akbar et al., 2012) that lack the TLR4 histidine 
pocket for cobalt binding and receptor activation.  
As described in section 6.4.2 there were some difficulties in assessing TLR4 expression levels 
following transfection of the 293-MD2-CD14 cells and these were mainly caused by cell 
clumping. As a result, flow cytometric analysis of TLR4 expression was not possible; to try and 
prevent cell clumping in future assays the cells could be incubated with 
ethylenediaminetetraacetic acid (EDTA), or sub-cultured at a reduced confluency. Caution 
would be required with the EDTA method because it can chelate metal ions which may affect 
the outcome of assays using cobalt ions.   
For this study immunofluorescence was selected as an alternative method to flow cytometry. 
This revealed TLR4 expression by cells transfected with the WT TLR4 and D299G TLR4 
plasmids. Further analysis of TLR4 expression by qRT-PCR confirmed receptor expression by 
the transfectants. To confirm that cells expressed functional TLR4, IL-8 secretion was assessed. 
Although the D299G TLR4 polymorphism can abrogate inflammatory responses (e.g. cytokine 
secretion and NFκB activity (Arbour et al., 2000)) to LPS, Figueroa et al  showed that it only 
partially inhibited IL-8 secretion (Figueroa et al., 2012), meaning that LPS-mediated IL-8 
release is still an indicator of TLR4 activation. D299G TLR4 cells secreted IL-8 following 
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stimulation with LPS, showing that the cells were expressing functional TLR4. Following 
CoCl2 treatment the cells also increased IL-8 release; this demonstrates that the D299G TLR4 
variant does not completely prevent CoCl2 activation of TLR4. Unfortunately the WT TLR4 
transfectants died before further assays could be conducted and therefore the D299G 
transfectant response cannot be compared to a wildtype control. The reasons for the differences 
in cell survival between the two groups are not clear but could be due to increased susceptibility 
of the WT TLR4 cells to low levels of contaminants (e.g. endotoxin) in the culture media. 
However this means that there is no indication of whether or not the response to cobalt ions is 
abrogated in D299G TLR4 cells and consequently further optimisation of these assays is 
required.  
The genetic aspect of this study is a preliminary investigation into the effect of TLR4 mutations 
on the inflammatory response to cobalt ions. A protocol was developed that can be used for 
studying other mutations in TLR4 and other aspects of the TLR4 signalling pathway. For a 
more comprehensive analysis of the effect of D299G TLR4, quantitation of TLR4 expression 
would be required to determine the amount of IL-8 released in direct relation to the amount of 
TLR4 expression. This will be discussed in more detail in section 6.5.1.  
Effect of LPS and NiCl2 on CoCl2-mediated responses 
The immunological effect of cobalt co-stimulation with other TLR4 ligands was also 
investigated. Co-stimulation of MonoMac 6 cells with CoCl2-LPS did not significantly increase 
cellular IL-8 secretion compared to treatment with CoCl2 alone. IL8 expression also decreased 
with increasing CoCl2-LPS concentrations but remained elevated compared to the untreated 
control. In contrast, although IL-6 secretion was upregulated by LPS, the addition of CoCl2 
resulted in a dose-dependent decrease in cytokine secretion. Expression of IL6 and CCL2 
showed a similar trend to IL-6 release, although the CoCl2-dependent decrease was greater at 
gene level. The large increase in LPS and NiCl2-mediated IL6 expression occurred because IL6 
in untreated cells had a Ct value of >37, which increased to approximately 27 following ligand 
stimulation.  
The CoCl2-NiCl2 assays revealed a similar pattern of IL-6 secretion to that observed for CoCl2-
LPS. IL-8 secretion showed a slight increase with 0.25mM CoCl2-NiCl2 but this dose-
dependently decreased with increased CoCl2 concentrations. IL6 and IL8 expression was 
upregulated by NiCl2 alone and abrogated with the addition of CoCl2. Unlike LPS there was no 
increased CCL2 expression following NiCl2 stimulation, although the addition of CoCl2 caused 
a small dose-dependent increase in expression towards untreated levels. The results of these 
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assays suggest that the effect of CoCl2 dominates over those of LPS and NiCl2. For example 
LPS alone upregulates CCL2 expression while cobalt ions alone cause downregulation 
(described elsewhere in this study and in Appendix I). Co-stimulation with both ligands results 
in decreased CCL2 expression. Similar effects were also observed for IL-6 secretion and 
expression.   
Of the three cytokines assessed in this aspect of the study, IL-8 was perhaps most likely to show 
synergistic upregulation because LPS, NiCl2 and CoCl2 can all individually activate TLR4 and 
increase its secretion. However no such effects were observed. This could be due to receptor 
saturation preventing any further cytokine secretion, particularly in the case of NiCl2 as CoCl2 
and NiCl2 activate TLR4 via the same mechanism (Raghavan et al., 2012). It is also conceivable 
that the two ligands in combination increase cytotoxicity which could mask any synergy. To 
overcome this problem cytotoxicity assays similar to those performed elsewhere in this study 
could be undertaken. Alternatively total protein assays would allow correlation of cell numbers 
with cytokine secretion levels.    
Cytotoxicity may also have affected the expression of housekeeping genes GAPDH and ACTB 
which were both downregulated with increasing concentrations of CoCl2 in combination with 
LPS or NiCl2 (GAPDH only). These changes were much smaller than those observed for the 
target cytokine genes and are therefore unlikely to have notably affected the assay results. The 
downregulation could not be attributed to loss of RNA integrity but is still significant and 
consequently further optimisation is required to provide a solution. This could involve using 
alternative housekeeping genes such as hypoxanthine phosphoribosyltransferase 1 (HPRT1) to 
identify a gene that is not affected by the co-stimulation treatments.  
As well as receptor saturation and cytotoxicity there may be other underlying molecular 
mechanisms contributing to the response observed in the co-stimulation assays. Recent work 
investigating the combined effects of NiCl2 and LPS showed that nickel ions cause 
downregulation of LPS-mediated IL-6 expression by decreasing expression of an IL-6 mRNA 
stabiliser normally induced in response to LPS (Asakawa et al., 2015). In the present study there 
was no evidence of total RNA degradation with different treatment combinations but this does 
not mean that the mRNA of an individual gene is not affected. Other potential mechanisms 
could include TLR4 tolerance developing in response to challenge with multiple ligands, or 
cell-mediated downregulation of cytokines and chemokines for protection against uncontrolled 
inflammation.  
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A potential role for hypoxia 
The results presented in this chapter raise questions about the role of hypoxia in cellular 
responses to cobalt. Cobalt is widely used in laboratories as a hypoxia mimetic (Salnikow et 
al., 2000) and data presented here shows similar patterns to hypoxic responses detected by other 
studies. Hypoxia results in activation of the transcription factor hypoxia inducible factor 1 
(HIF1). HIF1 upregulates the expression of genes that can counteract hypoxic conditions by 
promoting angiogenesis, erythropoiesis, and increased iron metabolism; these include 
erythropoietin and vascular endothelial growth factor (VEGF) (Forsythe et al., 1996). Cobalt 
stabilises hypoxia inducible factor 1α (HIF1α), a subunit of HIF1, resulting in increased gene 
transcription. A preliminary assay in this study showed that there is a small but significant 
upregulation in HIF1A (gene encoding HIF1α) expression by MonoMac 6 cells stimulated with 
0.75mM CoCl2 (Appendix J), suggesting that hypoxia and particularly HIF1α may be involved 
in some of the cellular responses described in this study. However this is purely speculative and 
further analysis would be required to support the hypothesis.  
Binding of NFκB to the IL8 promoter induces IL8 gene transcription. The hypoxia response 
element (HRE) is adjacent to the NFκB binding site and therefore when HIF1α binds to the 
HRE, IL8 transcription is also induced (Kim et al., 2006). This may account for the difference 
between IL8 expression patterns and those of IL6 and CCL2 when cells were treated with 
CoCl2-LPS. It may also explain why there were such large differences in the detected levels of 
cytokines in earlier chapters; IL-8 secretion following cobalt stimulation often reached 
>5000pg/ml whereas with the same concentrations of CoCl2 IL-6 and CCL20 secretion was 
usually <1000pg/ml. Although this effect has been reported in LPS-stimulated cells in other 
studies (Sawa et al., 2008) it is conceivable that it is potentiated by HIF1α.   
HIF1α appears central to cobalt-mediated inflammatory responses because HIF1α-deficient 
mice display a Th2 (immunomodulatory) phenotype compared to the Th1-dominated response 
in their wildtype counterparts (Saini et al., 2010a). However there are mixed reports regarding 
the effect of HIF1α on the secretion of specific inflammatory cytokines. CCL2 release can be 
upregulated in hypoxia as its promoter region contains several binding sites for HIF1α 
(Mojsilovic-Petrovic et al., 2007). Other work has indicated that CoCl2-induced hypoxia 
downregulates CCL2 secretion (Negus et al., 1998, Eleftheriadis et al., 2011) which is 
consistent with the results obtained in this study for both CoCl2 and CoCl2-NiCl2 stimulation. 
The variability between studies could arise due to different cell lines or cobalt concentrations 
used which could be an interesting avenue for further investigation.   
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Studies have also shown conflicting results when investigating the effect of hypoxia on LPS-
mediated inflammation. Jantsch et al reported that LPS can stabilise HIF1α via a TLR4, MyD88 
and NFκB-dependent signalling pathway (Jantsch et al., 2011). However other studies have 
observed anti-inflammatory responses to LPS and hypoxia; under hypoxic conditions LPS-
induced TLR4 activation and secretion of IL-8 and IL-6 is attenuated (Hu et al., 2014) and 
NFκB signalling is inhibited (Müller-Edenborn et al., 2015). In the case of IL-6 expression and 
secretion this appears to occur through downregulation of TLR4 expression (Shirasuna et al., 
2015).  
The potential importance of cobalt and hypoxia in MoM implant failure has recently been 
highlighted. In a study comparing patients with MoM implants to those with MoP devices, 
Samelko et al found increased HIF1α expression in the peri-implant tissues and synovial fluid 
of MoM patients (Samelko et al., 2013). Nyga et al reported dose-dependent increases in HIF1α 
stabilisation and expression in macrophages stimulated with cobalt nanoparticles from MoM 
implants (Nyga et al., 2015). Increased HIF1α production was also noted following cobalt ion 
treatment, although to a lesser extent than with nanoparticles (Nyga et al., 2015). Taken together 
this research suggests that there may be a link between cobalt, hypoxia, and TLR4 activation, 
which would warrant further investigation.  
Chromium and strontium 
Chromium and strontium ions were investigated for their ability to activate TLR4 and induce 
inflammatory cytokine secretion. Chromium was chosen because it is found as an alloy with 
cobalt and sometimes molybdenum in many MoM hip implants. Strontium is used in the cement 
that fixes hip replacements into the bone and was selected because hip implants can be 
cemented or uncemented, which introduces another aspect of patient variability. There was no 
evidence of TLR4 activation by either chromium or strontium ions using a HEK-Blue-hTLR4 
reporter cell assay. This assay does not exclude their ability to activate cells by other 
mechanisms, such as activation of different PRRs. Consequently MonoMac 6 cells were 
stimulated with the metal ions to investigate their inflammatory properties but no IL-6 or IL-8 
secretion was detected. The assay still does not entirely eliminate the possibility of immune 
activation by different pathways that are beyond the scope of this in vitro model. However IL-
6 and IL-8 are secreted via multiple signalling pathways and therefore their absence suggests 
that a significant inflammatory response is not taking place. It also supports the TLR4-
dependent nature of cobalt-mediated inflammatory responses, as without TLR4 activation there 
was no evidence of inflammatory cytokine secretion.  
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It is perhaps not surprising that strontium does not cause an inflammatory response because one 
of its beneficial properties is its chemical similarity to calcium; it is absorbed via the same 
mechanisms and therefore used in bone cement to promote bone growth, osseointegration, and 
help prevent osteolysis. The outcome of the assays conducted in the present study also support 
the work of Ninomiya et al who found that in comparison to the inflammatory effects of cobalt, 
chromium ions do not induce IL-8 or CCL2 secretion in endothelial cells, nor do they affect 
lymphocyte chemotaxis and adhesion molecule expression (Ninomiya et al., 2013). From the 
results described in the literature and in the present study it appears that cobalt is more involved 
in inflammatory responses than chromium or strontium.  
6.5.1. Future work 
293-MD2-CD14 cells, whilst good models for transfection studies, are not immune cells nor 
would they be found around a failed joint replacement. They also lack many of the typical 
characteristics of inflammatory cells including expression of a wide range of inflammatory 
cytokines and chemokines, and phagocytic capabilities. It would therefore be interesting to 
induce the D299G TLR4 mutation or other TLR4 SNPs in cells such as MonoMac 6 
macrophages to determine how this affects immune cells. The effects of SNPs on secretion of 
different inflammatory cytokines could also be investigated. 
The treatment combinations (CoCl2-LPS and CoCl2-NiCl2) represent a good starting point for 
modelling the effect of infection and nickel exposure on the TLR4 response to cobalt ions. 
However more work is required to refine the assays to better replicate the in vivo scenario; for 
example, pre-treating the cells with either nickel ions or LPS may alter the cellular response, as 
may changing the agonist concentrations used. These assays provide an appropriate in vitro 
model for further investigation into TLR4 tolerance and sensitisation; TLR4 can become 
sensitised or desensitised to ligands such as LPS, but it is not known whether or not metal ions 
can produce similar effects. Preliminary investigations were conducted in this regard using 
MonoMac 6 cells and HMEC-1, and LPS tolerance was established in both cell lines (data not 
shown). However the matter of cobalt cytotoxicity must be resolved before a complete study 
can be performed.   
As described earlier, simultaneous activation of TLR4 and other TLRs can enhance secretion 
of inflammatory cytokines. For example co-stimulation of dendritic cells with LPS and a TLR7 
agonist results in increased IFN-β secretion compared to treatment with individual ligands 
(Mäkelä et al., 2011). Synergistic effects can be the result of activation of multiple TLR-related 
signalling pathways, e.g. the MyD88-dependent and TRIF-dependent pathways (Ting Tan et 
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al., 2013). It would be interesting to investigate the effect of other TLR ligands on the 
inflammatory response to cobalt ions, and this could also provide a greater understanding of 
endogenous and exogenous factors that may be implicated in ARMD.   
The role of hypoxia in inflammation is complex and the effect of PAMPs such as LPS is yet to 
be fully elucidated. However there are similarities between the responses to cobalt reported in 
the present study and hypoxic effects described in others, including downregulation of CCL2. 
It is therefore conceivable that some of the inflammatory effects described in this study could 
be the result of hypoxia. Further work is required to determine whether HIF1α and other 
hypoxia mediators are regulated by cobalt activation of the TLR4 signalling pathway, and if 
they in turn can modulate cobalt-mediated TLR4 activation. This could be done using the TLR4 
inhibitors optimised in chapter 4 (CLI-095, MAb2-hTLR4 and PAb-hTLR4).  
This chapter has begun to investigate potential factors involved in ARMD patient variability 
but there is a considerable number remaining that have not yet been studied. It would be 
particularly interesting to investigate the role of hormones on inflammatory responses to metal 
ions as ARMD is more common in women than men, and the TLR4 signalling pathway can be 
modulated by hormones; progesterone inhibits LPS-mediated immunity by upregulating 
inhibitory suppressor of cytokine signalling-1 (SOCS-1) expression and preventing NFκB 
activation (Su et al., 2009). The effect of hormonal regulation on cobalt-mediated TLR4 
activation is unknown.   
6.5.2. Conclusion 
The results obtained in this chapter show the development of an assay designed to test the 
effects of a TLR4 SNP on inflammatory responses to cobalt ions. A common TLR4 SNP, 
D299G, did not inhibit IL-8 secretion following cobalt stimulation although comparison to the 
wildtype TLR4 response was not possible. The protocol used for these assays can be refined 
and used to investigate other polymorphisms within the TLR4 signalling pathway.  
The data presented here also shows that co-stimulation of cells with cobalt and LPS causes a 
significant decrease in IL6 and CCL2 expression, as well as in IL-6 secretion. A similar effect 
is observed when nickel and cobalt treatment is combined, although nickel does not upregulate 
CCL2 expression as LPS does. The results are an interesting effect given that individually the 
TLR4 ligands mainly exert pro-inflammatory responses. Further optimisation of these assays is 
required given the decrease in housekeeping gene expression caused by the combined 
treatments. Investigation into potential links between hypoxia and cobalt-mediated TLR4 
activation would also be of interest.  
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The final aspect of patient variability investigated in this chapter was the inflammatory effect 
of other orthopaedic biomaterials, specifically chromium and strontium. Neither of these metal 
ions activated TLR4, nor did they induce inflammatory cytokine secretion in MonoMac 6 cells. 
Consequently it can be concluded that chromium and strontium do not have the same TLR4-
stimulating properties as cobalt.  
The results of this chapter show that there are numerous factors that could affect inflammatory 
responses and contribute to the patient variability in ARMD development. The assays described 
in this chapter can be optimised further to allow for detailed investigation into endogenous and 
exogenous factors affecting the outcome of cobalt-mediated TLR4 signalling.   
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Chapter 7. Conclusions  
7.1. Aims and outcomes 
The hypothesis of this study was that cobalt activation of human TLR4 leads to cellular 
inflammatory responses that may play a role in adverse reactions to metal debris. The main 
aims and outcomes of this study were: 
A. To investigate the overall effect of cobalt ions on cellular immune responses 
The effect of cobalt ions on MonoMac 6 macrophages was investigated using SYBR Green 
qRT-PCR arrays and Proteome Profiler cytokine arrays. Cobalt ions upregulated the expression 
of numerous inflammatory genes, including IL8, IL1A, CCL20 and CCL25. These results were 
validated by TaqMan-based qRT-PCR. Secretion of inflammatory cytokines such as IL-8 and 
CXCL1 was also increased. There were notable differences in cytokine secretion profiles 
between CoCl2 and LPS-stimulated MonoMac 6 cells, particularly for the CCL chemokines 
including CCL2 and CCL3.  
B. To determine the role of TLR4 in observed responses 
IL-8 was selected as a marker of cobalt-mediated cellular responses based on the array data 
described in chapter 3. Further analysis by ELISA showed that cobalt ions increased IL-8 
secretion by MonoMac 6 and THP-1 macrophages, and U2OS osteoblasts. Using a small 
molecule TLR4 antagonist this was shown to be TLR4-dependent. TLR4-dependent CXCL10 
gene expression and IL-6 and CCL20 secretion were also observed in cobalt-stimulated 
MonoMac 6 cells. The potential of monoclonal and polyclonal anti-TLR4 neutralising 
antibodies to inhibit the response to cobalt was assessed using IL-8 as an inflammatory marker; 
the monoclonal antibody successfully inhibited cobalt-mediated IL-8 expression and secretion 
but the polyclonal antibody failed to do so. However both antibodies inhibited expression of 
other inflammatory genes; MAb2-hTLR4 inhibited expression of both CCL20 and IL1A 
following cobalt treatment while PAb-hTLR4 prevented CCL20 expression but not IL1A.  
C. To investigate the effect of cobalt ions on cell adhesion and immune cell migration  
The effect of CoCl2 on endothelial cells was assessed using IL-8 as a marker of TLR4 activation. 
HUVEC were unresponsive to CoCl2 stimulation with no IL-8 secretion detected across a broad 
range of concentrations and timepoints. Similar effects were observed for IL-6 secretion. 
However a second endothelial cell line, HMEC-1, secreted IL-8 and IL-6 in a cobalt/TLR4-
dependent manner. qRT-PCR revealed upregulated expression of the adhesion molecule 
ICAM1 in cobalt-treated MonoMac 6 cells and HMEC-1, and this was attributed to TLR4 
activation by cobalt ions. A TLR4-dependent increase in sICAM-1 release by both cell lines 
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following cobalt stimulation was also observed. Conditioned media from cobalt-stimulated 
MonoMac 6 cells was found to be chemotactic for primary human monocytes and neutrophils. 
TLR4 was again implicated as the response was prevented by CLI-095.  
D. To investigate factors that may impact upon patient variability in adverse reactions to 
metal debris 
293-MD2-CD14 cells were successfully transfected with D299G and WT TLR4 as ascertained 
by immunofluorescence and qRT-PCR. However issues with cell maintenance and passage 
prevented thorough analysis of the WT TLR4 cells. D299G TLR4 cells increased IL-8 secretion 
when stimulated with CoCl2 or LPS. This preliminary result suggests that the mutation does not 
abrogate inflammatory responses to cobalt ions, although comparison to WT TLR4 cells would 
be beneficial. Co-stimulation of MonoMac 6 cells with CoCl2-LPS and CoCl2-NiCl2 elicited 
some surprising results, including decreased IL6 expression compared to LPS or NiCl2 alone. 
The inflammatory properties of orthopaedic metals chromium and strontium were also 
investigated. These metals did not activate human TLR4, nor did they induce IL-6 and IL-8 
secretion by MonoMac 6 cells. 
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7.1.1. Overall conclusions 
The data presented in this study demonstrates that cobalt activation of human TLR4 regulates 
expression of inflammatory cytokines and chemokines in macrophages and endothelial cells. 
Responses are dependent on the cell line used as HUVEC did not respond to CoCl2 while all 
other cell lines showed inflammatory effects. IL-8 is an effective marker of TLR4 activation 
and was used in this study to assess the potential of TLR4 inhibitors in preventing receptor 
activation by CoCl2. A small molecule TLR4 antagonist and a monoclonal anti-TLR4 
neutralising antibody proved effective at abrogating cellular responses to cobalt ions while a 
polyclonal antibody provided less inhibition. Although the array data showed that cobalt 
affected both pro- and anti-inflammatory cytokine expression, further analysis of adhesion 
molecule expression and immune cell migration suggested a pro-inflammatory and TLR4-
dependent response. Surprisingly investigation into factors influencing ARMD patient 
variability indicated that nickel and LPS downregulate cobalt-mediated expression of 
inflammatory cytokines including IL6, although further investigation is required. In summary, 
activation of TLR4 by cobalt ions results in an inflammatory response that is similar but not 
identical to that which is induced by LPS. The TLR4 signalling pathway is therefore an 
interesting avenue for further investigation into the cell and molecular biology of ARMD, as 
well as an exciting potential therapeutic target. 
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7.2. Final discussion 
Since the emergence of adverse reactions to metal debris following MoM hip replacement there 
have been many studies investigating cellular responses to metal debris and ions. The majority 
of these studies reveal an inflammatory response to the metals, including cobalt, characterised 
by elevated secretion of pro-inflammatory cytokines and chemokines. In vivo, persistent peri-
implant inflammation is a key factor in osteoclastogenesis, osteolysis and aseptic implant 
loosening, which are major features of ARMD. The initial stimulus for this inflammation has 
previously been attributed to PRR activation by endogenous DAMPs released by stressed or 
damaged cells, or to endotoxin coating of wear debris leading to immune system activation 
(Greenfield et al., 2010). However the present study provides a new perspective on the 
mechanisms that lead to cobalt-mediated inflammation and ARMD; cobalt activation of TLR4 
may be an additional (or initial) stimulus that drives inflammatory responses or perpetuates 
existing inflammation.  
Macrophages and endothelial cell lines were used throughout this study and were selected to 
model the peri-implant environment. Macrophages are found in synovial fluid and peri-implant 
tissues, and much of the inflammation associated with ARMD is attributed to macrophage 
infiltration and activation (Nich et al., 2013).  Endothelial cells line blood vessels surrounding 
the joint and are also present in the pseudotumour vasculature. Both cell types displayed 
increased TLR4-dependent inflammatory cytokine secretion and adhesion molecule expression 
when challenged with cobalt ions in vitro, suggesting that the tissues surrounding the implant 
may be responsive to cobalt. This could account for the increased cytokine and chemokine 
levels detected around failed MoM implants (Singh et al., 2015), as well as being a potential 
stimulus for osteoclastogenesis, osteolysis, and implant loosening. Some of the cytokines 
secreted (e.g. CCL20) by cobalt-stimulated activated macrophages are also characteristics of 
M1 pro-inflammatory macrophages (Martinez et al., 2006), which suggests that the overall 
cellular response may be pro-inflammatory.  
Cytokine and chemokine secretion is a direct consequence of TLR4 activation by cobalt ions. 
Adhesion molecule expression was also TLR4-dependent but it is not clear whether this is a 
direct result of cobalt binding to TLR4 or if it occurs through TLR4-dependent cytokine 
secretion; ICAM-1 and VCAM-1 expression can be increased by cytokines including IFNγ and 
TNFα (Ren et al., 2010). The observed monocyte and neutrophil migration is modulated by 
chemokines because the chemotaxis assays were performed using conditioned media from 
cobalt-stimulated cells. However the exact chemokines responsible for each effect have not 
been identified. Further work to resolve this would be beneficial as it would provide more 
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insight into the individual factors that regulate inflammatory responses following TLR4 
activation.  
This study has also identified differences in the cellular inflammatory responses to LPS and 
CoCl2, including higher fold changes in gene expression (e.g. ICAM1) and increased monocyte 
and neutrophil migration with LPS compared to cobalt. Although these changes could be 
attributed to different ligand chemistry and concentrations, opposing effects such as 
downregulation of CCL2 in the presence of CoCl2 but upregulation in response to LPS indicate 
that immune regulation by the two ligands is not identical. This also shows that the CoCl2 
solutions used throughout this study are endotoxin-free, otherwise similar responses would be 
anticipated between the LPS and CoCl2 groups.  
Other studies have identified inflammatory responses to cobalt ions, but have not investigated 
the role of TLR4 in the observed effects. For example Ninomiya et al showed increased 
adhesion molecule expression and leukocyte binding capacity in cobalt-stimulated endothelial 
cells (Ninomiya et al., 2013), which correlates with results presented in this study and 
consequently they may be TLR4-mediated (Tyson-Capper et al., 2013b). This could be assessed 
using the chemotaxis and CLI-095 assays detailed in chapter 5. Further studies have shown 
increased TLR4 expression in cells from aseptically-loosened joint replacements (Lähdeoja et 
al., 2009) and this has been attributed to either sub-clinical levels of infection or endotoxin 
coating of wear debris, both of which activate PRRs including TLR4 (Greenfield et al., 2010, 
Bonsignore et al., 2013). However although endotoxin can coat most biomaterials (Greenfield 
et al., 2005), revision rates and incidence of adverse reactions are considerably higher for MoM 
implants than they are for ceramic-on-polyethylene and metal-on-polyethylene devices 
(Powers-Freeling, 2015). Additional factors must therefore be involved and it is conceivable 
that cobalt activation of TLR4 exacerbates other adverse reactions.  
A working model based on the results of this study and the current literature is shown in Figure 
7.1. 
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Figure 7.1: Working model 
1. A metal-on-metal hip implant releases cobalt ions and debris into the joint environment. 2. Cobalt activates TLR4 on resident tissue macrophages 
resulting in increased cytokine and chemokine secretion, including IL-8 and CCL20. 3. Chemokines induce circulating leukocyte migration towards 
the site of inflammation. 4. Engagement of Sialyl LewisX on leukocytes with E-selectin on endothelial cells slows leukocyte passage through the 
blood vessel; this is rolling adhesion. 5. E-selectin is shed by the endothelial cell allowing the leukocyte to transition to firm adhesion via 
engagement of LFA-1 (leukocyte) with ICAM-1 (endothelial cell). 6. Firm adhesion increases the ability of leukocytes to pass through the 
endothelial cell barrier and into the tissues. 7. TLR4 on migrated macrophages is also activated by cobalt ions, resulting in further cytokine and 
chemokine release. 8. TLR4-expressing endothelial cells are activated by cobalt from the MoM implant, and increase cytokine secretion and 
adhesion molecule expression. This also contributes to the adhesion described in step 5. 
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7.2.1. Study limitations 
Specific limitations for the individual assays conducted are discussed in their respective 
chapters. The main overall limitation of this study is that cell lines were used throughout, with 
the exception of the primary HUVEC used for the adhesion studies in chapter 5, and the primary 
monocytes and neutrophils used in the migration assays in the same chapter. The cell lines were 
appropriate for use in this study because the primary aim was to investigate the effect of cobalt 
on TLR4 signalling, downstream signalling pathway factors and the inflammatory outcome (i.e. 
cytokine and chemokine secretion), without the complexity of patient variability when 
considering the use of inhibitors and neutralising antibodies. However, a limitation of cell lines 
is that they do not provide the opportunity to study patient variability, for example investigating 
patient-specific differences in cytokine secretion levels in response to the same stimulus. To 
study aspects of patient variability in-depth, PBMC from patients and healthy volunteers could 
be used, but this was beyond the scope of the present study given the numbers required for 
comprehensive analysis.  
An additional limitation of cell lines is that they may not express all of the factors for 
investigation, particularly when studying a broad range of molecules such as in the arrays. It 
was particularly notable that the MonoMac 6 cells did not express high levels of TNFα in 
response to either LPS or cobalt, which is surprising because it is one of the key cytokines 
released when TLR4 is activated. Further work would be required to establish whether or not 
this response is unique to MonoMac 6 cells, and this is where the use of primary cells would 
again be advantageous.  
The study is also limited by the cobalt concentrations and stimulation times used. The cobalt 
concentrations were carefully optimised based on previous studies using in vitro assays but 
cytotoxicity was observed which may contribute to the cellular response. The use of a small 
range of timepoints and concentrations was necessary due to the scope of the study, particularly 
for the arrays in chapter 3, but could also prevent detection of temporal or dose-dependent 
inflammatory responses.     
The antagonists used in the study (CLI-095 and anti-TLR4 neutralising antibodies) do not 
exclude the possibility of TLR4 activation by endogenous DAMPs or exogenous ligands such 
as LPS. However previous studies have shown that mutation of the cobalt binding site in human 
TLR4 abrogates cobalt-mediated inflammatory responses (Raghavan et al., 2012) and murine 
TLR4 is not activated by cobalt, suggesting that cytokine release only occurs when cobalt binds 
directly to the receptor. Furthermore, endotoxin assays were negative (data not shown), 
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eliminating the possibility of cell culture contamination by endotoxins which could produce 
comparable inflammatory responses to cobalt. There were also differences in the LPS and 
cobalt-mediated inflammatory responses, such as increased CCL2 expression in LPS-
stimulated MonoMac 6 cells, but a decrease in expression of the same gene in response to cobalt 
ions. If the metal ion solutions were contaminated by endotoxin, the response of the cells to 
LPS and cobalt would be very similar.  
The final major limitation of this study is that it is based on in vitro assays. This was important 
to the study because of the specificity of cobalt in binding to human TLR4, thus eliminating the 
possibility of using animal cells or models. The investigation is also in the early stages in terms 
of the use of inhibitors (for example) and therefore it would not be feasible to introduce animal 
models. However the use of in vitro assays does mean that the cell-cell interactions (e.g. antigen 
presentation by macrophages to lymphocytes) that would take place in vivo cannot be studied. 
It is also not possible to identify any systemic or physiological effects of cobalt ions, including 
how the initial innate immune response mediated by TLR4 could be promoted or dampened by 
other aspects of the immune system. An appropriate animal model for further study could be 
mice expressing humanised TLR4, although given the species differences in receptor activation 
by cobalt, caution must be exercised when considering the validity of such models for furthering 
the work described in the present study.    
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7.3. Clinical implications  
MoM hip replacement and resurfacing use has declined dramatically since the emergence of 
the side effects now termed adverse reactions to metal debris. However there are still more than 
one million MoM hips implanted worldwide and the unpredictability of ARMD means that 
reactions can present at any time. An ARMD therapy could reduce the requirement for complex 
and costly revision surgery, particularly among an elderly and more vulnerable population. 
Moreover, CoCr alloys are used in trunnions in MoP and ceramic implants and therefore 
therapeutic prevention of the inflammatory activity of cobalt ions could also prevent adverse 
reactions in these implants. 
There are many factors to be considered in the development of a therapy targeting TLR4 for 
ARMD prevention and several are discussed elsewhere in this thesis (Chapter 4). An additional 
factor to be considered in the development of a therapy targeting TLR4 for ARMD prevention 
is the extent of the role TLR4 plays in adverse reactions. It is clear from the data presented in 
this study that cobalt activation of TLR4 can induce a cellular inflammatory response. TLR4 
antagonism by neutralising antibodies or a small molecule inhibitor abrogated many of the 
effects. In a lot of cases this was a near-complete blockade, for example CLI-095 reduced IL-8 
secretion in MonoMac 6 cells nearly to the levels of untreated controls, which suggests that the 
response is entirely TLR4-dependent. In other cases there was only partial inhibition of 
responses in the presence of an inhibitor or antibody which may be the result of feedback loops 
whereby cytokines promote further inflammation, compensatory cytokine secretion, or 
responses entirely independent of TLR4 activation. There must be additional factors involved 
in ARMD as TLR4 is universally expressed but not every MoM implant patient develops 
ARMD. As previously mentioned it could be that cobalt-mediated TLR4 activation acts as a 
‘trigger’ that combined with other stimuli (e.g. antigen presentation to adaptive immune cells) 
results in inflammatory responses to metal ions. The response could also be influenced by cobalt 
ion concentrations, carrier proteins, endogenous factors such as hormones, or the presence of 
other metal ions, wear debris or PAMPs like LPS.   
A greater understanding of the inflammatory mechanisms underlying ARMD could also allow 
the identification of factors influencing patient variability, which is currently a major 
confounding factor in ARMD development. Not all patients experience adverse reactions to 
their MoM hip implant and this suggests that MoM implants could work very well in the right 
patient group. A long-term clinical goal of research such as this is to identify factors that 
influence patient variability, allowing improved stratification of patients receiving hip 
replacements and as a result reducing the incidence of adverse reactions and revision surgery. 
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This could include investigating the relationship between ARMD, pre-existing medical 
conditions (e.g. rheumatoid arthritis) and their associated treatments, as well as immune 
regulation by hormones and other endogenous factors, and genetic variation. Given the number 
of potential causes of patient variability the TLR4 signalling pathway provides an excellent 
starting point for such investigations.  
The benefits of understanding the inflammatory effects of cobalt ions are not limited to MoM 
hip replacements as cobalt is also used in other medical devices such as dental implants, spinal 
hardware and coronary stents. Although these devices do not articulate and therefore release 
less debris than hip implants, they are still associated with increased serum metal ion levels 
(Cundy et al., 2014) and can cause adverse reactions which often resemble those linked to MoM 
implants (e.g. lymphocytic infiltrate or osteolysis) (Guyer et al., 2011, Zairi et al., 2013, Shang 
et al., 2014). Furthermore, other metal ions that are used in medical implants such as nickel and 
palladium are known TLR4 ligands (Figure 7.2). Nickel’s use is more widespread than that of 
cobalt as it is present in everyday items like coins, jewellery and cooking utensils, and is 
associated with allergic contact dermatitis. Palladium is used in dental implants, which have 
also been linked to hypersensitivity and other adverse reactions (Khamaysi et al., 2006, Muris 
et al., 2015). A greater understanding of the immunological effects of cobalt could therefore 
contribute to wider biomaterial research and benefit a broad range of patients receiving medical 
implants. In addition it could also help individuals who are exposed to metal ions via other 
means, for example by industrial exposure. There are many other metals used in orthopaedic 
devices that should be investigated for their inflammatory properties, including titanium, 
zirconium and rhodium. To date none of these metals are known to activate TLR4 although 
titanium enhances the inflammatory effects of LPS suggesting that it may influence the TLR4 
signalling pathway (Bianchi et al., 2015).    
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Figure 7.2: Metal ions known to activate TLR4 and other potential ligands  
Cobalt, nickel and palladium (red) are known TLR4 ligands. Copper and zinc (purple) 
can induce low level inflammatory cytokine secretion but it is not clear if this is TLR4-
dependent (Rachmawati et al., 2013, Tsou et al., 2013). Chromium, iron and strontium 
have been investigated but were not found to activate TLR4 (present study and 
(Rachmawati et al., 2013)).  
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7.4. Future directions 
This study investigated the inflammatory effects of cobalt ions, with a specific focus on the 
immunological outcomes of cobalt-mediated TLR4 activation. Many inflammatory factors 
were found to be regulated by cobalt including cytokines, chemokines and adhesion molecules. 
All of these factors have different functions which highlights numerous avenues for potential 
functional studies including cell adhesion experiments using a Cellix platform, and 
transendothelial migration assays.  
The assays developed during this study can be used to investigate the inflammatory effects of 
other biomaterials including metals like titanium and molybdenum, as well as polyethylene and 
ceramic. Given the specific nature of cobalt and nickel binding to TLR4, it is unlikely that a 
material as chemically different as UHMWPE will activate the same receptor but the 
subsequent assays, such as the chemotaxis and adhesion molecule assays could be used to 
identify the potential immunological properties of existing and newly developed orthopaedic 
materials.   
The work contained in this thesis could be furthered considerably by analysis of tissue samples 
from patients with MoM hip implants. For example quantification of cytokines in synovial fluid 
could be assessed alongside cobalt concentrations and TLR4 expression levels to determine the 
role of the TLR4 signalling pathway in ARMD. Genetic variation (e.g. in TLR4 or related 
signalling factors) could also be investigated through analysis of DNA extracted from blood 
samples.   
In summary this study demonstrates that cobalt ions from MoM hip implants can activate the 
innate immune receptor TLR4, resulting in cellular inflammatory responses such as cytokine 
secretion and adhesion molecule expression. These may create a pro-inflammatory environment 
that favours the adverse reactions associated with MoM hip failure including osteolysis and 
aseptic loosening. A greater understanding of the effect of cobalt on the TLR4 signalling 
pathway will allow further studies into ARMD patient variability, as well as the development 
of novel therapeutics that could prevent ARMD development and allow cobalt to be used as a 
safe and effective biomaterial in a wide range of orthopaedic devices.  
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 Toll-like Receptors and Signalling qRT-PCR array results 
Abbreviation Gene name Fold change p value 
BTK 
Bruton agammaglobulinemia tyrosine 
kinase 
-1.49 0.2810 
CASP8 Caspase 8 2.06 0.9255 
CCL2 Chemokine (C-C motif) ligand 2 -410.75 0.3654 
CD14 Cluster of differentiation 14 -8.76 0.0069 
CD180 Cluster of differentiation 180 -9.00 0.1021 
CD80 Cluster of differentiation 80 -1.15 0.4077 
CD86 Cluster of differentiation 86 -2.22 0.1955 
CHUK 
Inhibitor of NFκB kinase subunit 
alpha 
2.35 0.5675 
CLEC4E 
C-type lectin domain family 4 
member E 
2.01 0.4151 
CSF2 
Colony stimulating factor 
2/Granulocyte-macrophage colony-
stimulating factor (GMCSF) 
2.42 0.7848 
CSF3 Colony stimulating factor 3 -1.52 0.3793 
CXCL10 Chemokine (C-X-C motif) ligand 10 3.28 0.7637 
ECSIT 
Evolutionarily conserved signaling 
intermediate in Toll pathway 
1.12 0.8138 
EIF2AK2 
Interferon-induced, double-stranded 
RNA-activated protein kinase 
-1.24 0.4321 
ELK1 ETS domain-containing protein -2.67 0.2641 
FADD Fas-associated death domain -3.70 0.0222 
FOS Proto-oncogene c-FOS -1.41 0.3164 
HMGB1 High mobility group box protein 1 1.70 0.4836 
HRAS GTPase HRas -3.05 0.2659 
HSPA1A Heat shock protein A1A (70kDa) 202.40 0.0022 
HSPD1 Heat shock protein (60kDa), Hsp60 28.04 0.1072 
IFNA1 Interferon alpha 1 1.56 0.6302 
IFNB1 Interferon beta 1 -3.21 0.3791 
IFNG Interferon gamma -10.96 0.3738 
IKBKB 
Inhibitor of NFκB kinase, subunit 
beta 
1.86 0.8123 
IL10 Interleukin 10 -1.61 0.4795 
IL12A Interleukin 12, subunit alpha -5.46 0.3645 
IL1A Interleukin 1 alpha 17.11 0.0255 
IL1B Interleukin 1, beta 4.32 0.3126 
IL2 Interleukin 2 -32.56 0.3739 
IL6 Interleukin 6 1.48 0.481027 
IL8 Interleukin 8 40.91 0.0006 
IRAK1 
Interleukin 1 receptor-associated 
kinase 1 
-1.08 0.5917 
IRAK2 
Interleukin 1 receptor-associated 
kinase 2 
3.17 0.0133 
IRAK4 
Interleukin 1 receptor-associated 
kinase 4 
-2.18 0.0200 
IRF1 Interferon regulatory factor 1 1.94 0.8094 
IRF3 Interferon regulatory factor 3 1.14 0.5888 
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JUN Transcription factor AP-1 4.47 0.0159 
LTA Leukotriene A -1.53 0.4304 
LY86 Lymphocyte antigen 86 1.41 0.2815 
LY96 Lymphocyte antigen 96, MD2 1.57 0.5099 
MAP2K3 
Mitogen-activated protein kinase 
kinase 3 
1.34 0.1374 
MAP2K4 
Mitogen-activated protein kinase 
kinase 4 
-2.02 0.0204 
MAP3K1 
Mitogen-activated protein kinase 
kinase kinase 1 
-1.37 0.3713 
MAP3K7 
Mitogen-activated protein kinase 
kinase kinase 7 
1.05 0.8917 
MAP4K4 
Mitogen-activated protein kinase 
kinase kinase kinase 4 
1.70 0.6470 
MAPK8 Mitogen-activated protein kinase 8 1.41 0.7777 
MAPK8IP3 
Mitogen-activated protein kinase 8 
interacting protein 3 
1.66 0.8183 
MYD88 Myeloid differentiation protein 88 -3.36 0.0601 
NFKB1 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1 
7.62 0.0060 
NFKB2 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
2 
1.03 0.5086 
NFKBIA 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor alpha 
7.81 0.0435 
NFKBIL1 
Nuclear factor of kappa light 
polypeptide gene enhancer in B cells 
inhibitor-like 1 
-3.18 0.4328 
NFRKB 
Nuclear factor related to kappaB 
binding protein 
-1.97 0.0605 
NR2C2 
Nuclear receptor subfamily 2 group C 
member 2 
1.05 0.7292 
PELI1 Pellino homologue 1 4.42 0.0359 
PPARA 
Peroxisome proliferator-activated 
receptor alpha 
-1.54 0.0755 
PRKRA 
Protein kinase interferon-inducible 
double stranded RNA dependent 
activator 
-1.56 0.1023 
PTGS2 
Prostaglandin-endoperoxide synthase 
2 
1.55 0.1948 
REL 
V-rel reticuloendotheliosis viral 
oncogene homologue (avian) 
2.32 0.0285 
RELA 
V-rel reticuloendotheliosis viral 
oncogene homologue A (avian) 
1.19 0.9052 
RIPK2 
Receptor-interacting serine-threonine 
kinase 2 
2.25 0.629152 
SARM1 
Sterile alpha and TIR motif 
containing 1 
-1.04 0.6075 
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SIGIRR 
Single immunoglobulin and toll-
interleukin 1 receptor domain 
-2.39 0.3113 
TAB1 TGF-beta activated kinase 1 -3.01 0.0042 
TBK1 TANK-binding kinase 1 2.28 0.1925 
TICAM1 
Toll-like receptor adaptor molecule 
1 
3.68 0.0394 
TICAM2 Toll-like receptor adaptor molecule 2 4.92 0.1963 
TIRAP 
Toll-interleukin 1 receptor (TIR) 
domain containing adaptor protein 
3.47 0.9698 
TLR1 Toll-like receptor 1 -33.91 0.1837 
TLR10 Toll-like receptor 10 3.20 0.1737 
TLR2 Toll-like receptor 2 1.90 0.0235 
TLR3 Toll-like receptor3 -3.48 0.2466 
TLR4 Toll-like receptor 4 1.01 0.4157 
TLR5 Toll-like receptor 5 -3.23 0.1672 
TLR6 Toll-like receptor 6 -2.75 0.0251 
TLR7 Toll-like receptor 7 1.48 0.5228 
TLR8 Toll-like receptor 8 -12.88 0.3591 
TLR9 Toll-like receptor 9 -2.41 0.3893 
TNF Tumour necrosis factor 1.75 0.2205 
TNFRSF1A 
Tumor necrosis factor receptor 
superfamily member 1A 
1.66 0.3946 
TOLLIP Toll interacting protein -1.03 0.6979 
TRAF6 TNF receptor-associated factor 6 -1.02 0.9210 
UBE2N Ubiquitin-conjugating enzyme E2N 5.04 0.8119 
ACTB Βeta actin - - 
B2M Beta-2-microglobulin - - 
GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
- - 
HPRT1 
Hypoxanthine 
phosphoribosyltransferase 1 
- - 
RPLP0 Ribosomal protein, large, P0 - - 
HGDC Human genomic DNA control - - 
RTC Reverse transcriptase control - - 
PPC Positive PCR control - - 
Table A.1: Full list of genes, fold changes and p values from Toll-like receptor 
signalling RT2 Profiler qRT-PCR arrays (PAHS-018Z). 
  
206 
 
 Inflammatory Cytokines and Receptors qRT-PCR array results 
Gene Gene name Fold change p value 
ABCF1 ATP-binding cassette sub-family 4, member 
1 
-2.57 0.0360 
BCL6 B-cell CLL/lymphoma 6 1.88 0.3650 
C3 Complement component 3 7.20 0.8531 
C4a Complement component 4a -1.79 0.5547 
C5 Complement component 5 -2.12 0.1571 
CCL1 Chemokine (C-C motif) ligand 1 -1.36 0.5889 
CCL11 Chemokine (C-C motif) ligand 11 -3.82 0.2048 
CCL13 Chemokine (C-C motif) ligand 13 -3.96 0.1527 
CCL15 Chemokine (C-C motif) ligand 15 -4.10 0.2200 
CCL16 Chemokine (C-C motif) ligand 16 -1.82 0.2631 
CCL17 Chemokine (C-C motif) ligand 17) -1.82 0.5610 
CCL18 Chemokine (C-C motif) ligand 18 -1.02 0.6818 
CCL19 Chemokine (C-C motif) ligand 19 1.71 0.6805 
CCL2 Chemokine (C-C motif) ligand 2 -6.81 0.3378 
CCL20 Chemokine (C-C motif) ligand 20 34.96 0.0020 
CCL21 Chemokine (C-C motif) ligand 21 1.19 0.6931 
CCL23 Chemokine (C-C motif) ligand 23 -2.05 0.2375 
CCL24 Chemokine (C-C motif) ligand 24 -1.51 0.2616 
CCL25 Chemokine (C-C motif) ligand 25 7.71 0.8192 
CCL26 Chemokine (C-C motif) ligand 26 1.02 0.7988 
CCL3 Chemokine (C-C motif) ligand 3 1.71 0.7312 
CCL4 Chemokine (C-C motif) ligand 4 10.27 0.5958 
CCL5 Chemokine (C-C motif) ligand 5 -1.06 0.6667 
CCL7 Chemokine (C-C motif) ligand 7 -9.11 0.4229 
CCL8 Chemokine (C-C motif) ligand 8 -4.10 0.4464 
CCR1 Chemokine (C-C motif) receptor 1 -9.43 0.2044 
CCR2 Chemokine (C-C motif) receptor 2 -77.10 0.1127 
CCR3 Chemokine (C-C motif) receptor 3 -1.02 0.7038 
CCR4 Chemokine (C-C motif) receptor 4 -1.09 0.7666 
CCR5 Chemokine (C-C motif) receptor 5 -2.33 0.2005 
CCR6 Chemokine (C-C motif) receptor 6) -4.35 0.3660 
CCR7 Chemokine (C-C motif) receptor 7 -1.04 0.3856 
CCR8 Chemokine (C-C motif) receptor 8 -1.73 0.2276 
CCR9 Chemokine (C-C motif) receptor 9 -1.99 0.3338 
CEBPB CCAAT/enhancer binding protein (C/EBP) 
beta 
-1.61 0.7641 
CRP C-reactive protein, pentraxin-related -4.10 0.2200 
CX3CR1 Chemokine (C-X3-C motif) receptor 1 -3.25 0.3205 
CXCL1 Chemokine (C-X-C motif) ligand 1 1.32 0.5776 
CXCL10 Chemokine (C-X-C motif) ligand 10 1.04 0.4815 
CXCL11 Chemokine (C-X-C motif) ligand 11 -1.25 0.5168 
CXCL12 Chemokine (C-X-C motif) ligand 12 -3.03 0.1976 
CXCL13 Chemokine (C-X-C motif) ligand 13 -2.66 0.2746 
CXCL14 Chemokine (C-X-C motif) ligand 14 2.96 0.0837 
CXCL2 Chemokine (C-X-C motif) ligand 2 11.21 0.0629 
CXCL3 Chemokine (C-X-C motif) ligand 3 15.14 0.0879 
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CXCL5 Chemokine (C-X-C motif) ligand 5 -1.76 0.4191 
CXCL6 Chemokine (C-X-C motif) ligand 6 -2.53 0.4169 
CXCL9 Chemokine (C-X-C motif) ligand 9 -1.12 0.8718 
CARD18 Caspase recruitment domain family member 18 -4.42 0.2117 
IFNA2 Interferon alpha 2 1.50 0.4962 
IL10 Interleukin 10 -5.50 0.4154 
IL10RA Interleukin 10 receptor alpha 1.09 0.8428 
IL10RB Interleukin 10 receptor beta -2.10 0.0006 
IL13 Interleukin 13 2.98 0.3070 
IL13RA1 Interleukin 13 receptor alpha 1 -2.02 0.0993 
IL17C Interleukin 17C 1.63 0.4937 
IL1A Interleukin 1 alpha 1.83 0.2512 
IL1B Interleukin 1 beta 2.11 0.4250 
IL1F10 Interleukin 1 family member 10 (theta) -5.47 0.2784 
IL36RN Interleukin 36 receptor antagonist -1.06 0.8036 
IL36A Interleukin 36 alpha -6.25 0.3278 
IL37 Interleukin 37 -1.14 0.4714 
IL36B Interleukin 36 beta -3.60 0.2305 
IL36G Interleukin 36 gamma 2.73 0.9206 
IL1R1 Interleukin 1 receptor type I 2.76 0.2213 
IL1RN Interleukin 1 receptor antagonist -2.86 0.1482 
IL22 Interleukin 22 -1.88 0.6038 
IL5 Interleukin 5 (colony-stimulating factor, 
eosinophil) 
-2.82 0.5378 
IL5RA Interleukin 5 receptor alpha 2.74 0.3518 
IL8 Interleukin 8 14.53 0.0236 
CXCR1 Chemokine (C-X-C motif) receptor 1 -2.10 0.3066 
CXCR2 Chemokine (C-X-C motif) receptor 2 -2.50 0.1204 
IL9 Interleukin 9 -1.52 0.5004 
IL9R Interleukin 9 receptor -1.28 0.4003 
LTA Lymphotoxin alpha (TNF superfamily member 
1) 
2.53 0.0918 
LTB Lymphotoxin beta (TNF superfamily member 
3) 
-5.91 0.0817 
LTB4R Leukotriene B4 receptor -11.04 0.1395 
MIF Macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) 
-1.75 0.3582 
AIMP1 Aminoacyl tRNA synthetase complex-
interacting multifunctional protein 1 
-2.58 0.0452 
SPP1 Secreted phosphoprotein 1 1.07 0.6038 
TNF Tumor necrosis factor -3.25 0.0773 
CD40LG CD40 ligand -11.78 0.2447 
TOLLIP Toll interacting protein -2.54 0.1069 
XCR1 Chemokine (C motif) receptor 1 -1.52 0.5463 
B2M Beta-2-microglobulin - - 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 - - 
RPL13A Ribosomal protein L13a - - 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase - - 
ACTB Beta actin - - 
HGDC Human Genomic DNA Contamination - - 
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Table B.1: Full list of genes, fold changes and p values from Inflammatory Cytokines 
and Receptors RT2 qRT-PCR arrays (PAHS-011C) 
  
RTC Reverse Transcription Control - - 
PPC Positive PCR Control - - 
209 
 
 GAPDH Ct values following cell stimulation 
Cell stimulation (24h) Mean GAPDH Ct value 
0.75mM CoCl2 18.3 
100ng/ml LPS 18.6 
0 18.9 
Table C.1: Effect of CoCl2 on GAPDH Ct values  
MonoMac 6 cells were stimulated with 0.75mM CoCl2 or 100ng/ml LPS for 24h. RNA 
was isolated and cDNA synthesised by reverse transcription. GAPDH expression was 
quantified by qRT-PCR. Table shows mean Ct values from an assay performed in 
triplicate. Data is representative of five independent experiments. 
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 CLI-095 cytotoxicity assay 
 
Figure D.1: Effect of CLI-095 on MonoMac 6 cell viability 
MonoMac 6 cells were stimulated with 1, 5 or 10μg/ml CLI-095 for 30h (time represents 
a 6h pre-incubation followed by 24h cell treatment) and cytotoxicity was assessed by 
trypan blue staining. A Luna II automated cell counter was used to take images of the 
stained cells and they were then counted manually due to the issues described in section 
2.5. n=1.  
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 ICAM1 dose response curve 
 
Figure E.1: Effect of CoCl2 on ICAM1 expression 
A. MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 or 100ng/ml LPS for 24h. 
RNA was isolated and cDNA synthesised by reverse transcription. ICAM1 expression 
was quantified by qRT-PCR. B. ICAM1 expression shown without LPS, as LPS can mask 
the effects of CoCl2. n=1. Statistical significance was calculated by one-way ANOVA 
with Dunnett’s test for multiple comparisons comparing treated samples to the untreated 
control. This experiment was conducted in collaboration with MRes student Sami Anjum.  
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 CLI-095 optimisation in HMEC-1 
 
 
Figure F.1: CLI-095 optimisation in HMEC-1 
HMEC-1 were pre-treated with 0.01-1μg/ml CLI-095 for 6h before 24h stimulation with 
0.75mM CoCl2. Controls were a 6h pre-treatment with 1μg/ml CLI-095 followed by 
stimulation with 100ng/ml LPS (positive control) or untreated (negative control) for 24h. 
Supernatant was collected and IL-8 secretion measured by ELISA. n=1. Statistical 
significance was calculated by one-way ANOVA with Tukey’s test for multiple 
comparisons comparing all samples to each other. This experiment was conducted in 
collaboration with MRes student Sami Anjum.  
  
0
IL
-8
 s
e
c
r
e
ti
o
n
 (
p
g
/m
l)
0 1 0 0 .0 1 0 .0 5 0 .1 0 .5 1 0 1
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
C L I-0 9 5  ( g /m l)
0 .7 5 m M  C o C l2 1 0 0 n g /m l
L P S
***
***
213 
 
 Neutrophil chemotaxis and anti-TLR4 neutralising antibodies 
 
Figure G.1: Effect of anti-TLR4 neutralising antibodies on neutrophil migration 
MonoMac 6 cells were stimulated with 10μg/ml MAb2-hTLR4 for 1h or 5μg/ml PAb-
hTLR4 for 10 minutes followed by stimulation with 0.75mM CoCl2 for 16h. Supernatant 
was collected and its chemotactic properties assessed by transwell neutrophil migration 
assay. Data is representative of three independent experiments each using a different 
neutrophil donor. Statistical significance was calculated by one-way ANOVA with 
Tukey’s test for multiple comparisons comparing all samples to each other. *** indicates 
significance compared to cobalt-only control except where bar is shown. This data 
appears in Lawrence et al (Lawrence et al., 2016). 
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  D299G TLR4 transfectants 
 
Figure H.1: TLR4 expression by D299G TLR4 transfectants 
TLR4 expression by 293-MD2-CD14 transfected with plasmid DNA encoding the 
D299G TLR4 SNP. The DNA used was from four different bacterial colonies (1-4) and 
TLR4 expression was compared to untransfected 293-MD2-CD14 cells. UT=untreated 
cells. 
 
 
Figure H.2: IL-8 secretion by D299G TLR4 transfectants 
D299G TLR4 transfectants were stimulated with 0.75mM CoCl2 or 100ng/ml LPS for 
24h before supernatant was collected and IL-8 release quantified by ELISA. Statistical 
significance was calculated by one-way ANOVA comparing stimulated samples to the 
untreated control within each transfectant group (e.g. D299G (1)).  
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 Effect of cobalt on IL6 and CCL2 expression 
 
Figure I.1: Effect of CoCl2 on IL6 and CCL2 expression 
MonoMac 6 cells were stimulated with 0.25-1mM CoCl2 for 24h before RNA was 
isolated and cDNA synthesised by reverse transcription. A. IL6 and B. CCL2 expression 
was quantified by qRT-PCR. n=1. Statistical significance was calculated by one-way 
ANOVA comparing stimulated samples to the unstimulated control.   
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 Effect of cobalt on HIF1A expression 
 
Figure J.1: Effect of CoCl2 on HIF1A expression 
MonoMac 6 cells were treated with 0.75mM CoCl2 for 24h before RNA was isolated and 
cDNA synthesised by reverse transcription. qRT-PCR was performed to quantify HIF1A 
expression. Statistical significance was calculated by Student’s t test. n=1.  
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 Publications, presentations and prizes  
Publications 
Lawrence H*, Mawdesley AE*, Deehan DJ, Holland JP, Kirby JA, Tyson-Capper AJ (2016) 
‘Preventing the inflammatory response to cobalt ions’. Oncotarget 7(7):7578-7585 (*joint 
first authors)  
Lawrence H, Deehan DJ, Holland JP, Kirby JA, Tyson-Capper AJ. (2014) ‘Immunobiology of 
cobalt: demonstration of a potential aetiology for inflammatory pseudotumours after metal-on-
metal replacement of the hip’. Bone and Joint Journal 96-B:1172-1177 
Lawrence H, Deehan DJ, Holland JP, Kirby JA, Tyson-Capper AJ. (2014) Can cobalt from 
metal-on-metal joints activate human TLR4 and cause an inflammatory response? Bone and 
Joint Journal 96-B (Supp 11):292 
Tyson-Capper AJ, Lawrence H, Holland JP, Deehan DJ, Kirby JA. (2013). ‘Molecular 
mechanism of cell activation by cobalt ions. Comment on Ninomiya et al.: Metal ions activate 
vascular endothelial cells and increase lymphocyte chemotaxis and binding’. Journal of 
Orthopaedic Research 31(11):1859 
Manuscripts submitted 
Lawrence H, Deehan DJ, Holland JP, Kirby JA, Tyson-Capper AJ ‘Cobalt ions recruit 
inflammatory cells in vitro through human Toll-like receptor 4’. Submitted to Biochemical 
and Biophysical Research Reports, February 2016
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Presentations 
February 2016 
 
Cell biology and tissue analysis in retrieval studies 
Oral presentation, Northern Retrieval Centre annual meeting, 
Newcastle, UK 
 
September 
2015 
Role of TLR4 in the immunological response to cobalt 
Oral presentation, European Orthopaedic Research Societies meeting, 
Bristol, UK 
 
June 2015 Role of TLR4 in adverse reactions to cobalt ions 
Oral presentation, Immunology North East Annual Symposium, 
Durham University, UK 
 
June 2015 Role of TLR4 in adverse reactions to biomaterials 
Oral presentation, NIHR Postgraduate Research Day, Newcastle, UK 
 
May 2015 Role of TLR4 in adverse reactions to cobalt ions 
Oral presentation, American-British-Canadian Travelling Orthopaedic 
Fellows meeting, Hexham, UK 
 
May 2015 Fooled: How metal hips can confuse our immune system 
Oral presentation, INSIGHTS Public Lecture Series, Newcastle 
University, UK (Faculty of Medical Sciences public speaking prize) 
Available online at http://www.ncl.ac.uk/events/public-
lectures/item.php?three-tales-from-the-biomedical-frontier3 
 
April 2015 Fooled: How metal hips can confuse our immune system 
Oral presentation, INSIGHTS Public Lecture Prize heats and ICM 
poster evening, Newcastle University, UK 
 
October 2014 
 
Metal-on-metal joints: cobalt can cause an inflammatory response 
through human TLR4 
Oral presentation, North East Postgraduate Conference, Newcastle, UK 
 
June 2014 Metal-on-metal joints: cobalt can cause an inflammatory response 
through human TLR4 
Poster presentation, Immunology North East Annual Symposium, 
Northumbria University, UK 
 
June 2014 Metal-on-metal joints: cobalt can cause an inflammatory response 
through human TLR4 
Poster presentation, ICM Research Day, Newcastle University, UK 
 
May 2014 Metal-on-metal joints: cobalt can activate TLR4 and cause an 
inflammatory response 
Oral presentation, ICM Seminar Program, Newcastle University, UK 
 
October 2013 Can cobalt from metal-on-metal joints activate human TLR4 and cause 
an inflammatory response? 
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Oral presentation, Combined meeting of Orthopaedic Research 
Societies, Venice, Italy 
 
June 2013 Can failing metal-on-metal joints cause inflammation via an endotoxin-
like response? 
Poster presentation, NIHR Training Camp, Berkhamsted, UK 
 
June 2013 Do failing metal-on-metal joints cause inflammation via an endotoxin-
like response? 
Oral presentation, ICM Research Day, Newcastle University, UK 
 
 
Prizes and Awards 
August 2015 Faculty of Medical Sciences Graduate School Travel Award to attend 
the European Orthopaedic Research Societies meeting 
May 2015 Faculty of Medical Sciences postgraduate public speaking prize 
(INSIGHTS public lecture series) 
June 2014 2nd prize, Immunology North East Annual Symposium poster 
competition, Northumbria University 
June 2014 2nd prize, ICM Research Day poster competition, Newcastle University 
 
220 
 
Other co-authored abstracts 
Mawdesley AE, Anjum SA, Lawrence H, Deehan DJ, Kirby JA, Tyson-Capper AJ 
Preventing the inflammatory response to cobalt ions 
Presented at the North East Postgraduate conference, Newcastle, UK, October 2015 (Oral 
presentation, British Society for Immunology prize)  
 
Anjum SA, Mawdesley AE, Lawrence H, Deehan DJ, Kirby JA, Tyson-Capper AJ  
The effect of cobalt on inflammatory cytokine and adhesion molecule expression  
Presented at the British Orthopaedic Research Society meeting, Liverpool, UK, September 
2015 (Oral presentation) 
 
Anjum SA, Mawdesley AE, Lawrence H, Deehan DJ, Kirby JA, Tyson-Capper AJ  
The effect of cobalt on inflammatory cytokine and adhesion molecule expression  
Presented at the European Orthopaedic Research Societies meeting, Bristol, UK, September 
2015 (Oral presentation) 
 
Mawdesley AE, Anjum SA, Lawrence H, Deehan DJ, Kirby JA, Tyson-Capper AJ 
Preventing the inflammatory response to cobalt ions 
Presented at the European Orthopaedic Research Societies meeting, Bristol, UK, September 
2015 (Elevator pitch presentation, runner-up prize)  
 
Anjum SA, Mawdesley AE, Lawrence H, Deehan DJ, Kirby JA, Tyson-Capper AJ  
The effect of cobalt on inflammatory cytokine and adhesion molecule expression  
Presented at the Immunology North East Annual Symposium, Durham, UK, June 2015 (Poster 
presentation) 
 
Mawdesley AE, Anjum SA, Lawrence H, Deehan DJ, Kirby JA, Tyson-Capper AJ 
Preventing the inflammatory response to cobalt ions 
Presented at the Immunology North East Annual Symposium, Durham, UK, June 2015 (Poster 
presentation) 
 
Lawrence H, Deehan DJ, Holland JP, Deehan DJ, Kirby JA, Tyson-Capper AJ 
Metal-on-metal joints: cobalt can activate TLR4 and cause an inflammatory response 
Presented at the 6th Advanced Hip Resurfacing course, Ghent, Belgium, May 2014 (Oral 
presentation) 
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